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Abstract 
Malaria is a devastating and pervasive infectious disease and continues to be a major global 
health issue, with over half the world’s population being at risk of transmission. In the absence 
of a suitable vaccine, efforts to eradicate the disease rely heavily on clinically available drugs. 
Plasmodium falciparum, the deadliest species of malaria, has however become resistant to 
most conventional antimalarial treatments, resulting in the worldwide search for new, 
effective drugs. Amongst other requirements, these drugs should target resistant parasitic 
strains in an attempt to curb the escalation of the disease. In this regard, the incorporation of 
a metal into the organic framework of a biologically active compound has become an 
increasingly popular method of enhancing antiplasmodial activity in the drug-resistant 
parasite strains. 
Two series of 7-chloroquinoline-1,2,3-triazole ligands, one with the direct attachment of the 
triazole to the quinoline and one where the two entities are separated by an aminopropyl 
linker, were synthesised. Coordination of selected ligands with [IrCl(µ-Cl)(Cp*)]2 yielded six 
neutral, cyclometallated and two cationic, N,N-chelated iridium complexes. Computational 
analysis revealed that metal coordination to the quinoline nitrogen occurs first, forming an 
unstable kinetic product that, upon heating over time, forms the stable, cyclometallated, 
thermodynamic product. All of the compounds were fully characterised using an array of 
spectroscopic (1H, 13C{1H}, 19F{1H}, 31P{1H} NMR and FT-IR spectroscopy) and analytical (mass 
spectrometry and melting point analysis) techniques. Single crystal X-ray diffraction 
confirmed the proposed molecular structure and a pseudo-tetrahedral geometry around the 
metal centre for the cyclometallated and monodentate, quinoline nitrogen-coordinated 
complexes. 
The ligand series containing the propyl chain linker displayed superior in vitro antiplasmodial 
activity against the chloroquine-sensitive NF54 strain of P. falciparum in comparison with the 
series having the triazole directly attached to the quinoline moiety. Upon complexation with 
iridium, the activity of selected ligands is significantly enhanced (0.247 < IC50 (µM) < 2.34), 
with some complexes being over one hundred times more active than their respective ligands. 
For most of these compounds, their antiplasmodial activity is lower in the chloroquine-
resistant K1 strain, however, their calculated RI values suggest that they likely only experience 
vi 
mild cross-resistance, not to the same extent of chloroquine. Selected complexes were tested 
against the healthy, mammalian Chinese Hamster Ovarian (CHO) cell line and were found not 
to be cytotoxic. They were also determined to be more selective towards the parasite than 
healthy cells. An “IC50 speed assay” using the three most active complexes against the 
chloroquine-sensitive NF54 strain found the two neutral, cyclometallated complexes to be 
fast-acting compounds which reach their lowest IC50 values within 24 hours, while the active 
cationic complex was determined to be slow-acting, only reaching its lowest IC50 value after 
48 hours.  
To gain insight into the possible mechanisms of action of these compounds, selected ligands 
and complexes were tested for their ability to inhibit the formation β-haematin (the synthetic 
form of haemozoin), since one of the mechanisms of 7-chloroquinoline-containing 
compounds is the inhibition of haemozoin formation. All five of the tested compounds were 
found to inhibit β-haematin formation to some extent but were, in general, less effective 
β-haematin inhibitors than chloroquine itself. Interestingly, the aminopropyl-containing 
cationic complex which displayed the lowest antiplasmodial activity exhibited far greater 
β-haematin inhibitory activity (IC50 9.65 µM) than chloroquine (IC50 65.3 µM).  
Finally, three of the most active complexes were evaluated for their ability to facilitate 
transfer hydrogenation, by reducing β-nicotinamide adenine dinucleotide (NAD+) to NADH in 
the presence of hydrogen source, sodium formate. Through preliminary qualitative and 
quantitative cell-free experiments, it was found that the two most active neutral, 
cyclometallated complexes tested may be capable of acting as transfer hydrogenation 
catalysts while the active, cationic complex tested did not indicate reduction of NAD+ to NADH 
over 4 hours.  
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Introduction and Literature Review 
 
1.1 Malaria  
1.1.1 History and Prevalence 
Malaria is a life-threatening, mosquito-borne disease caused by blood parasites of the 
Plasmodium genus.1 Often seen as a disease of poverty, malaria has largely been neglected 
universally and, despite decades of research being done into its prevention and treatment, it 
remains one of the leading causes of mortality worldwide. According to the estimates of the 
World Health Organisation (WHO) in their 2018 World Malaria Report, progress towards 
global malaria control has stalled after an unprecedented period of success in previous years.2 
In 2017, there were an estimated 219 million cases of malaria with a reported  435 000 deaths, 
92% of which were reported from the WHO African Region.2 With these statistics in mind, it 
is clear why combating this disease, which affects predominantly the poorest countries in the 
world, is of great importance. Malaria is one of the world’s oldest diseases with ancestors of 
the parasite being believed to have existed half a billion years ago.3 After evolving alongside 
mankind throughout the years, the disease was first known to have been treated in the 1600s 
when the native South Americans made use of the bark of the Cinchona tree to relieve the 
“feverish” symptoms of malaria.4 Significant progress into the treatment of malaria only took 
off in the 19th century and, eventually, it was considered one of the best-studied diseases of 
the time in Western medicine.3,4 Western interest in the disease, however, began to decline 
towards the mid-20th century, even though the disease, on a global scale, has not.4 
 
1.1.2 Biology 
Malaria is a protozoan disease which is transmitted to the human host via the female 
Anopheles mosquito vector.1,5,6 Of the five species of Plasmodium that are infectious to 
humans, namely P. falciparum, P. vivax, P.ovale, P. malariae, and P. knowlesi, the species 




for 99.7% of the malaria cases in sub-Saharan Africa in 2017.1,2,5,6 The life cycle of                                     
P. falciparum is complex and involves different developmental stages in both the human and 













The parasite is injected into the human host via an infected mosquito and the sporozoites 
then enter the liver and infect hepatocytes.1,6–8 Next, the pathogenic asexual blood stage 
takes place where the parasite leaves the liver and invades and populates the red blood cells 
(RBCs). This part of the cycle involves four stages, namely the merozoite, ring, trophozoite, 
and blood schizont stages.1,6–8 A portion of the merozoites may also be converted into 
gametes, which are then taken up by another mosquito in which sexual reproduction 
occurs.1,6–8  Once the trophozoite stage in the RBC is reached, the parasite is able to ingest 
60–80% of the host cell haemoglobin (Hb) via phagocytosis and, thereafter, transports it into 
its acidic digestive vacuole.1,8–10 It is here where Hb degradation takes place, leaving 
ferriprotoporphyrin-IX, or “free” haem, as a by-product.1,8–11 Once in this “free” state, many 
studies have shown that this haem is toxic to the parasite as it is able to cause the generation 




of oxygen free radicals as a result of the oxidation of the haem iron centre.1,8–11 This, among 
other things, causes harmful lipid peroxidation of the parasite’s cell membrane and eventual 
cell lysis.1,8–10 To circumvent the deleterious effects of this “free” haem, the parasite has 
evolved a detoxification mechanism whereby the haematin is sequestered and crystallised 
into an insoluble, chemically inert substance known as haemozoin or malaria pigment, the 
structure of which can be seen in Figure 1.2.1,8–11 This haemozoin forms in the parasite’s 
digestive vacuole and is non-toxic to the parasite, appearing as purple-black, opaque crystals 
under the microscope in parasite stages that are actively degrading Hb.1,8,10 Because the 
parasite has limited capacity to synthesise amino acids, haemoglobin catabolism is thought 
to be necessary for parasite survival as it provides essential amino acids for growth and 
maturation.4,10 It is for this reason that targeting the haemoglobin metabolism pathway in the 
parasite has been the focus of many antimalarial drug treatments.4,10  
1.1.3 Antimalarial treatments and drug resistance 
There are many preventative methods in place as frontline measures in the control of malaria, 
some examples being the use of mosquito-repellent creams and insecticide-treated mosquito 
nets.2 Preventative medicines may also be used when visiting areas where malaria is 
prevalent.2 When prevention is no longer an option, however, there are a number of 
chemotherapeutic options available for people who have contracted the disease. The oldest 
and most well-known class of antimalarial drugs are those containing the heterocyclic 
aromatic quinoline moiety.4,12 The very first antimalarial agent, which forms part of this class 




of drugs, originated in the 1600s when the Countess of Chinchon was cured of malaria after 
being treated by the powdered bark of the Chinchona tree.4 It was only in 1820, however, 
when two French chemists, Pelletier and Caventou, were able to isolate the active alkaloid 
ingredient, quinine, in the bark of the tree.4 The structure of quinine can be seen in                    
Figure 1.3. Quinine has been used in antimalarial therapy ever since and is joined by other 
quinoline-containing compounds such as chloroquine, primaquine, amodiaquine, mefloquine 











1.1.4 Chloroquine and non-chloroquine-based drugs 
One drawback with quinine is that it has side effects associated with its toxicity and also needs 
to be administered three times a day for seven days, thus resulting in poor compliance.13 This 
led to the development of the class of fully synthetic 4-aminoquinoline compounds in the 
1940s, of which chloroquine (CQ) is the most popular.12,13 The reason for its popularity is 
because chloroquine is relatively inexpensive, non-toxic, efficacious and can be administered 
over three days.13 CQ is also only active against the blood stages of the parasitic life cycle in 
which active Hb degradation is taking place.14 Many structure-activity relationship 
investigations have been conducted by various groups (Figure 1.4), focussing specifically on 

























CQ and its derivatives, showing that there are numerous reasons for chloroquine’s enhanced 
antiplasmodial activity.15 Firstly, its 4-aminoquinoline core allows it to form a strong complex 
with haematin.15 Secondly, its 7-chloro group aids in the inhibition of haemozoin formation 
and, lastly, the basic nitrogen atoms, both on its core and on its side chain, aid in pH trapping, 
thereby promoting the accumulation of the drug within the parasitic food vacuole.15 Although 
chloroquine has been used as an effective antimalarial agent for decades, its mechanism of 
action is still not completely understood,  although, nowadays, it  has  been  widely  accepted 
that  it  likely  involves  the  interruption  of  the  formation of haemozoin, as shown in Figure 
1.5.1,4,10,12,15,16  It  has  been  suggested that chloroquine accumulates in the food vacuole and, 
once the parasite digests the host cell Hb, the drug is able to interact with the 
ferriprotoporphyrin-IX, or “free” haem, preventing its crystallisation into 




Figure 1.4: Structure-activity relationships of chloroquine.15 
The 7-chloro group is 
necessary for         
β-haematin inhibition 
Weak bases – aid in pH 
trapping and thus, drug 
accumulation 
4-Aminoquinoline core
forms a strong complex
with haematin 
Figure 1.5: Possible mode of action of CQ.16 
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membrane, as well as cause numerous other toxic effects, eventually leading to cell death via 
oxidative stress or cell lysis.1,10,12,16 For many years, CQ remained the vanguard antimalarial 
drug, however, over time, chloroquine-resistant (CQR) strains of P. falciparum began to 
emerge in Asia and South America, eventually spreading to West Africa.10,16,17 This resistance 
was discovered to occur through spontaneous mutations in the parasite’s genetic code, 
particularly to a gene known as the P. falciparum chloroquine resistance transporter (PfCRT) 
gene.18 This transporter is located on the membrane of the parasitic food vacuole and, when 
the gene encoding for this transporter undergoes a specific mutation, it results in the efflux 
of quinoline and quinoline-like drugs from the acidic food vacuole.18–20 This results in a 
decrease in the accumulation of these drugs, rendering them practically ineffective in CQ-
resistant P. falciparum strains.19,20 Owing to the proliferation of CQ-resistant parasites, CQ 
was virtually useless by the year 2000, with often extremely high treatment failure rates in 
most parts of  the world.10,16,17,21 This, thus, led to the need to  find  alternative ways  to treat  
malaria,  with  some  examples  being  the modification of known drugs and combination 
therapies.10,17,22 The World Health Organisation now recommends artemisinin-based 
combination therapies (ACTs) as the front-line treatment for P. falciparum malaria.10,13,23,24 
This involves the combination of artemisinin, or a derivative thereof (Figure 1.6), with a 
second drug that has a different mechanism of action.10,13,23 Artemisinin is a highly-effective 
drug which is fast-acting and capable of rapidly eliminating the malaria parasite.10,23 In 
combining it with another drug which targets a different mode of survival of the parasite, this 
combination approach aims to improve the efficacy of the treatment as well as to minimise 
the risk of resistance development.10,23 Although ACTs are the mainstay of recommended 
Figure 1.6: The general structure of artemisinin antimalarials. 
R = H Dihydroartemisinin 
R = Me  Artemether 
R = Et Arteether 







treatment for malaria, they too could start to lose their efficacy as resistant strains of the 
malaria parasite have begun to emerge in Southeast Asia.25 It is, therefore, necessary to 
continue to develop novel antimalarial therapies in order to manage a disease of this 
magnitude. This brings into play the concept of pharmacophore hybridisation, an attractive 
strategy in the attempt to circumvent antimalarial drug resistance.25 
1.2 Hybrid Molecules 
1.2.1 Structure 
With the unavoidable emergence of drug-resistant strains of P. falciparum, numerous 
antimalarial drug-discovery approaches are currently being pursued. Some of these strategies 
include the generation of optimized analogues of existing drugs, the repurposing of 
medicines, the evaluation and use of drug-resistance reversers and, most recently, the 
synthesis of hybrid molecules.5,26 The latter involves the covalent linking of two biologically 
active molecules, also known as pharmacophores, into one hybrid unit with a dual mode of 
action.5,26,27 In doing so, these hybrid compounds could potentially have an improved efficacy 
and safety, as well as be less susceptible to elicit resistance relative to the parent drugs.5,27 
There are a number of advantages of developing hybrid molecules over implementing 
combination therapies.26 The use of a single molecule means that the pharmacokinetics will 
be identical for each constituent, and it also means that there will be much less stress when 
it comes to things such as solubility and stability, which would be an issue in the 
administration of multiple agents.26,28 There is currently a number of hybrid molecules in use 
in the drug industry, with one such example being the effective anticancer agent, bleomycin 
(Figure 1.7).28 Originally isolated as an antibiotic from Streptomyces verticillus in 1966, 
bleomycin is a hybrid peptide-polyketide natural product used for the treatment of several 
malignancies.28,29 This drug has three distinct structural domains, each of which has its own 
different biological role: one domain for DNA binding, another for metal binding and a third 
containing carbohydrates, which facilitates cell penetration (Figure 1.7).28,30,31 As a well-
studied hybrid molecule featuring on the World Health Organisation’s List of Essential 
Medicines, bleomycin serves as a paradigm for the synthesis of hybrid drugs.32 Since this 
pharmacophore hybridisation approach is a hot topic in the field of drug discovery, research 
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is now being done into the development of hybrid antimalarial drugs in an attempt to 
circumvent the ever-increasing problem of antimalarial drug resistance. 
1.2.2 Aminoquinoline-triazole hybrids and their antiparasitic activity 
Although the global diffusion of antimalarial drug resistance has spread at an alarming rate, 
4-aminoquinoline derivatives, such as CQ, still remain the most sought out antimalarial agents
for chemical modification.27 Because of its favourable biopharmaceutical properties, as well
as its safety and cost effectiveness, the strategies aimed at overcoming resistance to CQ are
attractive and, for this reason, the quinoline derivatives dominate the antimalarial drug
pool.26,33 There are a number of recent examples of quinoline-based antimalarial drugs which
employ the method of pharmacophore hybridisation, some of which can be seen in
Figure 1.8.26 These include chloroquine-triazine hybrids,34,35 chloroquine-pyramidine
hybrids,27  the mefloquine-artesunate hybrid (MEFAS),36  and the organometallic chloroquine-
ferrocene hybrid, also known as ferroquine.37 Many of these compounds have shown
enhanced antimalarial activity in drug-resistant parasites compared to their respective parent
drugs, with MEFAS) and ferroquine advancing further to preclinical development and Phase
IIb clinical trials respectively.36,38 Moreover, the innovative hybrid salt, MEFAS, was found to
be more effective than just the combination of mefloquine and artesunate as separate
entities, further highlighting the need for novel hybrid drugs.36 Although there are no
Figure 1.7: Structure of the anticancer hybrid drug, bleomycin.31 
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examples of antimalarial hybrid drugs in clinical use, it is easy to see why the 7-
chloroquinoline moiety would be the pharmacophore of choice in the design of such a drug.25 
Another pharmacophore which is not as well-documented for antimalarial activity but which 
is undeniably important in medicinal chemistry is the 1,2,3-triazole entity.34,39–41 This aromatic 
heterocycle constitutes a five-membered ring of two carbon atoms and three nitrogen atoms 
and can easily be prepared using copper-catalysed click chemistry.34,39–41 Triazoles are 
particularly desirable pharmacophores as they are stable to acid-base hydrolysis, relatively 
resistant to metabolic degradation and readily associate with biological targets via hydrogen 
bonding.5,40,41 Although the 1,2,3-triazole entity does not exist in nature, there are a number 
of triazole-containing synthetic molecules which exhibit a multitude of biological activities, 
ranging from antifungal and antibacterial to anticancer, antituberculosis and antiHIV 
activities.39,40  In  combining  the stable  triazole moiety with the antimalarial properties of the 
aminoquinoline skeleton, the novel class of aminoquinoline-triazole hybrid molecules could 
likely display enhanced antimalarial activity in an attempt to overcome the primary limitation 
of resistance. A 2019 review by Chu et al. details some of the recent advances in the use of 









































quinoline-triazole hybrids as potential antiplasmodial and antimalarial agents.42 A few of 
these hybrid compounds described herein exhibited promising antiplasmodial activity, with a 
significant enhancement in activity shown upon the incorporation of an aminoalkyl chain 
linker between the triazole and quinoline entities.42 Although the quinoline-triazole hybrids 
were mostly found to have moderate, micromolar antiplasmodial activity, this activity could 
likely be improved by the incorporation of a metal into their structure, a method of 
antimalarial drug design which has also recently taken wind. 
1.3 Metals in Medicine 
 From the days of ancient medicine to the innovative times of modern pharmacology, the use 
of metals in medicine has played a substantial role in the field of drug discovery.10,43 Although 
the use of metal-based drugs was largely abandoned in the early part of the 20th century due 
to apprehension about systemic toxicity, over the past 30 years this outlook has changed with 
a resurgence of interest in the potential applications of metals in the design of novel 
therepeutics.43 The reason for this renewed interest is that research has found that transition 
metal compounds offer great versatility and chemical diversity not always seen in organic 
drugs.10,43–45 This diversity is brought about not only by the choice of the metal itself, but also 
by the ability to “fine-tune” the reactivity of the metal centres toward target biomolecules by 
altering the number and type of coordinated ligands as well as the coordination geometry of 
the complex.10,43–45 Transition metals in particular also have a unique binding capability and 
reactivity determined by their d orbitals, making their complexes important in biological 
systems.10,17,43 There are a number of examples that prove the success of metal complexes in 
modern medicine. Thought to have started with Ehrlich’s discovery of the arsenic-based 
organometallic drug, Salvarsan46 (Figure 1.9a), for the treatment of syphilis in the early 20th 










century, the field of organometallic drug design has since blossomed, with the preparation of 
other metal-based treatments including antiparasitic antimony complexes and gold 
compounds for the treatment of rheumatoid arthritis.47,48 Arguably, the most significant 
accidental discovery however, which fuelled interest in the field of metal-based drug design 
was that of the anticancer activity of the platinum-based compound, cisplatin 
(cis-[PtCl2(NH3)2]), by Rosenberg et al.49 in the late 1960s (Figure 1.9b).10,43,44,47–50  Cisplatin 
and its derivatives have been used in cancer therapy ever since, however, its severe dose-
limiting side effects, high toxicity and the development of drug resistance largely impede its 
effectiveness.49,51 With the aim of overcoming these limitations, other drug-design strategies 
include ligand modification and the use of alternative metals to platinum, such as the 
Platinum Group Metals (PGMs) ruthenium, rhodium, iridium, osmium and palladium.52 These 
metals are of particular interest because they have a decreased toxicity but show activity 
comparable to platinum itself. The use of metals in anticancer drug development has thus 
been well explored and, with these strategies in mind, the field of metal-based antimalarial 
research is currently being pursued. 
1.3.1 Metalloantimalarials 
Encouraged by the success of metal-containing compounds in cancer therapy, research into 
the relatively unexplored field of metalloantimalarials has recently begun to emerge.10  The 
term “metalloantimalarials” was first coined in 2003 by Goldberg, Sharma and co-workers53, 
who divided these compounds into three categories, namely metal chelators, intact metal 
coordination complexes of known antimalarial agents, and bioorganometallic 
compounds.10,53 Metal compounds are particularly suitable for the treatment of parasitic 
diseases such as malaria because they display a marked selectivity for certain parasitic 
biomolecules compared to the host’s biomolecules.43 With this in mind, Wasi et al. was the 
first to synthesise and evaluate the antimalarial activity of metal complexes of amodiaquine 
and primaquine – two well-known organic antimalarials.54 Some of the metals used for 
complexation included Cr(III), Fe(III), Cu(II), Zn(II), Rh(III), Pd(II), Au(II), Mn(II) and Pt(II), 
however, these complexes did not appear to exhibit enhanced antimalarial activity.54 It was 
later proposed that the complexation of transition metals with chloroquine would improve 
its antimalarial activity and also aid in overcoming the problem of drug resistance.  
12 
1.3.1.1       Rhodium, ruthenium and iridium complexes of CQ 
The first organometallic complex of chloroquine to be synthesised, characterised and 
biologically tested was the rhodium-containing [RhCl(COD)CQ] (COD = 1,5-cyclooctadiene), 
reported by Sánchez-Delgado et al. in 1996.1,17,43,55,56 Figure 1.10 shows how CQ is bound to 
Rh through the unsubstituted quinoline nitrogen, which acts as a good donor site on the 
molecule, thus forming a 16-electron, square planar structure.1,55 When tested for its activity 
against the P. berghei malaria species, this compound was found to display activity 
comparable to that of chloroquine diphosphate (CQDP).1,55 Similarly, when tested in vivo, the 
Rh complex showed impressive antiplasmodial activity, reducing parasitemia by 73% without 
any sign of acute toxicity.55 
Based on the promising activity displayed by this CQ-based rhodium complex, several 
ruthenium(II)-arene complexes of CQ were thereafter synthesised and tested against various 
strains of P. falciparum.1,57 Importantly, the activities of the complexes against the resistant 
parasitic strains were consistently higher than that of CQDP, demonstrating that the Ru-CQ 
complexes are able to interfere with the parasite’s resistance mechanisms.1,57 Encouraged by 
the success of the aforementioned rhodium and ruthenium complexes of CQ, in 2007, 
Navarro et al.58 developed three new iridium-CQ complexes, the most active of which is 
shown in Figure 1.11. This complex, in which the CQ binds to the iridium through both N atoms 
in its side chain, was determined to have an IC50 value of 59 nM against the in vitro growth of 
P. berghei. Again, this transition metal complex of CQ displayed enhanced antiplasmodial











activity over CQ itself, which was determined to have an IC50 value of 72 nM in the same 
study.58 
1.3.1.2       Ferroquine – a potent ferrocene-CQ complex 
In continuation with the search for metal complexes which have enhanced antimalarial 
properties, a molecule of particular interest is the small and rigid, sandwich-like molecule, 
ferrocene.1,10,59,60 Ferrocene is particularly attractive because it is non-toxic, relatively stable 
under most conditions, highly lipophilic and easily derivatised, making it a desirable structure 
in biological applications and drug-development.1,53,59,60 Inspired by the impressive research 
done by Jaouen et al.,61 who introduced ferrocene into the structures of various cancer 
chemotherapies, the same concept was followed for the modification of known antimalarial 
therapies.37,59 This was first accomplished by Biot et al.62 in 1997 by the introduction of a 
ferrocenyl moiety into the lateral side chain of CQ, thus producing ferroquine (FQ).1,37,56,59,60 
The structure of FQ, as seen in Figure 1.12a, comprises a ferrocene molecule covalently 
flanked by a 4-aminoquinoline moiety and a basic alkylamine chain.43,60,62 While FQ does 
retain some of the essential biological activity of CQ, the additional ferrocene unit further 
enhances this activity in both the CQ-sensitive and CQ-resistant strains of P. 
falciparum.1,10,37,60,62 In the CQ-sensitive strains, FQ was proven to be as effective as CQ, while, 
when tested in vitro against various CQ-resistant P. falciparum strains, it was found to display 
potency 22-times greater than that of CQ.37,62 Similarly, when tested in vivo in mice infected 
with various Plasmodium strains, including P. yoeli, P. berghei and P. vinckei vinckei, the 
activity of FQ was equally as respectable.37,62  It is because of this impressive activity combined 













with its ability to overcome CQ-resistance that FQ is now undergoing phase IIb clinical trials, 
in which the efficacy of a combination of FQ and artefenomel63, a novel synthetic trioxolane 
(Figure 1.12b), is being examined.1,10,11,37,38,43 The activity of FQ can likely be attributed to a 
dual mechanism of action.43 Firstly, FQ is able to inhibit the formation of β-haematin to an 
even greater extent than CQ, and second, the generation of free radicals could possibly occur 
by the redox activation from ferrocene [Fe(II)] to ferrocinium [Fe(III)].43 Since then, many new 
ferrocene analogues and FQ derivatives have been synthesised and screened for 
antiplasmodial activity.1,37,43,64,65  
1.4 Cyclometallated Complexes and Malaria 
Cyclometallation reactions involve the transition metal-mediated activation of a C–R bond, 
resulting in the formation of a new metal–carbon σ bond in the form of a metallacycle.66,67 
This type of intramolecular metalation reaction is one of the oldest reactions in the synthesis 
of organometallic complexes, having gained considerable popularity since its conception in 
the early 1960s.66–68 Over the past 50 years, many papers have been published involving 
cyclometallated complexes, making their synthesis undeniably one of the most advanced 
areas of current organometallic chemistry.66–68 The reason for this is because of the numerous 
advantages that cyclometallation has to offer. Firstly, because the reaction product is a 
metallacycle containing a metal bound by a chelating carboligand, it results in the 
strengthening of the highly susceptible M–C bond, thereby improving the stability of the 
complex as a whole.66,69 This improved stability means that the complex will be protected 
Figure 1.12: The structures of (a) ferroquine (FQ)62 and (b) artefenomel63, a combination therapy 











against biological reduction and ligand exchange reactions, as well as making it easier to 
characterise.66,67,69 Secondly, the ability to alter both the anionic and the ancillary ligands 
means that the cytotoxicity and the pharmacokinetics of the complex can be enhanced.69 
Almost all of the transition metals have been employed for cyclometallation, with some of 
the most successful cases incorporating the platinum group metals Ru, Os, Rh, Ir, Pd.66 While 
there are many examples of the use of cyclometallated complexes for anticancer therapy70,71, 
there appears to be a paucity of examples in antimalarial research, with Smith and co-workers 
being among the few to have produced results in this field.72–75 Much of their research with 
cyclometallated complexes for malaria has focused on cyclopalladated and cycloplatinated 
thiosemicarbozones, with their studies into the inhibitory effects of palladium-containing 
thiosemicarbozones being among the first to be reported in literature.72–74 Recently, they 
have also investigated the antiplasmodial activity of cyclometallated ruthenium(II), 
rhodium(III) and iridium(III) complexes of 2-phenylbenzimidazoles.75 These complexes 
exhibited promising antiplasmodial activities in both CQ-sensitive and CQ-resistant strains of 
P. falciparum, with some IC50 values found to be in the sub-micromolar range (Figure 1.13).75
Very little research, however, has been done into the use of quinoline-containing
cyclometallated complexes for antimalarial chemotherapy, making the synthesis and
evaluation of these types of compounds attractive. While the mechanism of action of
cyclometallated compounds within the malaria parasite is still quite vague, one theory, as
observed for metal complexes in anticancer therapy, is that of intracellular catalysis.
Figure 1.13: Structures of the most active 2-phenylbenzimidazole Ru(II) and Ir(III) complexes 









IC50 (NF54) = 0.19 µMIC50 (NF54) = 0.12 µM
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1.5 Transfer Hydrogenation Catalysis in Living Systems 
From Grubb’s ruthenium carbene catalysts76 for olefin metathesis to Noyori’s ruthenium 
arene complexes77 for the asymmetric hydrogenation of ketones, organometallic complexes 
have been well documented for their use as catalysts in organic chemical reactions.78 A 
developing frontier in the field of organometallic chemistry, however, is the use of metal 
complexes at the interface with biological systems.79,80 Over the past decade, the application 
of chemical processes within living organisms has evolved dramatically, meaning that today, 
many diverse and intricate synthetic molecules exist that are able to control and interfere 
with biological processes.80 With so many powerful chemical tools available for modulating 
biology, focus has now shifted towards the relatively untapped field of metal-complex 
catalysis within living biological systems.80 This brings into play the concept of “metallodrugs” 
with the idea that organometallic complexes are able to exhibit reactivities not possessed by 
either the metal or the organic ligands alone.81,82 The fact that these reactivities can be fine-
tuned and adjusted as desired means that organometallic complexes are able to provide a 
flexible platform for the field of drug design.82 Furthermore, the use of metal complexes as 
catalytic drugs is attractive since this will allow the transition from exploiting predominantly 
stoichiometric reactions to applying catalytic processes meaning that these drugs can be 
administered in low, safe, non-toxic doses.78,80 The concept of transition metal catalysis within 
living systems was first introduced in 2006 by Streu and Meggers,83 and, in so doing, they 
revealed the future potential of intracellular catalysis.84–86 In their research, they found that 
the relatively simple half-sandwich ruthenium complex, [Cp*Ru(COD)Cl] (Figure 1.14a, 





Figure 1.14: Structures of (a) Cp*Ru(COD)Cl used by Streu and Meggers83 and (b) the polystyrene 
microspheres containing entrapped Pd nanoparticles designed by Yusop et al.87
( b)
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allylcarbamates to their respective primary amines in the presence of air, water and thiols, as 
well as in mammalian HeLa cells.80,84–86 Following on from that, in 2011, Yusop et al.87 showed 
that palladium nanoparticles trapped within polystyrene microspheres are capable of 
entering cells and mediating various Pd0-catalysed reactions (Figure 1.14b).84,85  
There are many other examples of biocompatible metal-catalysed reactions, however, one 
which has attracted much attention of late, particularly in the field of cancer research, is that 
of transfer hydrogenation catalysis.78,79,81,88–90 Transfer hydrogenation reactions make use of 
various precious metal catalysts for the reduction of ketones, imines and C=C double bonds 
and are capable of being performed in aqueous media using sodium formate as the hydrogen 
source.81,88 Because these hydride transfer reductions can be done under such mild 
conditions, they are thus capable of being carried out with biomolecules, such as pyruvate 
and β-nicotinamide adenine dinucleotide (NAD+).81 In the area of  biocatalysis, NAD+, and its 
reduced form, 1,4-NADH, are abundant coenzymes required for many reactions involving 
enzymatic reductions.89 The ratio of NAD+/NADH has been studied extensively over the past 
few years and has been shown to play a role in various metabolic functions and even cell 
death.91 It is for this reason that these coenzymes have become promising drug targets in the 
treatment of diseases such as cancer and, because NADH is too expensive to be used in 
stoichiometric amounts, there is current interest in the in situ regeneration of this coenzyme 
under biologically relevant conditions.91 The reduction of NAD+ to regenerate NADH via metal 
complex catalysis can be seen in Figure 1.15.89 
Steckhan et al.92 developed the first series of transfer hydrogenation catalysts in 1991 that 
were capable of utilising high concentrations of sodium formate to regenerate NADH in 






































Figure 1.15: Reduction of NAD+ to NADH via metal complex catalysis, using sodium formate as the 
hydrogen source.89
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complexes have likewise been found to be able to catalyse hydride transfer reactions under 
biologically relevant conditions.78,86,88,90 Ruthenium(II)-arene complexes were shown to form 
hydride complexes in aqueous solution with formate as the hydrogen source while 
rhodium(III) and iridium(III) pentamethylcyclopentadienyl (Cp*) complexes are capable of 
catalysing the regioselective reduction of NAD+ to NADH, again in the presence of 
formate.78,80,88,89,92–94 Sadler and co-workers found that lung cancer cells (A594) are 
remarkably tolerant to formate, even at millimolar concentrations, leading the same group to 
suggest that transfer hydrogenation catalysis could possibly be achieved within cancer 
cells.78,88,89 They investigated many metal complexes as potential intracellular hydride 
transfer catalysts, one of which being the iridium-arene complex,  
[(η5-C5Me4C6H5 )Ir(phen)(H2O)]2+ (Figure 1.16a), which was shown to affect the NAD+/NADH 
ratio within human A2780 ovarian cancer cell lines, thereby possibly affecting the function of 
NADH-dependant redox enzymes.80,93 Another success story in this regard is the series of 
Ru(II) sulfonamido ethyleneamine complexes (Figure 1.16b) which, when co-administered 
with sodium formate, showed impressive activity towards human ovarian cancer cells by 
reducing the intracellular NAD+ levels.78,80 Combined with its ability to initiate catalysis, 
sodium formate at non-toxic concentrations has therefore been shown to enhance and 
potentiate the anticancer activity of metal complexes.78,88 Although no metal-based catalytic 
drugs have advanced through to clinical trials, catalytic reactions have successfully been 













Figure 1.16: Complexes capable of intracellular transfer hydrogenation catalysis;                                                      
(a) [(η5-C5Me4C6H5)Ir(phen)(H2O)]2+ by Betanzos-Lara et al.93 and (b) an example of a Ru(II) 
sulfonamido ethyleneamine complex synthesised by Soldevila-Barreda et al.78
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In terms of the use of transfer hydrogenation catalysts which could have an effect on the 
viability of the malaria parasite, P. falciparum, little to no research has been conducted. This 
was until 2019 when Stringer et al.95 showed that a quinoline-based half-sandwich iridium 
complex tested in vitro at a concentration of 1000 ng/mL against the CQR K1 strain of 
P. falciparum displays a significant stepwise decrease in parasite viability with increasing
concentrations of sodium formate.95 Although only a preliminary study, this result makes the
idea of testing metal complexes for their hydride transfer capabilities within the malaria
parasite an exciting and worthwhile endeavour.
1.6 Summary and Motivation for the Current Study 
Malaria is one of the most prevalent parasitic diseases in the world, however, efforts to 
eradicate the disease are hindered by the spread of drug-resistant parasitic strains. This 
means that research into finding novel, alternative therapies has become a priority. 
Pharmacophore hybridisation has recently become a way of developing new drugs by the 
combination of two antimalarial pharmacophores into one molecule, thereby producing 
molecules which have enhanced activity and reduced ability to elicit resistance relative to the 
parent drugs. Currently, a number of antimalarial hybrids being researched have focused on 
the drug CQ because of its excellent antimalarial activity as well as its low toxicity and cost-
effectiveness. It is for this reason that the 7-chloroquinoline entity of CQ will be employed, 
along with the highly stable triazole structure, for the synthesis of the hybrid ligands in this 
study. Various aromatic groups possessing electron-withdrawing or -donating functionalities 
will be included in the structure of these ligands, one of which will incorporate the ferrocenyl 
moiety, as used in the structure of ferroquine. Furthermore, because of the significant 
enhancement in activity shown upon the incorporation of an aminoalkyl chain linker between 
the triazole and quinoline entities in literature, one series of compounds will contain an 
aminopropyl linker while one will not. 
In addition to hybridisation as an effective strategy in the design of novel antimalarials, the 
incorporation of a metal into the structure of the molecule has shown great success, 
particularly in the development of anticancer drugs. The reason for this is that metal 
compounds offer great chemical diversity not always seen in organic drugs and the reactivity 
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of the metal centres can be “fine-tuned” to target certain biomolecules. Because of this, this 
study focusses on the coordination of the organic ligands to an iridium centre to produce 
neutral, cyclometallated and cationic, N,N-chelated half-sandwich Ir(III) complexes. This will 
be done in order to improve the antiplasmodial activity of the compounds further, as well as 
to examine the effect of metal coordination on parasitic cross resistance.  
The complexes will be tested for their ability to catalyse the hydride transfer reduction of 
NAD+ to NADH with sodium formate as the hydrogen source. This type of reaction has been 
performed within cancer cells, with Ir(III) Cp* complexes in particular showing very good 
catalytic ability. Transfer hydrogenation has, however, not until very recently been 
investigated within the malaria parasite, P. falciparum, although the success of these types of 
compounds as catalytic anticancer agents gives sufficient motivation for their use in this 
respect in this study. Figure 1.17 shows the rationale for the general structure of the 















An aminopropyl chain will be used as a linker 
and increases overall lipophilicity. Series 2 
compounds will contain this linker while 
series 1 compounds will not. 
The triazole entity has 
favourable characteristics such 
as stability and hydrogen-
bonding with biomolecules. 
A variety of aromatic substituents, 
differing in their electron-withdrawing or 
-donating capacities, will be used here to
enhance the antiplasmodial activity.
Iridium complexation via 
cyclometallation or         
N,N-chelation for improved 
stability, antiplasmodial activity 
and catalytic ability. 
Figure 1.17: Generalised structure of the Ir(III) half-sandwich complexes to be synthesised in this study, 
along with the structure-activity relationships of its constituents.  
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1.7      Aims and Objectives 
1.7.1 Overall Aims 
The overall aims of this study were: 
1) To synthesise and characterise various 7-chloroquinoline-1,2,3-triazole ligands and their
corresponding neutral and cationic half-sandwich iridium(III) complexes.
2) To evaluate the in vitro antiplasmodial activity of these ligands and complexes.
3) To investigate possible mechanisms of action of these complexes.
4) To elucidate the ability of the complexes to catalyse the hydride transfer reduction of
NAD+ to NADH using sodium formate in a cell-free environment.
1.7.2 Specific Objectives 
The specific objectives of this study were: 
1) To synthesise a series of 7-chloroquinoline-1,2,3-triazole ligands containing various






















2) To synthesise a second, smaller series of 7-chloro-4-aminoquinoline-1,2,3-triazole ligands
containing various aromatic side groups (Figure 1.19).
3) To synthesise two series of cyclometallated Ir(III) complexes using the quinoline-triazole
ligands described previously (Figure 1.20).
Figure 1.20: General structures of the two series of cyclometallated Ir(III) complexes. (Only the 



































Series 1 Series 2
Figure 1.19: General structure of the series of 7-chloro-4-aminoquinoline-1,2,3-triazole ligands 
synthesised in this study. 
Series 2
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4) To synthesise two N,N-chelated cationic Ir(III) quinoline-triazole complexes. (Figure 1.21)
5) To characterise all of the compounds synthesised using Nuclear Magnetic Resonance
spectroscopy (NMR), Fourier Transform - Infrared spectroscopy (FT-IR), High Performance
Liquid Chromatography (HPLC), Electrospray Ionisation Mass Spectroscopy (ESI-MS) and
melting point analysis. Single crystal X-ray diffraction (XRD) analysis was used to provide
further insight into the structure of some of the isolated complexes.
6) To investigate the in vitro antiplasmodial activity of all compounds against the CQS NF54
strain of P. falciparum. The most active compounds were further tested against the CQR
K1 strain of P. falciparum. The most active compounds against both parasitic strains were
tested for cytotoxicity against the Chinese Hamster Ovarian (CHO) cell line.
7) To carry out mechanistic studies on some of the active compounds, including speed-of-
action assays and tests for the inhibition of synthetic haemozoin (β-haematin) formation
using an NP-40 detergent-mediated assay.
8) Finally, to elucidate the ability of some of the Ir(III) complexes to catalyse the hydride
transfer reduction of NAD+ to NADH using sodium formate in a cell-free environment.
Figure 1.21: General structures of the two N,N-chelated cationic Ir(III) quinoline-triazole complexes 
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Chapter 2 
Synthesis and characterisation of 7-chloroquinoline-1,2,3-triazole 
compounds  
2.1  Introduction 
Malaria is the biggest killer of humans globally, with the deadliest species of the parasite, 
Plasmodium falciparum, having shown an ability to evade all prescribed treatments, most 
recently artemisinin-based combination therapies (ACTs).1–3 Focus therefore needs to be 
given to improving the activity of known pharmacophores within drug-resistant strains of the 
parasite. As mentioned in Chapter 1, an important chemical entity found in many antimalarial 
drugs, such as chloroquine and amodiaquine, is the highly successful 7-chloroquinoline 
pharmacophore.4–8 The success of many 7-chloroquinoline-based antimalarial drugs was 
founded not only on great clinical efficacy, but also on factors such as good host safety and 
cost effectiveness.9–11 Since chloroquine (CQ) was the mainstay of chemotherapy against 
malaria for much of the last 50 years, structural modification of this drug, particularly at the 
aminoalkyl side chain, with another bioactive entity could bring about the hybrid-drug 
therapy that is desperately needed to stem the tide of drug resistance.9,11–13 In this regard, a 
few excellent reviews on the use of hybrid drugs for malaria have been published over the 
last decade.13–16  
A good bioactive candidate for use in combination with 7-chloroquinoline is the 1,2,3-triazole 
group, and several 1,2,3-triazole derivatives have been reported as effective antimalarial 
agents against both CQ-sensitive and CQ-resistant P. falciparum strains.17 The importance of 
triazolic compounds in medicinal chemistry is irrefutable. This is underscored by the ability of 
the five-membered ring to undergo hydrogen bonding, therefore making it perfect in binding 
biological targets such as those within the malaria parasite.18–20 Several groups have reported 
the synthesis and antiplasmodial evaluation of 1,2,3-triazole-based quinoline compounds and 
some of the most active compounds of these studies are shown in Figure 2.1.6,21–23 Of these 
hybrid compounds, some have the quinoline directly attached to the triazole, while in others, 
the two entities are separated by a linear aminoalkyl chain linker. Guantai et al. synthesised 
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highly-active, directly-attached quinoline-triazole compounds with sub-micromolar IC50 
values against all three of the tested P. falciparum strains (D10, Dd2 and W2).23 Similarly,   
Pereira et al. also synthesised a series of directly-attached quinoline-triazole compounds with 
some having low micromolar activity, but found that having a linker between the triazole and 
quinoline entities is crucial for the antimalarial activity and that there is a direct correlation 
between this activity and the length of the alkyl linker.6 It is for this reason that many of the 
known quinoline-triazole hybrid compounds bear a one- to three-carbon spacer, such as the 
compounds synthesised by Joshi et al.21 and Manohar et al.22 (Figure 2.1), both of which 
exhibited good, micromolar activity against both sensitive and resistant strains.  
Owing to the success of the aforementioned 7-chloroquinoline-triazole hybrids as 
antimalarial agents, particularly in the resistant P. falciparum strains, this chapter will focus 
Figure 2.1. Selected examples of active quinoline-triazole compounds against various strains of    
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on the synthesis of various 7-chloroquinoline-1,2,3-triazole compounds, both new and 
previously-synthesised. Figure 2.2 shows the structure-function relationship of the compounds 
reported in this chapter. Encouraged by the results obtained by Guantai et al. for the direct 
attachment of the 7-chloroquinoline pharmacophore to the triazole entity, a similar synthetic 
route for the first series of 7-chloroquinolinotriazole compounds was followed.23 An 
aminopropyl chain linker was included in the scaffold of the second series of 7-chloro-4-
aminoquinolinotriazole compounds because of the reported improved antimalarial activity 
exhibited when incorporating a linear aminoalkyl chain between the two bioactive groups.6,17 
Furthermore, various aromatic moieties bearing side-groups ranging from electron-
withdrawing to electron-donating in nature were attached to position-4 on the triazole in 
order to delineate possible structure-activity relationships.  
Highly active 7-chloroquinoline pharmacophore 
Triazole entity is biologically advantageous, but also 
provides a nitrogen anchor for future cyclometallation 
Various aromatic substituents chosen to enhance the 
antiplasmodial activity 
Series 1 vs Series 2: 
Longer aminoalkyl linker improves lipophilicity 
and therefore cellular uptake 
Longer linker preferred 
Figure 2.2. The structure-function relationship of the quinoline-triazole ligands to be reported in this 
chapter. 
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2.2  Synthesis of a series of 7-chloroquinolinotriazole derivatives 
2.2.1 Synthesis 
The synthesis of the series of 7-chloroquinoline-1,2,3-triazole derivatives (2a-h) required two 
synthetic steps, as outlined in Scheme 2.1.  
The first step involved the synthesis of 4-azido-7-chloroquinoline, 1, from 
4,7-dichloroquinoline and excess sodium azide via a nucleophilic aromatic substitution 
reaction (SNAr).23 In this type of reaction, the addition of a nucleophile to an aromatic ring 
displaces the desired leaving group, the mechanism of which is shown in Figure 2.3.24 The 
highly nucleophilic azide anion attacks the quinoline at the carbon bearing the chloride-group 
at position-4 (numbering shown in Figure 2.3). This chloride, as opposed to the one at 
position-7 on the quinoline, is the favoured leaving group. This is a consequence of the 
position of the quinoline nitrogen, which acts like an electron sink and can accept a lone pair 
of electrons, thereby allowing the attack by the nucleophilic azide at carbon-4. Subsequent 
elimination of the chloride results in the desired quinoline-azide compound. This azide 
Scheme 2.1. Synthesis of the 7-chloroquinolinotriazole derivatives.  Reagents and conditions: (i) 
NaN3, DMF, 65 °C, 5 h; (ii) Aromatic alkyne, t-BuOH or DCM/ H2O (1:1), CuSO4.5H2O, sodium 


























precursor, 1, was isolated as pale-yellow, needle-like crystals in a good yield (70%). This 
compound is soluble in a range of polar and non-polar solvents, as well as alcoholic solvents. 
The second step involved reacting the 4-azido-7-chloroquinoline, 1, with various aromatic 
alkynes via a “click” reaction following the methodology of Sharpless and co-workers25,26 for 
the Cu(I)-catalysed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reaction. This method is 
commonly used for the synthesis of 1,2,3-triazole hybrid compounds and has become the 
benchmark of ‘click chemistry’. The reason for this is because the reaction is very reliable, 
biocompatible and high-yielding, with the copper(I) salts being reported to accelerate the 
reaction 10 million-fold.25,26 This copper catalyst is prepared in situ using sodium ascorbate to 
reduce Cu(II) to Cu(I). The catalytic mechanism subsequently proposed by Sharpless and 
Fokin et al.27 suggests a σ-bound copper acetylide bearing a π-bound copper forms from the 
terminal alkyne, which then coordinates to the terminal azide (Figure 2.4). This results in the 
formation of an unusual 6-membered copper metallacycle, with the second copper atom 
acting as a stabilising donor ligand. This is the point at which cyclisation and subsequent 
protonation occurs, resulting in the triazole product and regeneration of the catalyst which 
can be used for further catalytic cycles. For the synthesis of 7-chloroquinolinotriazole 
compounds, 2a-h, the various aromatic alkynes were chosen according to the electron-
withdrawing or -donating effect of the respective side-group. This was done to be able to 
draw conclusions on which type of functional group results in better overall antiplasmodial 
activity.  Following a literature method9, the reactions were carried out in a mixture of DCM 
or  t-butanol and water, in the presence of CuSO4.5H2O and sodium ascorbate. t-Butanol was 






















Figure 2.3. Proposed mechanism of the nucleophilic aromatic substitution (SNAr) reaction to afford 
azide compound 1.24 
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evaporating at 30 °C over time. In general, the synthesis of the ligands proceeded easily and 
quickly. The exceptions to this were the syntheses of ligand 2c (23%) and the pyridyl-
containing ligand, 2g, which was a sluggish reaction, taking 72 h to react and yielding only 
43% product. The other reactions reached completion within 24 h, resulting in white and pale-
yellow solids with moderate to good yields of 62-83%. All compounds were stable at room 
temperature and when exposed to air.  
2.2.2  Characterisation 
The 4-azido-7-chloroquinoline, 1, and 7-chloroquinolinotriazole derivatives, 2a-h, were 
characterised using various spectroscopic and analytical techniques. These included 1H, 

















































Figure 2.4. Proposed catalytic cycle for the CuAAC reaction to afford compounds 2a-h.27 
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heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR) 
spectroscopy, as well as infrared (IR) spectroscopy, liquid chromatography coupled with mass 
spectrometry (LCMS), electrospray ionisation-mass spectrometry (ESI-MS) and melting point 
analysis. 
NMR Spectroscopy 
Analysis of the 1H NMR spectrum of compound 1 and comparison of it to the spectrum of the 
4,7-dichloroquinoline starting material confirms the synthesis of the desired azide compound 
(Figure 2.5). Although the number, multiplicity and integrations of the peaks remain the same 
for both the starting material and compound 1, noticeable shifts in certain peaks attest to the 
synthesis of the desired azide product. The most notable peak shift is the upfield shift in the 
signal for the proton at position-3 from δH 7.49 ppm to δH 7.13 ppm. The reason for this is 
because the azide has a weaker electron-withdrawing effect compared to the chloride, thus 
the proton adjacent to the azide group will be more shielded. The product of the click reaction 
































Figure 2.5: Stacked 1H NMR spectra showing the aromatic regions of (a) 4,7-dichloroquinoline, 








































1H NMR spectrum (spectrum (c) in Figure 2.5) attests to its correct synthesis. Evidence for the 
success of the click reaction is indicated, most notably, by the presence of the triazole proton 
signal, H-11, which is present as a singlet integrating for one proton at δH 8.24 ppm.  The 
doublet for H-3 on the quinoline entity of 2a is present more downfield compared to the 
starting material, 1, since the triazole has a much greater electron-withdrawing effect 
compared to the azide functionality. The final indicator for the synthesis of the desired 
7-chloroquinolinotriazole compound is the presence of the phenyl proton signals, which exist
as multiplets in their different characteristic aromatic regions. Analysis of the 1H NMR spectra
of the rest of this series of 7-chloroquinolinotriazole compounds (i.e. 2b-h) confirms that all
nine desired compounds have been synthesised. Figure 2.6 shows the 1H NMR spectra for
three other representative compounds of this series. Again, the diagnostic triazole proton
signal provides the best evidence for successful 7-chloroquinolinotriazole formation, with the
characteristic singlet present between δH 7.89 (ligand 2h) and 8.68 ppm (ligand 2g). The much
lower chemical shift of the triazole proton resonance for compound 2h compared to the rest
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Figure 2.6: Stacked 1H NMR spectra of 7-chloroquinolinotriazole ligands: (a) 2c, (b) 2e and (c) 2h in 





























































other phenyl groups, causing the triazole proton to be more shielded. In some spectra, the 
doublet signal for H-2 is broadened, however, it still integrates for one proton as expected. 
Several other characteristic signals can also be seen in the spectra for the representative 
ligands in Figure 2.6. For 2c, the expected triplets and sextet are observed in the aliphatic 
region for the propyl chain, each integrating for two protons. In the spectrum of 2e, there are 
no aliphatic signals but the proton signals for the aromatic protons, H-14 and H-15, are 
present as multiplets, as expected, due to coupling with the NMR-active fluorine atom.  Lastly, 
in the spectrum of the ferrocenyl-ligand, 2h, the characteristic signals for the ferrocenyl 
moiety are present between δH 4.16 and 4.83 ppm. In CDCl3, the large singlet at δH 4.16 ppm 
represents the 5 protons of the lower unsubstituted Cp ring, while the resonances for H-14 
and H-15 on the upper monosubstituted Cp ring are present as broadened signals, integrating 
for 2 protons each. It is surprising that these signals are not triplets as expected, however, 
when 1H NMR spectroscopy was performed with the same compound in DMSO-d6, these 
signals do indeed present as pseudotriplets. The ferrocenyl region of this 1H NMR spectrum 
can be seen in the inset picture in Figure 2.6. 
13C{1H} NMR spectroscopy was used to characterise further the 4-azido-7-chloroquinoline, 1, 
and compounds 2a-h and the resulting spectra, again, confirm the synthesis of the desired 
compounds. Signals pertaining to the triazole carbons for ligands 2a-h are present in the range 
of δC 120.75 ppm (compound 2b) to δC 129.01 ppm (compound 2h). These triazole carbon 
chemical shifts are in the expected region of ~120 ppm as described for 1,2,3-triazoles in 
literature.28  Since the 13C{1H} NMR spectra of 2d and 2e are not 19F decoupled, C–F coupling 
is seen for the carbons closest to the fluorine atoms (Figure 2.7). Coupling constants for 1JC−F, 
2JC−F and 3JC−F are observed for both compounds and were found to be 272.1 Hz, 32.7 Hz and 
3.6 Hz respectively for 2d and 248.7 Hz, 21.9 Hz and 8.2 Hz respectively for compound 2e. The 
13C{1H} NMR spectrum for compound 2d (Figure 2.7a) shows that each of these carbons which 
experience C–F coupling appear as quartets due to coupling to the three fluorine atoms of 
the CF3 group. On the other hand, for compound 2e, which only has one fluorine atom in its 
structure, the carbons which experience C–F coupling are present as doublets (Figure 2.7b). 
Compounds 2d and 2e were also analysed using 19F{1H} NMR spectroscopy, with a single 
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resonance being observed at δF –62.7 and –112.2 ppm respectively, indicating the presence 
of only one type of fluorinated compound for each. Another compound which shows coupling 
in its respective 13C{1H} NMR spectrum is the ferrocenyl compound, 2h. The carbons of the 
ferrocene moiety, both on the upper and lower Cp rings, appear as multiplets due to C-C 






Figure 2.7: 13C{1H} NMR spectra of (a) 2d and (b) 2e in CDCl3, highlighting key carbon regions which 
display C-F coupling. 
Figure 2.8: 13C{1H} NMR spectrum of the ferrocenyl carbon region of 2h, showing the multiplets as a 































Infrared (IR) Spectroscopy 
Infrared spectroscopy is a technique used to identify the various infrared-active groups of a 
molecule based on the vibrations of the atoms within these groups. The infrared spectra 
recorded for the 4-azido-7-chloroquinoline compound, 1, as well as for all the 
7-chloroquinolinotriazole compounds, 2a-h, attest to the composition of the compounds and
are in accordance with literature data. Figure 2.9 shows the overlapping IR spectra of the
starting material, 4,7-dichloroquinoline, as well as azide compound 1 and
7-chloroquinolinotriazole compound, 2a. The infrared spectra of 2a-h are all quite similar,
therefore, the spectrum of 2a serves as a representative spectrum for all nine
7-chloroquinolinotriazole compounds. This characterisation technique proved useful in
determining the successful formation of the triazole entity from the azide and alkyne starting
materials. In the infrared spectrum of 1, a strong v(N=N=N) signal for the azide functional
group, which was not present in the spectrum of 4,7-dichloroquinoline, can be seen at
2119 cm-1, indicating the desired azide compound had indeed been formed. Infrared
spectroscopy was also useful in revealing the presence or absence of the reactant, NaN3 in








Figure 2.9: Stacked IR spectra of 4,7-dichloroquinoline (green), 4-azido-7-chloroquinoline 1 (blue) and 
7-chloroquinolinotriazole compound 2a (red).
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halogenated solvents, it was imperative to ensure its complete removal before the next 
synthetic step. If NaN3 was still present, more than one azide absorption band would be visible 
in the 2120–2160 cm-1 frequency range. As seen in Figure 2.9, this was not the case since only 
one strong v(N=N=N) signal is observed. Although this azide absorption band does have a few 
shoulders, these are at lower wavenumbers and likely due to other functional group 
vibrations. In the infrared spectrum of the representative 7-chloroquinolinotriazole 
compound, 2a, the absence of the characteristic azide absorption band indicates that all the 
4-azido-7-chloroquinoline, 1, had been reacted with the alkyne to form the desired triazolic
compound.
Mass spectrometry (LCMS and ESI-MS) 
Eight of the 7-chloroquinolinotriazole compounds, 2a-g, were evaluated using LCMS, to 
ascertain both their purity and to confirm their molecular weight. The purity of all eight 
compounds was determined to be above 95%. In terms of the mass spectral data, these 
compounds were all ionised as the protonated molecular ion, [M+H]+, confirming that the 
desired compounds were synthesised. The ferrocenyl compound 2h was analysed using high 
resolution ESI-MS, yielding a peak at m/z 414.0333, corresponding to the calculated mass of 
414.0335 for the molecular ion ([M]+). 
2.3  Synthesis of a series of 7-chloro-4-aminoquinolinotriazole derivatives 
Literature has shown that the inclusion of an alkyl chain between the aminoquinoline and the 
triazole moieties of similar compounds improves the antiplasmodial activity of the compound 
as a whole.9,17 This therefore led to the synthesis of a series of 7-chloro-4-
aminoquinolinotriazole compounds containing a propyl chain linker within their scaffolds. 
2.3.1  Synthesis 
The synthesis of the 7-chloro-4-aminoquinolinotriazole compounds (6a-e) involved four 
synthetic steps, as outlined in Scheme 2.2. The first step is a nucleophilic aromatic substitution 
(SNAr) of the chloride at position 4 on 4,7-dichloroquinoline with 3-aminopropanol to form 
the alcohol precursor compound, 3. This compound was synthesised following a literature 
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method7 and the mechanism of this reaction is the same as that seen in Figure 2.3 24, with the 
3-aminopropanol being the nucleophile instead of the azide. The completion of the reaction
was determined by TLC analysis, producing a beige solid in an excellent yield of 98%.
The second step, using the same literature method, involved converting the terminal alcohol 
of 3 to a better leaving group before the introduction of the azide.7 At first, thionyl chloride 
was used as a chlorinating agent, however, this was discontinued as the use of this reagent 
resulted in very poor yields (~20%). Another literature method was used, thereafter, in which 
the alcohol group was converted to a methanesulfonate (mesylate) group using 
methanesulfonyl chloride and triethylamine.29 The formation of this mesylate precursor 
compound, 4, is believed to proceed via the mechanism shown in Figure 2.10.30 The 
methanesulfonyl chloride first undergoes an E1cB elimination (unimolecular elimination via 
the conjugate base) whereby the non-nucleophilic base, triethylamine, abstracts a proton 
from the methyl group to form a carbanion, which then generates the highly reactive sulfene 
intermediate. Attack by the alcohol on this intermediate, followed by a rapid proton transfer, 
Scheme 2.2. Synthesis of the 7-chloro-4-aminoquinolinotriazole derivatives. Reagents and conditions: 
(i) 3-Aminopropanol, 80 °C, 1 h, then 130 °C, 17 h, neat; (ii) Methanesulfonyl chloride, Et3N, THF, 0 °C
 r.t., 5 h; (iii) NaN3, DMF, 65 °C, 15 h; (iv) Aromatic alkyne, t-BuOH/H2O (1:1), CuSO4.5H2O, Na



































results in the formation of the desired mesylate product. This desired product, 4, was isolated 
as a beige solid in a moderate yield of 43%. Although this yield is lower than expected, it is 
double that of the chloride-containing product produced when following the method using 
thionyl chloride as the reagent. The reason for this is likely due to the fact that the mesylate 
is a much better leaving group than the chloride as the sulfonate ions are capable of stabilising 
the negative charge via resonance.30 
The third step involved the formation of the azide precursor compound 5 from mesylate 
compound 4 following an SN2 substitution reaction, the mechanism of which is shown in 
Figure 2.11.31 In this reaction, the nucleophilic azide group from NaN3 attacks the carbon 
adjacent to the OMs leaving group, forming a transition state in which the carbon under 
nucleophilic attack is pentacoordinate. The mesylate leaving group is then eliminated from 







































Figure 2.10: Proposed mechanism for the conversion of an alcohol (3) to a mesylate (4).30 
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compound, 5. The reaction conditions for this reaction were the same as those in the 
synthesis of 1, producing the azide intermediate 5 as a fluffy, white powder in a moderate 
yield of 45%. 
The final step in the synthesis of the 7-chloro-4-aminoquinolinotriazole compounds, 6a-e, was 
the reaction of the azide precursor, 5, with five different aromatic alkynes following the 
copper-catalysed “click” reaction. These particular alkynes were chosen based on the good 
antiplasmodial activities (vide infra, chapter 4, section 4.2) of the 7-chloroquinolinotriazole 
Ir(III) complexes containing these R-groups.  The catalytic mechanism follows the same CuAAC 
cycle as that seen for the 7-chloroquinolinotriazole compounds, 2a-h (Figure 2.4).27 The yields 
for these five 7-chloro-4-aminoquinolinotriazole compounds, 6a-e, were moderate, ranging 
between 55% (6d) and 70% (6e). All compounds are also stable at room temperature and 
when exposed to air. 
2.3.2  Characterisation 
All of the precursor compounds, 3-5, and 7-chloro-4-aminoquinolinotriazole compounds,  
6a-e, were characterised by various spectroscopic and analytical techniques. These included 
1H, 13C{1H}, 19F{1H} (compound 6c), 1H-1H correlation spectroscopy (COSY) and heteronuclear 



















Figure 2.11: Proposed mechanism for the SN2 reaction to form compound 5.31 
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as infrared (IR) spectroscopy, liquid chromatography coupled with mass spectrometry (LCMS), 
electrospray ionisation–mass spectrometry (ESI-MS) and melting point analysis. 
NMR Spectroscopy 
The NMR spectra were recorded in DMSO-d6 for all the precursor compounds, 3-5, and   
7-chloro-4-aminoquinolinotriazole compounds, 6a-e. Figure 2.12 shows the 1H NMR spectra
of the precursor compounds 3-5 and analysis of these spectra confirmed the synthesis of the
proposed compounds. In all three spectra, the aromatic regions are almost identical as the
functional group conversions have occurred at the terminal end of the propyl chain a distance
away from the quinoline ring-system. These functional group conversions, going from alcohol
to mesylate and finally to azide, can be observed using 1H NMR spectroscopy. Starting with
the spectrum of the alcohol precursor compound, 3 (Figure 2.12a), the substitution of the

















































































was confirmed by the presence of several diagnostic signals. These signals include the three 
distinct resonances of the aliphatic propyl protons (H-12, H-13 and H-14), the triplet for the 
secondary amine proton (H-11) and the proton of the alcohol group (H-15). It is this alcohol 
proton, which is present as a broad signal at δH 4.57 ppm, that is absent in the spectrum of 
the subsequent compound, 4, since the alcohol is converted to a mesylate. The spectrum of 
4 (Figure 2.12b) instead shows a singlet integrating for 3 protons at δH 3.18 ppm 
corresponding to the methyl group on the mesylate, thereby confirming the successful 
substitution by the methanesulfonyl entity. Since this mesylate is more electron-withdrawing 
than the previous alcohol group, the triplet corresponding to the adjacent protons on the 
propyl chain (i.e. H-14 on Figure 2.12b) is shifted more downfield compared to the same signal 
in the spectrum of 3. In converting the mesylate to the subsequent azide compound, 5, the 
methyl protons from the previous mesylate group are now absent in the   1H NMR spectrum 
of 5 (Figure 2.12c). The same propyl proton signal, H-14, which had shifted downfield 
previously is now present upfield again as the azide functionality is less electron-withdrawing 
than the methanesulfonate group.  
The reaction of the azide intermediate, 5, with five different aromatic alkynes produced five 
7-chloro-4-aminoquinolinotriazole compounds, 6a-e, the structures of which can be
confirmed from their respective 1H NMR spectra. Figure 2.13 shows the 1H NMR spectra for
three representative compounds of this series. In all three spectra, the triazole proton signal
(found between δH 8.20 – 8.67 ppm) is the first indicator of successful triazole formation from
the preceding azide compound. In the 1H NMR spectrum of the compound bearing the
unsubstituted phenyl group, 6a (Figure 2.13a), additional aromatic signals corresponding to
the protons of the new phenyl group also testify to the correct synthesis of the desired
compound. This is likewise true in the spectrum of the fluorophenyl-containing compound,
6c, which shows two distinct signals for the aromatic protons (H-18 and H-19 in Figure 2.13b).
These signals, however, are present as multiplets due to the coupling of the aromatic protons
to the NMR-active fluorine atom. This coupling is confirmed by the presence of doublets for
carbons neighbouring the fluoride in the respective 13C{1H} NMR spectrum and the
19F{1H} NMR spectrum shows the presence of only one singlet at –114.24 ppm. The signal for
H-12 is completely hidden under the water signal of the 1H NMR spectrum for compound 6c
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and this is confirmed by the cross peak observed at this chemical shift using 2D NMR 
spectroscopic methods such as HSQC and COSY. Figure 2.13c shows the 1H NMR spectrum for 
the ferrocenyl-containing 7-chloro-4-aminoquinolinotriazole compound, 6e. As with the   
7-chloroquinolinotriazole ferrocenyl compound 2h, the triazole proton resonance of 6e is
present more upfield compared to that of the other ligands of this series since the ferrocene
is less electron-withdrawing than the phenyl substituents. The protons of the ferrocene are
observed as triplets at δH 4.30 and 4.70 ppm for the upper monosubstituted Cp ring and as a
large singlet at δH 4.03 for the five protons of the lower unsubstituted Cp ring. The successful
synthesis of the desired compounds of this series was further corroborated using 13C{1H} NMR
















































Figure 2.13. Stacked 1H NMR spectra of the representative 7-chloro-4-aminoquinolinotriazole 



































































Infrared (IR) Spectroscopy 
Further evidence for the synthesis of the desired precursor compounds, 3-5, and 7-chloro-4-
aminoquinolinotriazole compounds, 6a-e, was provided using infrared spectroscopy. The 
presence of the broad v(O-H) signal for the alcohol group of 3, the subsequent absence of this 
alcohol absorbance band for 4 and the presence of the azide v(N=N=N) absorbance band for 
5 were all within the expected spectral regions, providing further evidence for the correct 
functional group conversions for these compounds (Figure 2.14). The infrared spectra of the 
7-chloro-4-aminoquinolinotriazole compounds, 6a-e, look very similar to those of the
7-chloroquinolinotriazole compounds, 2a-h. The only noticeable difference in the spectra of
6a-h is the presence of the secondary amine v(N-H) signal, visible in the expected between
3296 and 3337 cm-1.
Mass spectrometry (LCMS and ESI-MS) 
The percentage purity of the series of 7-chloro-4-aminoquinolinotriazole compounds, 6a-e,  
was evaluated using liquid chromatography coupled with mass spectrometry and all were 
determined to be greater than 98% pure. The mass spectra of 6a-e show that all five 








compounds were all ionised as the protonated molecular ion, [M+H]+, confirming that the 
desired compounds were synthesised. The ferrocenyl compound 6e was analysed using high 
resolution ESI-MS, yielding a base peak at m/z 472.0997, corresponding to the calculated 
mass of 472.0986 for the molecular ion ([M]+). 
2.4  Summary 
A series of 7-chloroquinolinotriazole compounds (2a-h), with the direct attachment of the 
triazole entity onto the quinoline system, was successfully synthesised and isolated in 
moderate to good yields. A second, smaller, series of 7-chloro-4-aminoquinolinotriazole 
compounds (6a-e), each bearing a propyl chain linker between the triazole and quinoline 
entities, was subsequently synthesised. Click chemistry was used to synthesise both series of 
compounds and was proven to be a quick and easy way to synthesise triazole compounds in 
relatively good yields. Both series of compounds were fully characterised using various 
spectroscopic and analytical techniques and all compounds were stable at room temperature. 
1H, 13C{1H}, 19F{1H} NMR spectroscopy, infrared spectroscopy, LCMS and mass spectrometry 
were predominantly used to elucidate the structures of the products correctly. 2D NMR 
experiments, such as COSY and HSQC, were used to assign proton and carbon resonances and 
correlations correctly for all the triazole compounds (2a-h and 6a-e).  
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Chapter 3 
Synthesis and characterisation of neutral cyclometallated and cationic 
N,N-chelated Ir(III) half-sandwich complexes based on        
7-chloroquinoline-1,2,3-triazole ligands
3.1 Introduction 
The success of metal-containing compounds in cancer treatment, namely cisplatin and its 
analogues1, sparked a prolific increase in interest towards the use of metal complexes in 
medicinal chemistry. Over the past decade, the burgeoning field of bioorganometallic 
chemistry has provided effective and promising therapeutic alternatives to purely organic 
drugs.2–5 It has been well established that the incorporation of a metal onto the scaffold of a 
particular pharmacophore significantly enhances its biological activity through the unique 
chemical versatility provided by the metal complex as a whole.6–8 In this regard, great success 
has been achieved in the synthesis of organometallic antimalarial agents, with particular focus 
being given to the modification of the chloroquine pharmacophore by the incorporation of a 
metal moiety.9–11 This is exemplified by the organometallic compound ferroquine, the 
ferrocenyl analogue of chloroquine.12,13 In combination with its impressive antimalarial 
activity, its marked ability to overcome chloroquine-resistance has resulted in the further 
testing of this compound in clinical trials, along with the trioxolane, artefenomel.13–15  
While the inclusion of the ferrocene moiety into the lateral side chain of the drug chloroquine 
proved an effective method of improving antimalarial drug activity, there is a myriad of other 
ways in which a similar result may be achieved. Other drug design approaches include the use 
of Platinum Group Metals (PGMs), while generally avoiding the use of platinum itself due to 
its high toxicity and negative side-effects.2,16 Complexes incorporating ruthenium, rhodium, 
osmium, palladium and iridium are particularly attractive as they have similar activity to 
platinum-based complexes while being safer and more biofriendly.17 Using these transition 
metals, a number of coordination complexes of the quinoline moiety have been synthesised, 
examples of which are shown in Figure 3.1.11,18,19 Li et al. synthesised a series of ruthenium 
54 
and rhodium half-sandwich aminoquinoline complexes, all of which contained an 
organosilane moiety in their lateral side chain (Figure 3.1, 3.1-3.6).18 When tested against the 
chloroquine-sensitive (CQS) NF54 and chloroquine-resistant (CQR) Dd2 strains of 
P. falciparum, all the complexes were found to have IC50 values in the nanomolar range, with
selected complexes even displaying an antiplasmodial activity of less than 100 nM. In
derivatising the aminoquinoline with a salicylaldimine moiety, Ekengard et al. was able to
create ligands with multiple possible sites of metal-coordination.11 Their N,O-chelating
salicylaldimine ruthenium and osmium complexes (Figure 3.1, 3.7-3.19) displayed good
antiplasmodial activity in the nanomolar range (IC50 < 0.73 µM) when tested against the CQS
strain, NF54.11 Similar good activity in the same P. falciparum strain was observed with the
N,O-chelating salicylaldimine iridium and rhodium complexes synthesised by Stringer et al.19
(Figure 3.1, 3.20-3.21). Unfortunately, both series of aminoquinoline salicylaldimine
complexes displayed cross-resistance in the CQR strain, indicated by the loss in antiplasmodial
activity at the tested concentrations.11,19
For many years, a popular method of metal coordination to an organic scaffold has been via 
cyclometallation – the formation of a new metal-carbon σ bond in the form of a 
metallacycle.20 A number of biologically active cyclometallated complexes have been 
synthesised, with their activity likely enhanced by the strong M-C bond formed, which may 
prevent biological reduction and ligand exchange reactions.21–23 To date, not much research 
has been done into the use of cyclometallated complexes as antiplasmodial agents. 
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Cyclometallation, however, may provide a beneficial stabilising effect on the metal complex 
within the malaria parasite. Rylands et al. showed this to be the case with their recent 
investigation into the antiplasmodial activity of cyclometallated ruthenium(II), rhodium(III) 
and iridium(III) half-sandwich complexes of 2-phenylbenzimidazoles (Figure 3.2).24 
Antiplasmodial activity assays revealed the cyclometallated complexes to have superior 
activity in comparison to their respective organic ligands against both sensitive and resistant 
parasite strains, with IC50 values in the low to sub-micromolar range (0.12-5.17 mM).24  
In this chapter, the synthesis and characterisation of novel neutral, cyclometallated and 
cationic, N,N-chelated half-sandwich Ir(III) complexes of 7-chloroquinoline-1,2,3-triazoles is 
described. This follows the well-documented concept of incorporating a metal into the 
scaffold of a known pharmacophore in the hope of improving its biological activity, 
particularly in parasite resistant strains.9–11 Iridium was selected as the metal of choice for 
these complexes because, in addition to its efficacy, it is generally regarded as safe and 
biofriendly. The negatively charged pentamethylcyclopentadienyl (Cp*) ligand was chosen as 
a good stabilising ligand for Ir(III).25 A variety of spectroscopic and analytical techniques were 
used to elucidate and confirm the structures of the proposed complexes. 
Figure 3.2. Ru(II), Rh(III) and Ir(III) cyclometallated complexes of 2-phenylbenzimidazoles synthesised 










M = Ir, Rh
R = H, Cl, CH3, CF3
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3.2  Synthesis and characterisation of half-sandwich Ir(III) complexes based on 
the series of 7-chloroquinolinotriazole ligands 
3. 2.1 Synthesis
3.2.1.1 Synthesis of the neutral 7-chloroquinolinotriazole Ir(III) complexes 
The synthesis of the neutral cyclometallated iridium pentamethylcyclopentadienyl (Cp*)   
7-chloroquinolinotriazole complexes (7a-f) was achieved via sodium acetate-mediated C-H
activation (Scheme 3.1).
Although complexes 7a-f are new, their synthesis was conducted following a modified 
literature method.26 This literature method was used because it involved a similar triazole-
phenyl system for cyclometallation via C-H activation. The synthesis required dissolving the 
respective 7-chloroquinolinotriazole ligand (2a-f), 2 equivalents of NaOAC and 0.7 equivalents 
Scheme 3.1. Synthesis of the neutral cyclometallated Ir(III) 7-chloroquinolinotriazole complexes 
(7a-f). Reagents and conditions: (i) [IrCp*(μ-Cl)Cl]2 (0.7 eq.), NaOAc (2 eq.), ACN, 65 °C (72 h), r.t.    


























of the pentamethylcyclopentadienyliridium(III) dimer in dry acetonitrile. This reaction mixture 
was then heated to 65 °C for 72 h, after which it was stirred for another 72 h at room 
temperature, allowing the respective complex (7a-f) to precipitate as a yellow solid. The 
pentamethylcyclopentadienyliridium(III) dimer was synthesised previously and used without 
further purification.27 The dimer was used in slight excess (0.7 equivalents instead of 0.5 
equivalents) because this encouraged more of the ligand to react to form the respective 
complex, thereby, slightly improving the complex yields overall. This excess dimer remained 
in solution when the complex precipitate was removed via vacuum filtration. The synthesis of 
the neutral Ir(III) 7-chloroquinolinotriazole complexes (7a-f) was generally sluggish, taking 6 
days to react and resulting in only the partial consumption of the ligands, as determined via 
TLC analysis. It is for this reason that the yields for the cyclometallated Ir(III) complexes were 
inconsistent, with the highest being 85% (7c) and the lowest being 10% (7f). 
The synthesis of cyclometallated complexes is generally achieved via intramolecular C-H 
activation in the presence of a suitable base, such as NaOAc. Although the exact mechanism 
of this process and the role of the acetate has not yet been determined, several key 
intermediates have been identified through theoretical and experimental studies conducted 
by Davies and co-workers (Figure 3.3).28–30 Based on their proposed mechanism for the 
cyclometallation of amines, imines and oxazolines using various metal dimers28, the 
suggested mechanism for the synthesis of the cyclometallated Ir(III) 7-chloroquinolinotriazole 
complexes (7a-f) is shown in Figure 3.3. Studies show that one of the possible roles of the 
acetate is to promote the cyclometallation of the ligand with [IrCp*(μ-Cl)Cl]2 by helping to 
facilitate the break-up of the dimer and the exchange of one of the chloride ligands.28 This 
can occur either before or after the ligand associates, as seen by intermediates I and II on the 
way to form intermediate III in Figure 3.3. Next, for C-H activation to occur, a vacant site is 
needed and, thus, the loss of an anion from intermediate III is necessary. It had previously 
been suggested that C-H activation may occur through one of two possible mechanisms, the 
first being via oxidative addition of the aryl C-H bond, followed by reductive elimination, as 
depicted by intermediate IV1 in Figure 3.3.28 The alternative route would be by the 
electrophilic attack of the metal on the arene, via the Wheland intermediate IV2, followed by 
the loss of a proton.28  
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In order to gain better insight into the structure of the transition state in these 
cyclometallation reactions, Davies et al. conducted a different study in which computational 
methods were used to investigate the cyclometallation of dimethylbenzylamine with 
[Pd(OAc)2].29 Through density functional theory (DFT) calculations, their results suggested the 
existence of a six-membered transition state through which an acetate-assisted hydrogen-
transfer process occurs.29 This was found to be the most accessible route towards the 
formation of the final cyclometallate, however, it was discovered to proceed via an agostic 
C-H intermediate complex rather than the previously-suggested Wheland intermediate.28,29
In this process, the acetate plays a key role in acting as an intramolecular base for
deprotonation, as well as possibly stabilising the agostic intermediate through hydrogen
bonding. Based on this literature, a proposed transition state for the cyclometallated
complexes in this chapter is illustrated in Figure 3.4. The reason why the proton-transfer via
a six-membered transition state is more accessible than a previously-suggested four-
membered transition state is because it allows the acetate to be orientated in a manner
appropriate for it to act as an intramolecular base.29 This allows deprotonation to occur with
minimal distortion to the system, meaning that the reaction pathway can proceed via a low-
























































energy transition state, as suggested by Davies et al. in a further study using {Cp*Ir} 
complexes.30 It also means that C-H activation is able to occur at the ortho-position on the 
arene, as the pendant acetate arm is in close proximity to the ortho-proton, thereby putting 
it in a position to facilitate the proton-transfer. 
Since the discovery made by the Davies group in 2003 that harsh reaction conditions and a 
strong base are not needed to activate the C-H bond, cyclometallation reactions under mild 
reaction conditions have become increasingly popular.28 Their reported method was one of 
the first for the cyclometallation of nitrogen donor ligands using metals such as Ir, Rh and Ru, 
with the C-H activation reaction occurring at room temperature and promoted by the mild 
base, sodium acetate.28 It was, therefore, surprising when the synthesis of the 
cyclometallated Ir(III) complexes described in this chapter did not follow the mild conditions 
prescribed for reactions of this kind. Instead, these complexes were only able to be 
synthesised when heated in acetonitrile at over 65 °C and when the reactants were stirred 
together for almost a week. It was discovered that, when attempting this reaction at room 
temperature, a bright yellow precipitate was formed about one minute after adding the 
solvent to the reactants. Upon isolation and characterisation of this yellow precipitate, it was 
determined that the metal was not coordinated to the third nitrogen of the triazole as 
desired, but rather coordinated to the more basic quinoline nitrogen in a monodentate 












Figure 3.4. Proposed 6-membered transition state of the C-H activation mechanism, resulting in the 
formation of the cyclometallated complexes (7a-f).29 
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the monodentate complex was formed first in the synthesis of all six cyclometallated 
complexes (7a-f), however, only the monodentate complex 8, synthesised using ligand 2a, 
was properly isolated and fully characterised. It was also discovered that, upon heating the 
monodentate complexes in acetonitrile to a temperature of 65 °C and above, the bright 
yellow precipitate gradually went back into solution over a period of three days and, when 
cooled, another yellow precipitate formed. This precipitate was that of the desired 
cyclometallated Ir(III) complexes, 7a-f, in each case. This observation gave rise to the idea that 
kinetic versus thermodynamic control could be taking place in this reaction, with the 
monodentate complex being the fastest-formed kinetic product while more energy is 
required to form the cyclometallated, thermodynamic product.  
3.2.1.2  Computational studies of the kinetic vs thermodynamic outcome of the C-H activation 
reaction with ligand 2a 
Various computational simulations were performed to investigate this hypothesis. Two 
methods were used, namely optimisation to find a stationary point and a relaxed geometry 
scan to scan the Ir-N bond length. The ORCA software (v 4.1.1)31 was used and dispersion-
corrected DFT was chosen as the level of theory32, specifically the BLYP-D3 method with def2-

















Scheme 3.2. Synthesis of the neutral monodentate Ir(III) 7-chloroquinolinotriazole complex, 8. 
Reagents and conditions: (i) [IrCp*(μ-Cl)Cl]2 (0.7 eq.), NaOAc (2 eq.), ACN, r.t., ~ 1 min.  
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frequencies and molecular orbitals were calculated, and scans were carried out with the same 
level of theory. The labelled pathway for these studies is shown in Figure 3.5, detailing the 
reaction process from the iridium metal dimer, I, through the plausible intermediates and 
















































Figure 3.5. Labelled pathway for the reaction process from the Ir Cp* dimer to the final complexes. 
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Firstly, an optimisation of the cations of IIIa and IIIb, the plausible intermediates on the way 
to the final compounds, was carried out. The energy calculated for these molecules can be 
directly compared as these molecules contain the same atoms but in a different arrangement. 
A chloride anion is removed at this stage to provide a vacant site for potential 
cyclometallation. The results of this study found that intermediate IIIb, with the Ir 
coordinated to the triazole nitrogen, is lower in energy than the quinoline-coordinated-Ir 
intermediate IIIa by 4 x 10-4 hartrees or 2 kcal/mol. While a small change, this shows that 
intermediate IIIb is already more stable than intermediate IIIa. 
The reaction to form product IV or V from intermediate II and the ligand, L, was then 
investigated. The energy barrier between the reactants and the products is estimated by 
creating a neutral complex of II with the ligand, as shown in Figure 3.6. A scan is carried out 
where the Ir-N bond is then pulled from a short bond length to several Angström away. This 
process, although modelled as the inverse of the ligand binding, represents how the ligand 
binds to II. A small energy barrier which can be overcome at standard state temperature 
(25 °C) would be considered to lead to a kinetic product, while a larger energy barrier which 
leads to a lower energy product would be considered the thermodynamic route. Figure 3.6 
shows the outcome of the two simulations performed, one with the ligand bound to the metal 
at the quinoline nitrogen and one with the ligand binding at the triazole nitrogen. Figure 3.6a 
shows the energy diagram for the former, illustrating that the outcome for the coordination 
of the metal to the quinoline nitrogen is a small energy barrier. When the distance between 
the Ir and quinoline nitrogen is 6.0 Å, the resulting complex structure is relatively low in 
energy. As the distance thereafter decreases, the energy increases until it eventually reaches 
an energy barrier of over 5.4 kcal/mol. At this energy, the bond forms, resulting in a higher 
energy complex. This energy barrier can be overcome at standard state temperature, which 
explains why the monodentate complex 8 formed relatively quickly at room temperature and 
suggests a kinetic product. The outcome for the latter, the coordination of the metal to the 
triazole nitrogen, is shown in the energy diagram in Figure 3.6b. In this case, the energy barrier 
for the formation of the Ir-N bond is very high, with no minimum observed thus far. When 
the distance between the Ir and triazole nitrogen is 5.2 Å, the resulting complex structure is 
low in energy, however, as the distance decreases, the energy increases until it eventually 
reaches an energy barrier of nearly 12 kcal/mol. The higher predicted energy required to form 
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the cyclometallated complex 7a explains the need for the high temperature required to 
synthesise this product. These calculations support the hypothesis that the complex 7a is a 













~ 5 kcal/mol 







Figure 3.6. Energy diagrams of the two outcomes of metal coordination to the ligand at either 
(a) the quinoline nitrogen or (b) the triazole nitrogen.
Reaction Coordinate (Å) 


























3.2.1.3  Synthesis of the cationic 7-chloroquinolinotriazole Ir(III) complex 
The synthesis of the cationic N,N-chelated half-sandwich iridium(III) 7-chloroquinolinotriazole 
complex (7g) was achieved via a bridge-splitting reaction of the iridium dimer and 
coordination of the ligand 2g, as shown in Scheme 3.3. In this entropically-driven reaction, 
the ligand coordinates to the metal via the triazole and pyridyl nitrogen atoms, forming a 
stable five-membered ring. A salt metathesis using hexafluorophosphate was then carried out 
to replace the chloride counterion and to allow for the precipitation of the cationic complex 
from the solution.  
The cationic N,N-chelated half-sandwich iridium(III) 7-chloroquinolinotriazole complex (7g) 
was isolated as a pale yellow powder in a good yield of 79%. It is soluble in a wide range of 
solvents and sparingly soluble in water.  
3.2.2 Characterisation 
The neutral cyclometallated Ir(III) complexes (7a-f), neutral monodentate Ir(III) complex (8) 
and cationic Ir(III) complex (7g) were characterised using various spectroscopic and analytical 
techniques. These included 1H, 13C{1H}, 19F{1H} (compounds 7d and 7e), 31P{1H} (compound 
7g), 1H-1H correlation spectroscopy (COSY) and heteronuclear single quantum coherence 
(HSQC) nuclear magnetic resonance (NMR) spectroscopy, as well as infrared (IR) 
spectroscopy, electrospray ionisation mass spectrometry (ESI-MS), single-crystal X-ray 


















Scheme 3.3. Synthesis of the N,N-chelated Ir(III) 7-chloroquinolinotriazole cationic complex (7g). 
Reagents and conditions: (i) [IrCp*(μ-Cl)Cl]2 (0.5 eq.), NH4PF6 (4 eq.) DCM/EtOH, r.t., 22 h. 
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3.2.2.1 Characterisation of the neutral 7-chloroquinolinotriazole Ir(III) complexes 
NMR Spectroscopy 
Analysis of the 1H NMR spectra of the neutral cyclometallated iridium 
pentamethylcyclopentadienyl 7-chloroquinolinotriazole complexes (7a-f) confirmed the 
successful coordination of the respective ligands to the metal centre. Figure 3.7 shows the 1H 
NMR spectra of cyclometallated complex 7a and monodentate complex 8, as well as the 
spectrum of their respective ligand, 2a. In spectrum (b) in Figure 3.7, evidence for 
coordination to the metal is first provided by the presence of a singlet at 1.81 ppm, which 
integrates for 15 protons and corresponds to the protons on the Cp* ligand. Further evidence 
is the absence of a proton signal at the ipso-carbon of C-H activation relative to the 1H NMR 
spectrum of the respective ligand starting material (Figure 3.7a). It can additionally be seen 










































































































Figure 3.7. Stacked 1H NMR spectra of (a) 7-chloroquinolinotriazole ligand, 2a, (b) neutral 
cyclometallated Ir(III) 7-chloroquinolinotriazole complex, 7a, and (c) neutral monodentate Ir(III)   
7-chloroquinolinotriazole complex, 8, in CDCl3.
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ligand, these proton signals become distinct triplets-of-doublets upon metal coordination. 
These two triplets-of-doublets are visible in the inset section of the respective spectrum in 
Figure 3.7b. This occurrence is likely due to the effect of cyclometallation, which “locks” the 
phenyl ring in place thereby preventing its free rotation and causes protons 15 and 16 to 
resonate in different environments. This is in contrast to the spectrum of the monodentate 
Ir(III) complex, 8, which is shown in Figure 3.7c. The spectrum of this complex is almost 
identical to that of the ligand, however, the presence of a singlet at 1.58 ppm, which 
integrates for 15 protons corresponding to the Cp* ligand is evidence for metal coordination. 
In addition to this, the downfield shift and broadening of proton signals 2 and 8 indicates that 
metal coordination is most likely to the quinoline nitrogen as these are the protons which are 
closest to the site of coordination. The broadening of these signals is possibly due to long-
range coupling to the Cp* moiety, which is in the vicinity of the protons in question. 
Figure 3.8 shows two more representative 1H NMR spectra of complexes 7c and 7e in the 
series of neutral cyclometallated Ir(III) 7-chloroquinolinotriazole complexes. As with the 





































Figure 3.8. Stacked 1H NMR spectra of neutral cyclometallated Ir(III) 7-chloroquinolinotriazole 




















































assigned to the Cp* ligand in 7c and 7e. Furthermore, the absence of one aromatic proton 
relative to the 7-chloroquinolinotriazole starting material also supports cyclometallation via 
C-H activation. In the spectrum of complex 7c (Figure 3.8a), two distinct multiplets are
observed at 2.48 and 2.59 ppm. These two multiplets correspond to the methylene protons
closest to the phenyl ring and HSQC spectroscopy further confirms that the two proton signals
are assigned to one carbon peak. The change from a triplet before complexation to two
distinct signals is a result of the chirality induced by the stereogenic metal centre, causing
these protons to become diastereotopic and thus non-equivalent. Additionally, coordination
of the ligand to the metal for complex 7e was further confirmed by the presence of the signal
for proton 15 integrating for one proton in its respective 1H NMR spectrum. The same
resonance in the 1H NMR spectrum of the ligand integrated for two protons, because of the
symmetry of the 1,4-disubstituted phenyl ring. This symmetry is, however, removed upon
cyclometallation and the signal exists as a multiplet, visible in the enlarged section of
spectrum (b) in Figure 3.8, due to coupling of the proton to the NMR-active fluorine atom.
13C{1H} NMR spectroscopy was also used to confirm that complexation had been successful. 
The two carbon resonances for the quaternary and methyl carbons of the 
pentamethylcyclopentadienyl (Cp*) ligand are observed at around 9.2 and 89 ppm 
respectively. 2D NMR techniques such as HSQC and COSY, were used to confirm the carbon 
assignments made. Compounds 7d and 7e were also analysed using 19F{1H} NMR 
spectroscopy, with a single resonance being observed at δF –62.13 and –112.2 ppm 
respectively, indicating the presence of only one type of fluorinated compound for each. 
Infrared Spectroscopy 
The infrared spectra of the cyclometallated complexes 7a-f are almost identical to those of 
their respective ligands, displaying analogous absorbance bands at similar wavenumbers. The 
IR spectrum of cyclometallated complex 7a and its corresponding ligand 2a can be seen in 
Figure 3.9. In these two spectra, the quinoline v(C=N) absorption band is present at 
1560 cm-1, slightly lower than the expected region for the C=N functional group due to the 
electron-withdrawing effect of the highly conjugated quinoline-triazole-phenyl system. In the 
IR spectrum of monodentate complex 8 (Figure 3.9), the v(C=N)quinoline absorption band has 
shifted to a higher wavenumber of 1593 cm-1. This shift to a higher wavenumber corroborates 
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the downfield shift of the aromatic quinoline C=N proton signal in the respective 1H NMR 
spectrum (Figure 3.7c). This is due to a significant degree of π-electron donation from the 
lone-pair of electrons on the quinoline nitrogen atom of the ligand to the vacant d-orbitals on 
the metal centre. Absorbance band shifts of this kind have been reported for similar 
complexes in literature.18,33 
High Resolution Mass Spectrometry 
High resolution electrospray Ionisation mass spectrometry (ESI-MS) was used to further 
confirm the structural integrity of the neutral Ir(III) 7-chloroquinolinotriazole complexes 7a-f 
and 8. In general, the mass spectrum of the complexes recorded in DCM show base peaks 
which correspond to the molecular ion with the loss of a chloride ion, [M-Cl]+. On the other 
hand, those complexes in which the mass spectra were recorded in DMSO yielded 
[M-Cl+DMSO]+ fragments corresponding to the molecular ion which has had the chloride ion 









Figure 3.9. Stacked IR spectra of ligand 2a and neutral Ir(III) complexes 7a and 8. The shift of the 
quinoline v(C=N) absorption band is highlighted. 
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Single Crystal X-Ray Diffraction (XRD) 
The molecular structures of the Ir(III) cyclometallated complex 7a and the Ir(III) monodentate 
complex 8 were elucidated by single crystal X-ray diffraction (Figure 3.10). Single crystals of 
complexes 7a and 8 were grown by the slow diffusion of diethyl ether into a concentrated 
dichloromethane solution.  
From the ORTEP diagrams of complexes 7a and 8, it can be seen that both Ir(III) complexes 
adopt the well-documented “three-legged piano-stool” structure where the 
pentamethylcyclopentadienyl (Cp*) ligand forms the seat of the piano-stool while the three 
“legs” are formed from the chloride and 7-chloroquinolinotriazole chelating ligand (complex 
7a), or two chlorides and the monodentate 7-chloroquinolinotriazole ligand (complex 8). The 
piano-stool structure is also commonly observed in many other iridium, rhodium and 
ruthenium half-sandwich complexes reported in literature.24,25,34 Table 3.1 summarises the 
crystal data and refinement parameters for both complexes. Complex 7a crystallizes in a P21/c 
space group with a monoclinic system while complex 8 crystallises in a Pbca space group with 
an orthorhombic system. A total of 4 and 8 molecules per unit cell were observed for 
complexes 7a and 8 respectively. Selected bond distances and angles for both complexes are 
listed in Table 3.2. This data suggests that the geometry around the metal centre is pseudo-
tetrahedral as the bond angles around the metal centre range between 77.58 and 88.39° for  
Figure 3.10. X-ray crystallographic ORTEP diagrams of neutral Ir(III) Cp* 7-chloroquinolinotriazole 
complexes a) 7a (cyclometallate) and b) 8 (monodentate), where thermal ellipsoids are drawn at 40% 
and 50% probability level respectively. 
 (a) (b) 
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both complexes. These angles are too low for both a tetrahedral (109.5°) or square planar 
(90.0°) geometry. For complex 7a, the new 5-membered ring formed by cyclometallation is 
not entirely planar as expected with a torsion angle of 4.6°, while the quinoline moiety and 
the triazole-phenyl ring system of this complex are also not co-planar, with a torsion angle of 
32.5°. In the case of the monodentate complex, 8, the quinoline moiety and the triazole-
Complex 7a Complex 8 
Chemical formula C27H25Cl2IrN4 C27H26Cl3IrN4 
Formula weight 668.63 705.09 
Crystal system monoclinic orthorhombic 
Space group P21/c (No. 14) Pbca (No. 61) 




α, β, γ (°) 90, 97.192(3), 90 - 
V (Å3) 2455.1(5) 5126.9(5) 
Z 4 8 
D (g.cm-3) 1.809 1.827 
µ (mm-1) 5.680 5.546 
F (000) 1304 2752 
Crystal size (mm) 0.03 x 0.07 x 0.09 0.07 x 0.08 x 0.09 
T (K) 173 173 
Scan range (°) 1.7 < θ < 28.4 1.4 < θ < 28.4 
Unique reflections 6162 6441 




R indices (all data) R 0.0314, wR2 0.0682, S 1.01 R 0.0266, wR2 0.0546, S 1.01 
Goodness-of-fit 1.01 1.01 
Max, Min Δρ (e Å-3) -1.14, 0.70 -0.63, 0.51
Table 3.1. Crystallographic data and refinement parameters for complexes 7a and 8. 
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phenyl ring system are similarly not co-planar, but rotated 47.8° from each other. Also, 
without the rigidity afforded by cyclometallation, the torsion angle between the triazole and 
phenyl rings is 22.8°, much larger than the 4.6° for the same angle of the cyclometallated 
complex.  
 
3.2.2.2 Characterisation of the cationic 7-chloroquinolinotriazole Ir(III) complex 
NMR Spectroscopy 
Analysis of the 1H NMR spectrum of the cationic N,N-coordinated Ir(III) complex, 7g, 
confirmed the coordination of the metal to the respective ligand, 2g. Figure 3.11 shows the 
1H NMR spectrum of the cationic Ir(III) complex 7g and that of its respective organic ligand, 
2g. The first indicator of successful metal-coordination is provided by the presence of a singlet 
at 1.76 ppm, which integrates for 15 protons and corresponds to the protons of the Cp* 
ligand. Further evidence is the general downfield shift in all the aromatic signals of complex 
   Complex 7a  Complex 8 
Bond lengths (Å) 
Ir1-N1 2.071(3) Ir1-N1 2.159(3) 
Ir1-Cl1 2.3986(12) Ir1-Cl1 2.4167(12) 
Ir1-C1 2.062(4) Ir1-Cl2 2.3952(9) 
Ir1-C21 2.166(4) Ir1-C18 2.154(4) 
Ir1-C22 2.153(4) Ir1-C19 2.177(4) 
Ir1-C23 2.242(4) Ir1-C20 2.156(3) 
Ir1-C24 2.242(4) Ir1-C21 2.133(4) 
Ir1-C25 2.149(4) Ir1-C22 2.156(4) 
Bond angles (°) 
Cl1-Ir1-N1 88.39(9) Cl1-Ir1-N1 87.76(8) 
N1-Ir1-C1 77.58(14) Cl2-Ir1-N1 87.29(9) 
Cl1-Ir1-C1 85.84(11) Cl1-Ir1-Cl2 85.34(3) 
Torsion angles (°) 
N1-C7-C6-C1 4.6(5) N4-C11-C12-C13 47.8(5) 
C17-C9-N3-N2 -32.2(5) N4-N2-C5-C9 22.8(6) 
Table 3.2: Selected bond lengths and angles for Ir(III) complexes 7a and 8. 
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7g compared to the same signals of the free ligand, 2g. This downfield shift in the aromatic 
protons of the complex, particularly for protons 17 and 11, is expected for cationic complexes 
and is likely as a result of the metal centre being electron-deficient. This, again, confirms that 
the metal has coordinated to the triazole and pyridyl nitrogen atoms.  
13C{1H} NMR spectroscopy was also used to confirm that coordination of the Ir(III) 
functionality had been successful. The two carbon resonances for the quaternary and methyl 
carbons of the pentamethylcyclopentadienyl (Cp*) ligand are present at around 8.3 and 89 
ppm. 2D NMR techniques such as HSQC and COSY, were used to confirm the carbon 
assignments. The presence of the PF6-anion was confirmed using 31P{1H} NMR spectroscopy, 
which resulted in a septet at -144.17 ppm (J = 711.2 Hz). This also confirmed that only one 











































































Figure 3.11. Stacked 1H NMR spectra of (a) 7-chloroquinolinotriazole ligand, 2g and (b) cationic 





In addition to NMR spectroscopy, infrared spectroscopy was used to verify further the   
N,N-coordination of the Ir(III) centre to ligand 2g (Figure 3.12). A shift in the pyridyl v(C=N) 
absorption band is characteristic of complexation, as is the presence of a broad v(P-F) 
absorbance band, characteristic of the PF6-counterion. In the IR spectrum of complex 7g, the 
v(C=N)pyridyl stretching frequency is present at 1630 cm-1, which is at a higher wavenumber 
than that of the ligand, observed at 1605 cm-1. This is likely due to the decreased back-
donation of electrons into the empty anti-bonding (π*) orbitals of the ligand as a result of the 
metal-centre being electron-deficient. This decreased synergic effect therefore causes a 
weakening of the Ir-N bond and strengthening the C=N bond, forcing the v(C=N)pyridyl 
absorbance band to shift to a higher frequency. The shift of the v(C=N) absorbance band in 
pyridiyl moieties to higher wavenumbers upon complexation has been observed in other 
pyridine complexes35,36 and thus confirms metal coordination to the pyridyl nitrogen. Finally, 
at a lower frequency range of 950–800 cm–1 in the IR spectrum of complex 7g (Figure 3.12), a 
broad, strong band at 825 cm–1 is observed, which is caused by the stretching vibrations of 












the PF6 anion. This is further proof that a cationic complex with a PF6-counterion has been 
synthesised.  
High Resolution Mass Spectrometry 
High resolution electrospray Ionisation mass spectrometry (ESI-MS) was used to confirm the 
synthesis of the desired cationic Ir(III) complex. The mass spectrum of the complex shows a 
peak which corresponds to the molecular ion without the PF6-ion, [M-PF6]+. This m/z value of 
670.1107 corresponds to the calculated value of 670.1116.  
3.3  Synthesis and characterisation of half-sandwich Ir(III) complexes based on 
the series of 7-chloro-4-aminoquinolinotriazole ligands 
3.3.1 Synthesis 
3.3.1.1 Attempted synthesis of the neutral 7-chloro-4-aminoquinolinotriazole Ir(III) complexes 
The synthesis of the neutral cyclometallated 7-chloro-4-aminoquinolinotriazole Ir(III) 
complexes 9a-c from ligands 6a-c (Scheme 3.4) was attempted a multiple times using various 
reaction conditions and solvents, as detailed below. No evidence of a cyclometallated product 
was found in each case, therefore, the synthesis of desired complexes 9a-c was unsuccessful. 
The details of the different cyclometallation attempts using ligand 6a, including the reaction 
conditions and results, can be seen in Table 3.3. Only the attempts using ligand 6a to 
Scheme 3.4. Attempted synthesis of the neutral cyclometallated Ir(III) 7-chloro-4-




















synthesise complex 9a will be discussed as all reactions using ligands 6b or 6c showed similar 
unsuccessful results. 
The 1H NMR spectra of the products of some of the reaction attempts in Table 3.3 can be seen 
in Figure 3.13. The first attempt involved using the same reaction conditions used for the 
synthesis of cyclometallated complexes 7a-f. This involved heating the ligand, NaOAc and 
iridium Cp* dimer in ACN at 65 °C for 72 h and, thereafter, stirring the reaction mixture at 
room temperature for a further 72 h. After heating for 72 h, however, the reaction mixture 
turned dark black and was thus assumed to have decomposed at the high reaction 
temperature. The next attempt, therefore, involved stirring the reactants at room 
temperature for 2 days in a 1:1 mixture of DCM and MeOH, since the ligand was insoluble in 
room temperature ACN and pure DCM. The 1H NMR spectrum of the resulting product of this 
reaction is shown in Figure 3.13d, in which no evidence for successful cyclometallation is 
observed. Instead, many of the signals correspond to those of the unreacted ligand, but could 
also be as a result of metal coordination to the quinoline nitrogen. This, however, could not 
be confirmed as there are multiple signals in the aliphatic region where the Cp* proton 
resonances are usually found, as well as many other new signals which are not present in the 
spectrum of the ligand. The 1H NMR spectrum of the product of attempt 3 (Figure 3.13c) 
shows similar, unsuccessful results. The difference with this attempt was that the ratio of 
DCM to MeOH used was increased to 4:1 and the reaction was left to stir for 6 days at room 
temperature. In addition to using a different mixture of solvents (i.e. DCM/EtOH), it was also 
then decided that gentle heat should be used next to encourage the reactants to react, which 
Attempt Reaction Conditions Result 
Solvent Temperature Total time 




r.t. 2 d Yellow precipitate forms 
3 DCM/MeOH 
(4:1) 
r.t. 6 d Yellow precipitate forms 
4 DCM/EtOH 
(1:1) 
40 °C (48 h), 
then r.t. (48 h) 
4 d Orange precipitate forms 
5 THF 50 °C (24 h) 1 d Dark red liquid product 
Table 3.3. Details of the different reaction attempts to synthesise complex 9a from ligand 6a. 
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is what was done in attempt 4. Although the reaction mixture did not turn black at this heat, 
the 1H NMR spectrum of the resulting precipitate shows, again, no clear evidence that the 
cyclometallation reaction was successful (Figure 3.13b). In the final attempt, namely 
attempt 5, a completely different solvent and set of reaction conditions were used. After 
heating the reactants in THF at 50 °C for 24 h, the solution turned from pale orange to dark 
red. Although TLC analysis showed the presence of the ligand in the reaction mixture after 
this time, the reaction was stopped as the mixture had turned dark red. The 1H NMR spectrum 
of the resulting dark liquid shows that the heat had likely caused the reactants to decompose, 











Figure 3.13. Stacked 1H NMR spectra of various cyclometallation reaction attempts, namely (a) 
attempt 5, (b) attempt 4, (c) attempt 3 and (d) attempt 2, as well as (e) 7-chloro-4-







Since none of the attempts to synthesise the cyclometallated Ir(III) complexes 9a-c showed 
any success, it was decided not to continue pursuing this strategy. 
3.3.1.2 Synthesis of the cationic 7-chloro-4-aminoquinolinotriazole Ir(III) complex 
The synthesis of the cationic N,N-chelated iridium(III) half-sandwich 7-chloro-4-
aminoquinolinotriazole complex (10) was achieved, as with cationic complex 7g, via a bridge-
splitting reaction of the iridium dimer and coordination of the ligand 6d (Scheme 3.5). In this 
entropically-driven reaction, the ligand coordinates to the metal via the triazole and pyridyl 
nitrogen atoms, forming a stable five-membered ring. A salt metathesis was carried out 
thereafter using hexafluorophosphate, which was done to replace the chloride counterion 
and allow for the easy precipitation of the complex.  
The cationic N,N-chelated iridium(III) 7-chloroquinolinotriazole complex (10) was isolated as 
a pale yellow powder in a poor yield of 25%. Since TLC analysis showed that all of the ligand 
had been consumed during the reaction, the likely reason for this low yield is because the 
precipitate was very sticky and clumped together. This made filtration and collection very 
difficult as the precipitate stuck to the bottom of the reaction vessel. Although a variety of 
solvents (i.e. MeOH, EtOH, pentane, Et2O) were used to try to isolate the complex the 
precipitate remained sticky, with the highest yield being achieved when filtered and washed 
with cold EtOH.  
Scheme 3.5. Synthesis of the cationic N,N-chelated Ir(III) 7-chloro-4-aminoquinolinotriazole complex 





















The N,N-chelated iridium(III) Cp* 7-chloro-4-aminoquinolinotriazole cationic complex (10) 
was characterised using various spectroscopic and analytical techniques. These included 1H, 
13C{1H}, 19F{1H}, 31P{1H}, 1H-1H correlation spectroscopy (COSY) and heteronuclear single 
quantum coherence (HSQC) nuclear magnetic resonance (NMR) spectroscopy, as well as 
infrared (IR) spectroscopy, electrospray ionisation–mass spectrometry (ESI-MS) and melting 
point analysis. 
3.3.2.1 Characterisation of the cationic 7-chloro-4-aminoquinolinotriazole Ir(III) complex 
NMR Spectroscopy 
The 1H NMR spectrum of the N,N-chelated cationic Ir(III) complex, 10, as well as its respective 
7-chloro-4-aminoquinolinotriazole ligand, 6d, is shown in Figure 3.14. Coordination of the








































Figure 3.14. Stacked 1H NMR spectra of (a) 7-chloro-4-aminoquinolinotriazole ligand, 6d and (b) 

































































1.68 ppm, which corresponds to the protons of the Cp* ligand (Figure 3.14b). Secondly, as 
seen with cationic complex 7g, the general downfield shift of all the aromatic signals of 
complex 10 compared to its respective ligand 6d (Figure 3.14a) is further evidence for the 
cationic complex formation. This is as a result of the cationic complex being electron-deficient 
compared to the ligand. Lastly, the splitting of the methylene protons of the propyl chain 
linker into distinct multiplets compared to the same protons on the ligand is the final proof 
that metal coordination has occurred. This splitting is observed for all three of the propyl 
proton signals for complex 10, namely protons 12, 13 and 14, with some of the signals 
enlarged in Figure 3.14b. As discussed previously, this phenomenon is as a result of the 
chirality induced by the stereogenic metal centre, causing these protons to become 
diastereotopic and thus non-equivalent. 
In addition to the above 1H NMR data, the data obtained from the 13C{1H}, 19F{1H} and 31P{1H} 
NMR spectra of this complex is also in agreement with the proposed cationic Ir(III) complex 
structure.  31P{1H} NMR spectroscopy, which shows a septet at -144.18 ppm (J = 711.2 Hz), 
was used to confirm the presence of the PF6 anion. This also affirmed the existence of only 
one type of PF6-containing compound and that no excess NH4PF6 was present in the product 
mixture. 
Infrared Spectroscopy 
Infrared spectroscopy was used to verify further the N,N-coordination of the Ir(III) centre to 
ligand 6d (Figure 3.15). A shift in the pyridyl v(C=N) absorption band from 1580 cm-1 in the IR 
spectrum of the ligand (6d) to a higher wavenumber of 1615 cm-1 in the spectrum of complex 
(10) is observed. This is as a result of the decreased synergic effect with cationic complexes,
as discussed previously, and is therefore evidence for metal coordination to the pyridyl
nitrogen. A broad, strong band at 825 cm–1 is also observed in the IR spectrum of complex 10.
This is as a result of the v(P-F) stretching vibrations of the PF6 anion and is evidence for the
synthesis of a cationic complex with a PF6 counterion.
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High Resolution Mass Spectrometry 
High resolution electrospray ionisation mass spectrometry (ESI-MS) was used to confirm the 
structural integrity of the cationic Ir(III) complex 10. The mass spectrum of the complex shows 
a peak which corresponds to the molecular ion without the PF6-ion, [M-PF6]+. This m/z value 
of 727.166 corresponded to the calculated value of 727.170.  
3.4 Summary 
A series of new Ir(III) complexes based on a 7-chloroquinolinotriazole scaffold were 
synthesised successfully. This series consists of six neutral cyclometallated Ir(III) complexes 
(7a-f), one neutral monodentate Ir(III) complex (8) and one cationic N,N-chelated Ir(III) 
complex (7g). The complexes were synthesised in poor to very good yields (10 – 85%), with 
the inconsistency in the yields a result of the sluggish nature of the cyclometallation reaction. 
Computational analysis revealed the monodentate Ir(III) complex, 8, to be the fastest-formed 
kinetic product while more heat and time is required to form the more stable, 
Figure 3.15. Stacked IR spectra of ligand 6d and cationic N,N-coordinated Ir(III) 7-chloro-4-












thermodynamic cyclometallated products, 7a-f. The synthesis of a second series of novel 
cyclometallated Ir(III) 7-chloro-4-aminoquinolinotriazole complexes (9a-c) was attempted, 
however, this was unsuccessful likely due to the inability of the respective ligands to undergo 
C-H activation under the tested conditions. On the other hand, the cationic N,N-chelated Ir(III)
7-chloro-4-aminoquinolinotriazole complex (10) of this series was successfully synthesised.
All complexes were fully characterised using NMR (1H, 13C{1H}, 19F{1H}, 31P{1H}, COSY, HSQC)
spectroscopy, as well as infrared spectroscopy and high resolution ESI-mass spectrometry.
Single crystals of complexes 7a and 8 were analysed by X-ray diffraction, which proved the
bidentate and monodentate coordination modes of the ligand to the metal respectively. The
spectroscopic and analytical data therefore validate and attest to the integrity of the
proposed structures of the complexes (7a-g, 8, 10).
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Chapter 4 
Biological evaluation of the 7-chloroquinoline-1,2,3-triazole ligands and 
their respective Ir(III) half-sandwich complexes including preliminary 
transfer hydrogenation catalytic studies 
4.1 Introduction 
Antimalarial drug resistance has emerged as one of the greatest challenges in the push 
towards malaria eradication worldwide. This increased resistance is largely the result of 
specific gene and protein mutations within the parasite, such as in the case of the Plasmodium 
falciparum CQ-resistance transporter (PfCRT) protein.1–3 Mutations in this protein are thought 
to cause the efflux of the antimalarial drug, chloroquine, from the digestive vacuole, therefore 
leading to a decreased accumulation of the drug in CQ-resistant P. falciparum strains.1–3  This 
thus highlights the urgent need for novel chemotherapies which have improved efficacy 
against resistant strains of the parasite. Over the past decade, the derivatisation of existing 
antimalarial drugs with transition metals has been explored in an attempt to combat the issue 
of resistance.4 This strategy is exemplified by ferroquine, the metal-based derivative of 
chloroquine which displays potent antimalarial activity in CQ-resistant strains.5–7 Owing to its 
increased lipophilicity afforded by the ferrocene moiety, it is able to accumulate to a greater 
extent within the digestive vacuole of parasite resistant strains than chloroquine itself.6,7 
While the improved activity observed upon metal complexation could be attributed to 
enhanced lipophilicity, as seen with ferroquine, the exact mechanism of action of many metal-
based compounds within the malaria parasite is still relatively unknown. Knowledge of the 
mechanism of action of an effective drug is crucial as it can be used as a tool in the drug-
design process in order to enhance biological activity while avoiding the emergence of 
parasitic resistance.8  To this effect, the mechanism of action of metal-chloroquine derivatives 
has been explored and their potent activity is largely attributed to the inhibition of haemozoin 
formation by the parasite.8–10 While it is uncertain how the mechanism of these types of drugs 
operates within the parasite, it is well established that chloroquine itself complexes to 
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haematin in solution, thereby inhibiting the formation of β-haematin, the synthetic form of 
haemozoin used in cell-free experiments.11,12 Interaction studies of haematin with various 
metal-chloroquine complexes has also shown that this mechanism holds in the presence of a 
metal, with the metal-chloroquine derivatives often interacting with haematin in a manner 
analogous to chloroquine.13,14 
Although diverse in structure, many of the metal-based antimalarial drug candidates 
synthesised to date share a common characteristic – they are all stoichiometric agents which 
react only once with their targets.15 While many have shown success in this regard, this 
concept is limited by the often high doses of the metallodrug required to produce the desired 
effect, consequently resulting in significant toxicity and side-effects.15 As an alternative 
strategy, the use of metallodrugs capable of performing catalytic reactions within biological 
systems is becoming increasingly popular.16–18 In particular, great interest has been directed 
towards the use of metal-based catalytic compounds capable of interfering with the 
NAD+/NADH transfer hydrogenation reactions within cancer cells as a novel mechanism of 
action.19–21 Examples of these types of intracellular catalytic complexes are shown in 
Figure 4.1. Iridium(III)-pyridine complexes have been shown to use NADH as a hydrogen 
source to target cancer cells, while hydride transfer by ruthenium(II)-arene complexes to 
NAD+ from formate have also been demonstrated, with both types of reactions exhibiting 
significant efficacy in the overall enhancement of anticancer activity.20,22 Intracellular transfer 
hydrogenation reactions have therefore been thoroughly studied in terms of anticancer 
applications, however, very little research has been done into the use of transfer 













Figure 4.1: Examples of iridium(III)-pyridine and ruthenium(II)-arene complexes capable of catalysing 
intracellular transfer hydrogenation reactions in cancer cells.20,22 
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This chapter is concerned with the biological activity of the 7-chloroquinoline-1,2,3-triazole 
ligands (2a-h and 6a-e) and their respective Ir(III) half-sandwich complexes (7a-g, 8 and 10). 
All synthesised compounds were tested for their antiplasmodial activity against the 
chloroquine-sensitive (CQS) NF54 strain of P. falciparum and the most active compounds of 
these were further tested against a chloroquine-resistant (CQR) K1 strain of P. falciparum. 
This was done to ascertain whether the compounds retain their activity in the resistant strain, 
a characteristic which is vital for overcoming antimalarial drug resistance. Selected complexes 
were also tested against the healthy, mammalian Chinese Hamster Ovarian (CHO) cell line to 
determine complex cytotoxicity and selectivity, and speed-of action assays were conducted 
to establish how quickly selected complexes act within the parasite. To gain insight into the 
possible mechanisms of action of these compounds, a β-haematin inhibition assay, as well as 
catalytic transfer hydrogenation experiments were carried out. The transfer hydrogenation 
experiments were conducted in a cell-free environment, with the future goal being to test the 
most active complexes for their catalytic ability within the malaria parasite. 
4.2 In vitro antiplasmodial evaluation against P. falciparum strains 
4.2.1.  Antiplasmodial evaluation against the chloroquine-sensitive (CQS) NF54 strain 
The 7-chloroquinoline-1,2,3-triazole ligands 2a-h and 6a-e, as well as the Ir(III) half-sandwich 
complexes 7a-g, 8 and 10 were evaluated for their antiplasmodial activity in vitro against the 
NF54 CQS strain of P. falciparum. The parasite lactate dehydrogenase (pLDH) assay, 
developed by Makler et al., was used to perform a full dose-response experiment on all the 
synthesised compounds to determine their IC50 values.23 An IC50 value is defined as the 
concentration of a drug at which 50% of the parasite growth is inhibited. The results for the 
ligands are summarised in Table 4.1 and those of the metal complexes in Table 4.2. 
The antiplasmodial activity results in Table 4.1 show that ligands 2a-h, with the triazole 
directly attached to the quinoline, exhibited low antiplasmodial activity. Of these, ligand 2c 
bearing the propyl functionality was found to be the most active, with an IC50 value of 
9.87 µM, followed closely by the ferrocenyl ligand, 2h, with an IC50 value of 12.3 µM. The 
lipophilic nature of the propyl and ferrocenyl moieties is likely the reason for their enhanced 
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R 22.73 ± 3.48 
2b CH3 19.88 ± 3.46 
2c (CH2)2CH3 9.87 ± 0.57 
2d CF3 22.30 ± 4.43 






R 27.87 ± 2.24 
2g N 28.02 ± 1.37 






0.190 ± 0.063 
6b CH3 0.324 ± 0.057 






1.35 ± 0.37 




N 0.0106 ± 0.0023 
activity, although there is no discernible trend in antiplasmodial activity with any of the other 
ligands from this series. On the other hand, when the quinoline and triazole moieties are 
separated by an aminopropyl linker, as in the case of ligands 6a-e, the antiplasmodial activity 
increases significantly, with some even displaying over a 100-fold increase in activity. The IC50 
values of the ligands containing an aminopropyl linker (6a-e) and the analogous ligands of the 
series without a linker (2a, 2b, 2e, 2g and 2h) are displayed pictorially in Figure 4.2. The graph 
demonstrates a clear trend in the IC50 values between the two series, indicating that the 
presence of an aminopropyl chain is crucial for antiplasmodial activity, a trend which is 
Table 4.1: In vitro antiplasmodial activity of 7-chloroquinolinotriazole ligands 2a-h and 4-amino-7-
chloroquinolinotriazole ligands 6a-e against the chloroquine-sensitive NF54 strain of P. falciparum. 
88 
confirmed by similar compounds in literature.24 Interestingly, not only is the lipophilic propyl 
linker important for antiplasmodial activity, but the positioning of the propyl chain, as well as 
the presence of the secondary amine also plays a key role in enhancing the activity of the 
compound. This is indicated by the fact that the IC50 value of ligand 2c (9.87 µM) is fifty times 
higher than that of ligand 6a (0.190 µM), with the difference between the two compounds 
being the placement of the propyl functionality within the scaffold of the compound. This 
result therefore indicates that having the propyl group as a linker between two separate 
moieties is advantageous, as is the presence of the secondary amine, which aids in the 
formation of a strong complex with haematin within the digestive vacuole of the parasite.25 
The activity of selected ligands is significantly enhanced upon metal complexation with 
iridium, with some complexes being over one hundred times more active than their 



























Figure 4.2. Graph depicting the IC50 values of analogous ligands from series 1 (2a, 2b, 2e, 2g, 2h) and 
series 2 (6a-e). 
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in reducing parasite viability, which may be linked to an increase to the overall lipophilicity of 
the compound or to the interaction of the metal centre with target compounds, although the 
mechanism for this is still unknown. The most active complex of all the Ir(III) complexes 
synthesised is the cationic, N,N-chelated complex 7g, with a submicromolar IC50 value of 
0.247 µM. The reason for this is likely due to the solubility of this complex, which went readily 
into the water-based medium used for the assay while the neutral, cyclometallated 
complexes formed a precipitate when in the same medium. The neutral cyclometallated 
complex solutions were therefore sonicated to improve solubility before being used in the 
assay, resulting in low micromolar IC50 values for all six complexes (7a-f). Of the neutral 
cyclometallated complexes, complex 7a displayed the best activity (0.688 µM), followed by 
7e (0.993 µM) and 7b (1.02 µM). This shows that introducing more hydrophobic side groups 
to metal complexes does not necessarily confer greater antiplasmodial activity, since the 
unsubstituted complex, 7a, was the most active of the neutral series. Surprisingly, although 
ligand 2c displayed the lowest IC50 value of all synthesised ligands, its activity is not retained 
upon complexation. This likely means that a precise balance of lipophilicity is required to 
ensure cellular uptake by the parasite. The antiplasmodial activity of complex 8, in which the 
ligand is coordinated in a monodentate fashion to the iridium via the quinoline nitrogen, was 
also determined. This complex was found to have poor activity, with an IC50 value of 48.4 µM, 
indicating that the mode of metal coordination has a large impact on parasite viability. This 
also validates the effort put into synthesising the cyclometallated complexes of this series 
because, although their synthesis takes much more time and energy than the monodentate, 
quinoline nitrogen-coordinated complex, the antiplasmodial results confirm that 
cyclometallation vastly improves the antiplasmodial activity of the complex. The final complex 
to be tested for its antiplasmodial activity against the CQS NF54 strain was the second series 
N,N-chelated complex, 10. Interestingly, this complex does not follow the same trend as that 
seen for the cationic complex 7g of the first series, where antiplasmodial activity is greatly 
enhanced upon metal coordination. In this case, the IC50 value of the complex could not be 
determined accurately at the tested concentration and was thus said to be greater than 
11.5 µM. This could be a result of the compound becoming too hydrophobic upon 
complexation, since the ligand already contains a hydrophobic propyl linker. Further tests 
should be done to confirm this theory. 
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Compound Structure IC50 (µM) ± SE 
NF54 
7a 0.688 ± 0.169 
7b 1.02 ± 0.17 
7c 2.34 ± 0.38 
7d 1.10 ± 0.16 
7e 0.993 ± 0.220 
7f 2.00 ± 0.16 
7g – 
0.247 ± 0.108 
8 
48.45 ± 1.73 
10 – 
> 11.5
CQDP - - 0.0106 ± 0.0023 
Table 4.2: In vitro antiplasmodial activity of Ir(III) half-sandwich complexes 7a-g, 8 and 10 against the 
chloroquine-sensitive NF54 strain of P. falciparum. 
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4.2.2.  Antiplasmodial evaluation against the chloroquine-resistant (CQR) K1 strain 
Since ligands 6a-e and Ir(III) complexes 7a-g exhibited good antiplasmodial activity against the 
CQS NF54 strain of P. falciparum, they were also tested for activity against the CQR K1 strain. 
Complex 10 was also tested against this strain to determine whether it might be more active 
in the resistant strain compared to the sensitive strain. The results are presented in Table 4.3. 
The inhibitory data for these compounds tested against the K1 strain somewhat resembles 
the trend observed for the NF54 strain. Again, the cationic complex 7g exhibits the best 
activity of all the Ir(III) complexes 7a-g with an IC50 value of 0.646 µM. Unlike with the CQS 
Compound IC50 (µM) ± SE NF54 IC50 (µM) ± SE K1 Resistance Index 
(RI)a 
6a 0.190 ± 0.063 0.335 ± 0.102 1.8 
6b 0.324 ± 0.057 0.846 ± 0.087 2.6 
6c 0.200 ± 0.003 0.245 ± 0.015 1.2 
6d 1.35 ± 0.37 1.23 ± 0.10 0.9 
6e 10.71 ± 0.38 11.82 ± 1.34 1.1 
7a 0.688 ± 0.169 1.06 ± 0.16 1.5 
7b 1.02 ± 0.17 2.22 ± 0.18 2.2 
7c 2.34 ± 0.38 3.06 ± 0.22 1.3 
7d 1.10 ± 0.16 2.59 ± 0.45 2.4 
7e 0.993 ± 0.220 1.01 ± 0.20 1.0 
7f 2.00 ± 0.16 1.40 ± 0.16 0.7 
7g 0.247 ± 0.108 0.646 ± 0.063 2.6 
10 > 11.5 7.00 ± 3.24 n.d.b
CQDP 0.0106 ± 0.0023 0.134 ± 0.041 12.6 
Table 4.3: In vitro antiplasmodial activity of ligands 6a-e and Ir(III) half-sandwich complexes 7a-g and 
10 against the CQS NF54 and CQR K1 strains of P. falciparum. 
a (IC50 K1/ IC50 NF54) 
b Not determined 
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NF54 strain however, the unsubstituted compounds 6a and 7a are not the most active of the 
ligands (6a-e) and neutral complexes (7a-f) respectively in the CQR K1 strain. The most active 
of these series in the K1 strain were compounds 6c and 7e, both of which have a fluoride 
substituent, which could mean that increased lipophilicity is required for activity in the 
resistant strain. 
In order to draw conclusions about the difference in activity of the compounds across the two 
strains, the resistance index (RI) value is calculated. The resistance index is useful in the 
analysis of compounds as potential drug candidates and is defined as the quotient of the IC50 
value obtained in the resistant strain and the IC50 value obtained in the sensitive strain. A 
smaller RI value (i.e. 1 or < 1) is indicative of the compound being equally or more active in 
the resistant parasitic strain relative to the sensitive strain. In most cases, the RI values for 
compounds 6a-e and 7a-g were slightly greater than 1 with some even being greater than 2. 
These values suggest that the compounds likely experience mild cross-resistance similar to 
that of chloroquine, however, not to the extent of chloroquine, which has an RI value of 12.6. 
Since there is a slight decrease in activity for most compounds in the resistant strain, it 
suggests that these compounds may mildly encounter the same issue as CQ does, with 
decreased accumulation of the drug in the resistant strain compared to the sensitive strain. 
This is  as a result of mutations in a gene encoding for the P. falciparum chloroquine-resistant 
transporter (PfCRT) – a protein located in the membrane of the digestive vacuole.1,14 The 
mutation allows for some of the CQ to be expelled from the digestive vacuole in the case of 
the CQ-resistant strains. Since there are structural similarities between the compounds 
discussed here and chloroquine, these compounds may experience a similar fate in the 
resistant strain to some extent. 
4.3 In vitro cytotoxicity studies 
Since some compounds were found to have good antiplasmodial activity against various 
strains of P. falciparum, it was important to screen them further for cytotoxicity against a 
healthy, mammalian cell-line as well to determine their selectivity towards the parasitic cells. 
With the use of metal complexes in medicine, the issue of toxicity brought about by the metal 
is often a concern. For this reason, five of the most active metal complexes, namely 7a, 7b, 
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7d, 7e and 7g, were tested for cytotoxicity against the mammalian Chinese Hamster Ovarian 
(CHO) cell line using the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay. The results of this assay are summarised in 
Table 4.4.
Compound Structure IC50 (µM) ± SE CHO Selectivity Index 
(SI)a 
7a 
(R = H) 78.67 ± 3.07 114.3 
7b 
(R = CH3) 25.64 ± 1.43 25.1 
7d 
(R = CF3) 54.59 ± 4.16 49.6 
7e 
(R = F) 104.01 ± 16.75 104.7 
7g 123.54 ± 4.65 500.2 
Emetine – 0.124 ± 0.0430 – 
The results in Table 4.4 show that all five of the tested compounds are not cytotoxic compared 
to the control, Emetine. Emetine is a natural product alkaloid, the medicinal use of which has 
been discouraged due to its known toxicity and is therefore used as the standard control in 
this assay.26  Compound 7b was determined to be the most cytotoxic compared to the other 
Ir(III) complexes, with an IC50 value of 25.64 µM, while cationic complex 7g is the least 
cytotoxic, with an IC50 value of 123.54 µM. 
The selectivity index (SI) value for each of the five compounds was also calculated. This value 
is defined as the quotient of the IC50 value obtained in the CHO cell-line and the IC50 value 
Table 4.4: IC50 values obtained for selected Ir(III) complexes (7a, 7b, 7d, 7e and 7g) against the Chinese 
Hamster Ovarian (CHO) cell line. 
a (IC50 CHO/ IC50 NF54) 
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obtained in the NF54 P. falciparum strain. This value is useful in determining the selectivity of 
a compound towards a particular cell type, with a large value indicating selectivity towards 
the parasitic cells as opposed to the healthy, CHO cells. From the calculated SI values 
displayed in Table 4.4, all five Ir(III) complexes display far greater selectivity towards the 
parasitic cells, with cationic complex 7g being 500 times more selective towards the parasite 
than the healthy cell-line. Even the least selective complex 7b is over 25 times more selective 
towards parasitic cells, showing that all the synthesised complexes will likely not cause 
damage to healthy cells. 
4.4 In vitro speed-of-action study 
One of the current challenges in the drug-discovery process is the narrowing-down of 
antiplasmodial drug hits to a handful of potential drug candidates. One of the ideal criteria 
for new drug candidates is that they are fast-acting, thereby providing a rapid relief of 
symptoms for the infected patient.27,28 This is also to ensure that very few parasites survive 
after drug exposure, thereby lowering the occurrence of mutations which could lead to the 
development of new drug resistance mechanisms.27,28  
In order to evaluate the speed-of-action of the synthesised Ir(III) complexes with the greatest 
antiplasmodial activity (7a, 7e and 7g), an assay experiment was performed following a 
modified method of the “IC50 speed assay” previously described by Le Manach et al.29 A 
schematic representation of this assay is shown in Figure 4.3. This assay was performed using 
Figure 4.3: Schematic representation of the in vitro speed-of-action assay. 
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synchronized ring cultures of the chloroquine-sensitive NF54 strain in order to determine 
whether compounds 7a, 7e and 7g are either fast- or slow-acting. Known antimalarial agents, 
chloroquine (CQ), ferroquine (FQ) and artemisinin (ART) were used as the controls in this 
experiment. The compounds and controls were added at time zero and were thereafter 
exposed to the parasites for 10, 24 and 48 h, after which the drugs were removed, as depicted 
in Figure 4.3. Each drug exposure time-point of 10, 24, 48 and 72 h was represented by a  
96-well plate, therefore, four plates, each with a final incubation time of 72 h, were used.
Parasite survival after drug exposure was measured using a SYBR Green flow cytometry-based
method. SYBR Green is a nucleic acid stain which only stains viable parasites as the host
erythrocytes lack nuclei.
The results of this speed of action experiment are summarised in Figure 4.4. The IC50 values 
determined at the 10, 24 and 48 h time-points are represented as a ratio relative to the 72 h 
time-point. The dotted line at a ratio of 1.0 therefore represents the baseline IC50 ratio at 
72 h (i.e. IC50 72 h/ IC50 72 h = 1.0). Compounds which have an IC50 ratio (relative to 72 h) of 1 
or less than 1 early on in the incubation period are described as “fast-acting” while those with 
ratios greater than 1 are described as “slow-acting.” The results in Figure 4.4 show that the 
Figure 4.4: IC50 speed assay profiles of 7a, 7e, and 7g, as well as controls, CQ, ART and FQ. The mean 
IC50 values at each time point are presented as ratios relative to the IC50 value of the standard   
72-hour assay. The dotted line indicates the baseline IC50 ratio at 72 h.


















time it takes for the controls, CQ, ART and FQ to exert their maximum killing effect is within 
24 h, where the IC50 values are similar to those of the standard 72 h assay. The respective 
IC50 24 h/IC50 72 h ratios of 0.9, 0.8 and 1.0 for these compounds are indicative of these drugs 
being fast-acting compounds, which has been observed in previous experiments.29 Similarly, 
compounds 7a and 7e also have their onset of action within 24 h, with their respective 
IC50 24 h/ IC50 72 h ratios being 0.9 and 0.8 respectively. It can therefore be concluded that 
Ir(III) complexes 7a and 7e are likely fast-acting compounds. In contrast to this, the IC50 ratio 
of 7g at 10 h is 2.3-fold higher than the respective IC50 value at the 72 h time point. The 
IC50 24 h/ IC50 72 h ratio only reaches 1.2 after 48 h of drug exposure, therefore, 7g 
demonstrates the characteristics of a slow-acting compound. This result complements the RI 
values calculated for these complexes (Table 4.3) where the fast-acting complexes 7a and 7e 
have low RI values of 1.5 and 1.0 respectively while the slow-acting complex 7g has a much 
higher RI value of 2.6. This supports the observation that slower-acting compounds are far 
more likely to promote the development of drug-resistance mechanisms within the 
parasite.27,28  
4.5 β-Haematin inhibition studies 
Like chloroquine, the target for many aminoquinoline-based compounds is the erythrocytic 
stage of the life cycle of P. falciparum and, more specifically, the formation of 
haemozoin.9,10,30 Upon entering the digestive vacuole of the parasite, these compounds bind 
to haematin, the toxic product of host haemoglobin degradation, thereby preventing its 
conversion into the crystalline haemozoin.9,10,30 This inhibition of the parasite’s innate 
detoxification mechanism leads to the build-up of free haematin and thus the death of the 
parasite.9,10,30 The ability of a compound to inhibit haemozoin formation can be evaluated 
using the Nonidet P-40 (NP-40) detergent-mediated β-haematin inhibition assay, with 
β-haematin being the synthetic form of haemozoin.31 Research suggests that the formation 
of haemozoin is not a spontaneous process, with crystallisation solely occurring in the 
presence of neutral lipids found within the parasite’s digestive vacuole.32,33 Since the presence 
of these lipids is vital for the formation of haemozoin, these lipids are mimicked by the neutral 
detergent, NP-40, in this assay, thereby mediating β-haematin formation. Two organic 
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compounds, 6a and 6d, a neutral Ir(III) complex, 7d, and two cationic Ir(III) complexes, 7g and 
10, were tested for their ability to inhibit β-haematin formation, the results of which are 
shown in Figure 4.5. The compounds were all screened in triplicate up to a concentration of 
1000 µM and the amount of synthetic haemozoin formed was quantified using the 
colorimetric pyridine ferrochrome method published by Egan et al.34 This method allows for 
the amount of synthetic haemozoin formed to be measured, since pyridine is only capable of 
complexing to free haem and not β-haematin. Figure 4.5, therefore, shows the dose-response 
curves of the tested compounds, representing the relationship between the absorbance of 
the haematin-pyridine complex formed with increasing drug concentration. 
All of the compounds tested were found to inhibit β-haematin formation, indicated by the 
characteristic sigmoidal curve for each, however, their IC50 values differed drastically. These 
IC50 values are represented graphically in Figure 4.6. In general, the activity of most of the 
compounds was lower than or comparable to chloroquine itself, which has an IC50 value of 
65.3 µM. Organic compound 6a has an IC50 value of 61.4 µM, but it surprisingly loses activity 
at concentrations higher than 250 µM, as seen by the curve for 6a in Figure 4.5. Organic 





























Figure 4.5: Dose-response curves obtained for compounds 6a, 6d, 7d, 7g, and 10, as well as CQDP, 
using the NP-40 detergent-mediated β-haematin inhibition assay. 
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compound 6d exhibited the worst activity with a very high IC50 value of 274 µM, however, 
upon coordination of this compound to the metal fragment to form Ir(III) complex 10, the 
activity improves considerably. The IC50 value of complex 10 is 9.65 µM, meaning that it is far 
more active than chloroquine itself. This was unexpected since complex 10 displayed the 
lowest antiplasmodial activity of all the complexes tested in both the sensitive and resistant 
strains of P. falciparum. Entry of complex 10 into the parasitic digestive vacuole, where the 
haemozoin crystallisation takes place, must therefore be somewhat limited, since it has very 
good cell-free β-haematin inhibitory activity but very poor antiplasmodial activity. This thus 
shows that incorporation of the metal fragment onto the organic ligands leads to an 
enhancement of the β-haematin inhibitory activity of the free ligands, likely due to the effect 
of increased lipophilicity. Moreover, since complex 10 has better β-haematin inhibitory 
activity than the other cationic complex, 7g (IC50 = 102 µM), this highlights the importance of 
having a secondary amine and aliphatic chain in the structure of the compound. These, in 
combination with the 7-chloroquinoline moiety, have been proven to be instrumental in 
forming a strong complex with haematin, therefore aiding in parasitic cell death.25 Since the 
results of this cell-free assay suggest that these compounds do inhibit the formation of 
β-haematin, they are likely candidates for the inhibition of haemozoin in the parasite.  











Figure 4.6: IC50 values obtained from the β-haematin inhibition studies for compounds 6a, 6d, 7d, 7g, 
and 10, as well as CQDP. 
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4.6 Preliminary transfer hydrogenation studies 
The coenzyme β-nicotinamide adenine dinucleotide (NAD+) and its reduced form (1,4-NADH) 
play a vital role in cell metabolism and are required for many enzymatic reactions.20,35 In 
recent years, it has been suggested that a disturbance in the intracellular NAD+/NADH ratio 
may affect the cellular redox status, thereby bringing about metabolic changes and possibly 
even cell death.20 It is for this reason that significant attention has been given to the use of 
organometallic complexes capable of regioselectively reducing NAD+ to 1,4-NADH under 
biological conditions.35 These types of reactions have been thoroughly studied in terms of 
anticancer applications, however, only just recently have they been applied to antimalarial 
therapy.36 In 2019, Stringer et al. tested two quinoline-based half-sandwich organoiridium 
and organorhodium complexes (Figure 4.7) in the presence of various concentrations of 
sodium formate (0, 5, 10 and 20 mM) against the CQ-resistant K1 strain of P. falciparum.36 
While the organorhodium complex (complex 2, Figure 4.7) did not display any significant 
change in parasite viability, the organoiridium complex (complex 1, Figure 4.7) at 1000 ng/mL 
was found to exhibit a significant stepwise decrease in parasite viability with an increase in 
the concentration of sodium formate.36 The results of the in vitro formate assays for both 
complexes in this study are shown in the bar graph in Figure 4.7. Although only a preliminary 
study, it demonstrated that co-administration of metal-based complexes with a hydrogen 
source may be useful in targeting essential co-factors such as NAD+, thereby possibly 






M = Ir (1), Rh (2)
Figure 4.7. Parasite viability observed in the K1 strain when 1000 ng/mL concentrations of complexes 
1 and 2 were incubated with various concentrations of sodium formate (0, 5, 10 and 20 mM). The 
structure of the complexes used in the study by Stringer et al. is also shown.36 
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4.6.1.  Qualitative 1H NMR spectroscopic studies for the conversion of NAD+ to NADH by 
complexes 7a and 7g 
Thus far, no examples of iridium(III) 7-chloroquinoline-1,2,3-triazole half-sandwich complexes 
have been reported for transfer hydrogenation reactions. The complexes which displayed the 
best antiplasmodial activity, namely 7a and 7g, were therefore tested for their ability to 
regioselectively catalyse the transfer hydrogenation reduction of NAD+ to NADH, using 
sodium formate as the hydrogen source. The proposed mechanism of the catalytic cycle for 
cyclometallated complex 7a can be seen in Figure 4.8 and is based on the mechanism 
previously reported by Lo et al.37 The complex is first believed to become solvated, forming 
cationic solvated complex A. This then reacts with sodium formate, forming complex B, which 
then undergoes a β-hydrogen elimination reaction to form the metal-hydride species C and 
liberating CO2 in the process. The oxygen of the amide functionality of NAD+ then coordinates 























































Figure 4.8: Proposed catalytic cycle for the regioselective reduction of NAD+ by Ir(III) complex 7a.37  
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D. This allows for the regioselective hydride transfer at C-4 of NAD+, forming the 1,4-dihydro
product, NADH, and the solvated catalyst precursor, A. The mechanism for the cationic
complex, 7g, should follow the same catalytic cycle, as described by Lo et al.37
Qualitative tests by means of 1H NMR spectroscopy were performed using complexes 7a and 
7g as catalyst precursors to test whether they are able to facilitate the hydride transfer 
reduction of NAD+ to form NADH. To demonstrate this, a solution of the complex (7a or 7g), 
NAD+ and sodium formate was made in a mixture of MeOD and D2O and a 1H NMR spectrum 
was recorded roughly 5 minutes after sample preparation and again after 4 h, with incubation 
at 37 °C. If regioselective reduction of NAD+ to NADH has occurred, changes in characteristic 
1H NMR spectral signals should be observed. The catalytic 1H NMR spectroscopy experiments 
for complexes 7a and 7g are shown in Figure 4.9 and Figure 4.10 respectively.  
In the 1H NMR experiment for complex 7a (Figure 4.9), the spectrum at t = 0 h shows 
predominantly the presence of NAD+, however, the presence of signals pertaining to 
1,4-NADH are also observed at this time. This thus means that the catalytic reduction begins 
immediately once all the reactants are in solution. After 4 h, the absence of characteristic 
Figure 4.9: 1H NMR spectra of a mixture of Ir(III) complex 7a, NAD+ and sodium formate in MeOD/D2O 
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NAD+ signals indicated that no more NAD+ was present in solution, with only signals 
characteristic of 1,4-NADH observed at this time interval. This means that neutral 
cyclometallated Ir(III) complex 7a is capable of catalysing the regioselective reduction of NAD+ 
to 1,4-NADH, using sodium formate as the hydrogen source. 
Since cationic Ir(III) complex 7g exhibited the best antiplasmodial activity of all the tested 
complexes, the 1H NMR experiment performed for 7a was repeated with 7g. The same 
method was applied, with a spectrum being recorded 5 minutes after sample preparation and 
again after 4 h (Figure 4.10). Interestingly, unlike what was observed for the experiment with 
7a, after 4 h there was still mostly NAD+ left in the solution. The 1H NMR spectrum at t = 4 h 
looks almost identical to that at t = 0 h. Very small signals corresponding to NADH are present 
at this time interval, meaning that the complex could be acting as a transfer hydrogenation 
catalyst, however, the reaction likely proceeds very slowly. In light of this, this complex was 
not used for further testing as it did not exhibit effective catalytic ability in reducing NAD+ to 
NADH. 
Figure 4.10: 1H NMR spectra of a mixture of Ir(III) complex 7g, NAD+ and sodium formate in MeOD/D2O 
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4.6.2.  Cell-free assay to detect the conversion of NAD+ to NADH by complexes 7a and 7e 
In order to verify further the ability of the Ir(III) 7-chloroquinoline-1,2,3-triazole complexes to 
catalyse the reduction of NAD+ to NADH, a cell-free assay, modified from the pLDH assay38, 
was performed.36 The principle behind the pLDH assay is shown in Figure 4.11.23 Parasite 
lactate dehydrogenase (pLDH) is an enzyme found within the parasite which catalyses the 
interconversion of pyruvate to lactate and, in so doing, converting cofactor NAD+ to NADH 
and back.23,38 The pLDH assay makes use of this intracellular catalytic process specifically to 
detect the pLDH enzyme, thereby allowing conclusions to be drawn as to the parasite viability 
since the pLDH enzyme is only effective in live parasites. Makler et al. developed the Malstat™ 
method for the detection of parasite viability in 1993 and this method is still followed 
today.23,39 This method for the pLDH assay makes use of the fact that pLDH is able utilise the 
3-acetyl pyridine analogue of NAD+ (APAD+) while human lactate dehydrogenase (hLDH)
enzymes do not readily use this analogue, therefore allowing the assay to detect pLDH activity
over hLDH activity.39,40 In parasite-infected, lysed red blood cells, the pLDH enzyme oxidises
lactate to pyruvate, reducing APAD+ (found within the Malstat™ reagent) to APADH in the
process. The yellow-coloured tetrazolium dye (in the form of nitroblue tetrazolium (NBT)) is
added thereafter, which is reduced by the APADH to the dark blue formazan in the presence
of the electron acceptor, phenazine ethosulfate (Figure 4.11).
In order to monitor the transfer hydrogenation catalytic activity of neutral cyclometallated 
complexes 7a and 7e, a cell-free experiment, modified from the pLDH method, was used 
(Figure 4.11). This modified method was first described by Stringer et al. for detecting the cell-









Figure 4.11: Principle of the pLDH Malstat™ assay for the detection of parasite viability.23 
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complexes.36 Following this method, different concentrations of complexes 7a and 7e  were 
incubated with NAD+ and sodium formate at 37 °C and pH 7.4 for 6 h. If the complexes are 
able to facilitate the reduction of NAD+ to NADH in the presence of sodium formate, the NADH 
should reduce the nitroblue tetrazolium (NBT) to formazan, as shown in Figure 4.12.36 This 
process is analogous to the reduction of the yellow tetrazolium salt to the dark blue formazan 
compound by APADH in the Malstat™ assay. The absorbance at 600 nm is then taken and is 
proportional to the amount of formazan present, therefore providing a means of detecting 
the transfer hydrogenation catalytic ability of the complexes. The results of this cell-free assay 
experiment are shown in Figure 4.13. As seen in Figure 4.13a, the experiment was performed 
in a 96-well plate in which 10 concentrations of each complex were plated in triplicate and 
two negative controls were included in the first two columns (column 1 = DMSO only; column 
2 = NAD+ only). Upon addition of the NBT reagent, the wells containing the higher 
concentrations of the complexes changed from yellow to blue and the change in absorbance 
with increasing complex concentration was plotted, as shown in Figure 4.13b. These results 
show that, as the concentration of the complex increases, the absorbance also increases and 









































7a: R = H































Figure 4.12: Principle used to detect transfer hydrogenation activity of complexes 7a and 7g.36 
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method of detecting coenzyme conversion, the results show that complexes 7a and 7e, in the 
presence of sodium formate, can act as transfer hydrogenation catalysts, facilitating the 
reduction of NAD+ to NADH in a cell-free environment. While complex 7e displays slightly 
better catalytic activity than complex 7a, both demonstrate a positive correlation between 
the concentration of the complex and the amount of formazan formed. 
The preliminary transfer hydrogenation experiments described in this section showed that 
Ir(III) complexes 7a and 7e are capable of catalysing the reduction of NAD+ to NADH in the 
presence of sodium formate in a cell-free environment. Future in vitro experiments should 
therefore be performed with these complexes to determine whether they retain their 
catalytic activity within various strains of P. falciparum. Although the groundwork for the 
in vitro formate assay has been laid by Stringer et al. in this regard36, many more tests using 
a variety of different metal-based compounds need to be performed in order to test the 
reproducibility of this method. Stringer et al. were able to show, however, that metal-
mediated transfer hydrogenation reactions could potentially be achieved within the malaria 
parasite36, paving the way for future experiments of this kind. 





























Figure 4.13: Results of the cell-free transfer hydrogenation experiment for complexes 7a and 7e.   
(a) Plate set-up showing the presence of dark blue formazan at higher drug concentrations;









Two series of 7-chloroquinoline-1,2,3-triazole ligands, 2a-h and 6a-e, as well as the Ir(III) half-
sandwich complexes 7a-g, 8 and 10 were evaluated in vitro for their antiplasmodial activity 
against the NF54 CQS strain of P. falciparum. The ligand series containing the propyl chain 
linker (6a-e) displayed superior activity to those with the triazole directly bonded to the 
quinoline moiety (2a-h). Upon metal complexation with iridium, the activity of selected 
ligands is significantly enhanced, with some complexes being over one hundred times more 
active than their respective ligands. Cationic complex 7g displayed the best activity of all the 
complexes with an IC50 value of 0.247 μM while complex 7a was the most active of the neutral, 
cyclometallated complexes, having an IC50 value of 0.688 μM. Surprisingly, the cationic 
complex 10, which contains a propyl linker in its scaffold, exhibited the lowest antiplasmodial 
activity of all the synthesised complexes. Ligands 6a-e and complexes 7a-g and 10 were, 
thereafter, tested for their antiplasmodial activity against the K1 CQR strain of P. falciparum. 
For most of these compounds, their activity is lower in the resistant strain, however, their 
calculated RI values suggest that they likely experience cross-resistance but not to the extent 
of chloroquine. Compounds 7a, 7b, 7d, 7e and 7g were tested against the healthy CHO cell 
line and were found not to be cytotoxic. They were also determined to be more selective 
towards parasitic cells, with complex 7g being almost 500 times more selective towards the 
parasite than healthy cells. An “IC50 speed assay” using the CQS NF54 strain found complexes 
7a and 7e to be fast-acting compounds, which reach their lowest IC50 values within 24 h, while 
cationic complex 7g was determined to be slow-acting, only reaching its lowest IC50 value 
after 48 h. To gain insight into the possible mechanisms of action of these compounds, a 
β-haematin inhibition assay was performed on selected ligands (6a and 6d) and complexes 
(7d, 7g and 10), since 7-chloroquinoline-containing compounds are known to inhibit the 
formation of haemozoin within the parasite. All five of the tested compounds were found to 
inhibit β-haematin formation to some extent but were, in general, poorer β-haematin 
inhibitors than chloroquine itself. Interestingly, complex 10, which has the lowest 
antiplasmodial activity, exhibited far greater β-haematin inhibitory activity than chloroquine. 
Its IC50 value of 9.65 µM is also 28-times lower than that of its respective ligand, 6d (274 µM), 
indicating that the inclusion of a metal fragment could improve complexation of the 
compound to haematin. Finally, the most active complexes 7a, 7e and 7g were evaluated for 
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their ability to facilitate transfer hydrogenation, by reducing β-nicotinamide adenine 
dinucleotide (NAD+) to NADH in the presence of the hydrogen source, sodium formate. 
Through 1H NMR spectroscopy experiments and a cell-free assay modified from the pLDH 
assay, it was found that complexes 7a and 7e are capable of acting as transfer hydrogenation 
catalysts while cationic complex 7g is not, showing no reduction of NAD+ to NADH over 4 h. 
This preliminary study into the catalytic potential of active antiplasmodial complexes shows 
great promise, and future testing of these compounds as transfer hydrogenation catalysts in 
vitro could lead to the discovery of a novel mechanism of action, particularly in drug-resistant 
parasitic strains. 
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Chapter 5 
Conclusions and future outlook 
5.1 Overall summary and conclusions 
The primary aim of this project was to synthesise various 7-chloroquinoline-1,2,3-triazole-
based ligands and their corresponding Ir(III) half-sandwich complexes to be tested as 
antiplasmodial agents. The first series of ligands (2a-h) and complexes (7a-g, 8) had the 
triazole ring directly bonded to position-4 of the quinoline system while the second series 
complex (10) and ligands (6a-e) included an aminopropyl chain linker between the two 
entities. Coordination of select ligands using [IrCl(µ-Cl)(Cp*)]2 yielded six neutral, 
cyclometallated (7a-f) and two cationic, N,N-chelated (7g, 10) iridium complexes. All of the 
compounds were fully characterised using an array of spectroscopic (1H, 13C{1H}, 19F{1H}, 
31P{1H} NMR and FT-IR spectroscopy) and analytical (mass spectrometry and melting point 
analysis) techniques. 
The ligands in both series (2a-h and 6a-e) were prepared by Cu(I)-catalysed azide-alkyne 
cycloaddition “click” reactions and were isolated in moderate to good yields. The aromatic 
alkynes used in these reactions had side groups which varied according to their electron-
withdrawing or electron-donating capacities. Ligands 2a-f were then reacted with  
[IrCl(µ-Cl)(Cp*)]2, undergoing C-H activation to form cyclometallated complexes 7a-f. The 
synthesis of the cyclometallated complexes revealed a surprising result – the ligands first 
coordinate to the metal in a monodentate-fashion via the quinoline nitrogen. Complex 8, the 
monodentate complex of this type formed with ligand 2a, was isolated and fully 
characterised. With continued heating over time, the metal detaches from the quinoline 
nitrogen and then coordinates to nitrogen-3 on the triazole, thereafter undergoing C-H 
activation to form the cyclometallated products, 7a-f. Computational analysis of the reaction 
of ligand 2a with [IrCl(µ-Cl)(Cp*)]2 revealed that the fastest-formed monodentate-type 
complex 8 is the kinetic product, which is formed at room temperature. At a temperature of 
65 °C, the cyclometallated complex 7a, which is the thermodynamic product, is formed. The 
structures and nature of metal-coordination of these complexes (7a and 8) were confirmed 
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using single-crystal X-ray diffraction, which also corroborated the pseudo-tetrahedral 
geometry about the metal centre for both complexes. Cyclometallation using ligands 6a-c was 
attempted multiple times, however, these reactions were unsuccessful. The pyridyl-
containing ligands 2g and 6d were complexed using [IrCl(µ-Cl)(Cp*)]2 via a bridge-splitting 
reaction to afford the respective N,N-chelated Ir(III) cationic complexes, 7g and 10. 
All synthesised compounds were screened in vitro for their potential antiplasmodial activity 
against the chloroquine-sensitive NF54 strain of P. falciparum. Ligands 2a-h exhibited low 
antiplasmodial activity while ligands 6a-e displayed excellent activity, with submicromolar IC50 
values. This is likely due to the presence of the secondary amine and propyl chain linker in the 
structures of these compounds, both of which aid in accumulation of the drug within the 
parasite. Upon coordination of ligands 2a-g with iridium to form complexes 7a-g, the 
antiplasmodial activity is significantly enhanced, with some complexes being over one 
hundred times more active than their respective ligands. Cationic complex 7g displayed the 
best antiplasmodial activity and monodentate complex 8 interestingly displayed very poor 
activity, indicating that the location of metal coordination is important. The complexes were 
further tested for their antiplasmodial activity against the chloroquine-resistant K1 strain of 
P. falciparum. The results of these experiments revealed that, in general, the complexes had
decreased activity compared to that in the sensitive strain. The calculated RI values suggest
that they likely experience mild cross-resistance, however, not to the same extent of
chloroquine. Surprisingly, cationic complex 10 of the second series exhibited the worst
antiplasmodial activity of all the tested complexes in both parasitic strains. A likely reason for
this is the inability of this larger complex to permeate the parasitic membrane, although
further tests need to be conducted to verify this hypothesis. Furthermore, selected active
complexes (7a, 7b, 7d, 7e and 7g) were tested against the healthy, mammalian Chinese
Hamster Ovarian cell line. These were all found not to be cytotoxic and determined to be
more selective towards the parasite than the healthy cells.
An “IC50 speed assay” was carried out using the three most active complexes, 7a, 7e and 7g, 
against the chloroquine-sensitive NF54 strain. The cyclometallated complexes 7a and 7e were 
found to be fast-acting compounds which reach their lowest IC50 values within 24 h, while the 
cationic complex 7g was determined to be slow-acting, only reaching its lowest IC50 value 
after 48 h. Since the controls CQ and FQ are fast-acting compounds, it can be assumed from 
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these results that the cyclometallated complexes 7a and 7e likely have a similar mode of 
action to the controls within the parasite, while the slow-acting, cationic complex 7g does 
not. To gain insight into a potential mechanism of action of these compounds, selected ligands 
and complexes were tested for their ability to inhibit the formation of β-haematin (the 
synthetic form of haemozoin), since one of the targets of 7-chloroquinoline-containing 
compounds is haemozoin. Two organic compounds, 6a and 6d, a neutral Ir(III) complex, 7d, 
and two cationic Ir(III) complexes, 7g and 10, were all found to inhibit the formation of 
β-haematin, some to a greater extent than others.  All, except complex 10, were less effective 
β-haematin inhibitors than chloroquine itself. Complex 10, the aminopropyl-containing 
cationic complex which displayed the lowest antiplasmodial activity, interestingly exhibited 
far greater β-haematin inhibitory activity (IC50 9.65 µM) than chloroquine (IC50  65.3 µM). The 
likely reasons for this impressive activity are the combined effects of the secondary amine 
and aliphatic chain, the 7-chloroquinoline entity and the metal fragment in the structure of 
the complex, all of which are instrumental in parasitic digestive vacuole accumulation and in 
the formation of a strong complex with haematin. 
Finally, the three most active complexes 7a, 7e and 7g were evaluated for their ability to 
facilitate transfer hydrogenation, by reducing β-nicotinamide adenine dinucleotide (NAD+) to 
NADH in the presence of the hydrogen source, sodium formate. Through preliminary 1H NMR 
experiments and a cell-free assay adapted from the pLDH assay, it was found that neutral 
complexes 7a and 7e may be capable of acting as transfer hydrogenation catalysts. 
Conversely, cationic complex 7g is not an effective transfer hydrogenation catalyst as it 
showed no regioselective reduction of NAD+ to NADH over 4 h. Although transfer 
hydrogenation using complex 7g as a catalyst may be occurring very slowly, it can be assumed 
that this complex likely acts with a different mechanism of action which confers excellent 
antiplasmodial activity within the parasite.  
5.2 Future Outlook 
Based on the results of this study, the 7-chloroquinoline-1,2,3-triazole complexes exhibit 
promising antiplasmodial activity. Selected complexes also displayed great potential in their 
ability to catalyse the hydride transfer reduction of NAD+ to NADH. Further mechanistic and 
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catalytic studies could thus be made in order to gain insight into the mechanism(s) of action 
of these compounds within the parasite. Several structural modifications could also be made 
in order to improve the solubility and efficacy of the compounds.  
5.2.1 Further mechanistic studies 
While the compounds tested did display the ability to β-haematin inhibition, they generally 
did not have the same inhibitory activity as CQ. This implies that these compounds must have 
other possible modes of action which confer good antiplasmodial activity. Since the 
β-haematin inhibition assay is a cell-free experiment, haem fractionation studies could be 
performed with these compounds in vitro, thereby determining whether the compounds do 
indeed inhibit haemozoin formation within the parasite.1 The ability of a compound to 
produce ROS and thus kill by oxidative stress could be determined by incubating the 
compound with an antioxidant like N-acetylcysteine (NAC).2 The use of this antioxidant would 
lower the antiplasmodial activity of the compounds if they work by means of oxidative 
damage, thus providing insight into whether ROS formation is a possible mode of action. This 
oxidative stress could also be detected by means of flow cytometry using a fluorescent 
oxidative stress sensor in combination with a nucleic acid-binding dye to distinguish infected 
red blood cells.3 In order to visualise where these compounds localise within the parasite, a 
fluorescent tag could be incorporated onto the compound scaffold and could be tracked using 
confocal microscopy. Finally, in addition to the speed-of-action studies, stage specificity 
assays could be formed with these compounds to provide information about which stage of 
the asexual life cycle these compounds target.4 
5.2.2 Further catalytic studies 
Since selected compounds exhibited a good ability to catalyse the hydride transfer reduction 
of NAD+ to NADH in a cell-free environment, the next step would be to determine whether 
activity holds within the parasite. In vitro tests should be performed with these complexes in 
the presence of increasing concentrations of sodium formate in both CQS and CQR strains of 
P. falciparum.5 If there is a decrease in parasite viability with increasing formate
concentrations, this will indicate that intracellular catalysis is indeed taking place.
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Furthermore, the amount of NAD+/NADH can be determined using NAD+/NADH ratio test kits 
and possible cellular localisation tests could also be performed in this regard. 
5.2.3 Structural modifications 
Although the biological results of the compounds indicate promising antiplasmodial activity, 
this activity was not comparable to that of CQ. In order to extend the activity into the 
nanomolar range, further modification of the 7-chloroquinoline-1,2,3-triazole compounds 
needs to be made in order to improve the solubility and efficacy of the compounds. Figure 
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Figure 5.1: Suggested structural modifications for the compounds in this study. 
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Due to its ability to inhibit β-haematin formation, the aminoquinoline motif should still be 
considered when designing antimalarial compounds. Similarly, the triazole entity should also 
be kept since it proved useful in acting as an anchor for metal coordination and for introducing 
aromatic functional groups through simple click chemistry. Owing to the impressive increase 
in activity upon inclusion of the lipophilic aminopropyl linker, this should also be considered 
in the design of active drugs. Effort should be made towards the cyclometallation of ligands 
of this type, as this could improve the antiplasmodial activity into the nanomolar range. 
Suggested functional groups on the phenyl ring attached to position-4 of the triazole include 
various lipophilic entities as well as groups containing amines, which have been proven to aid 
in pH trapping and thus accumulation of the drug within the parasitic digestive vacuole. Since 
the solubility of the neutral compounds in the water-based biological media was an issue in 
this study, the inclusion of a group like NaSO3– on this phenyl ring could improve aqueous 
solubility. 
In terms of the metal and its ligands, other bioactive metals such as Rh(III) and Ru(II) can be 
used for complexation, as these metals have shown great efficacy within antimalarial 
compounds, as well as for transfer hydrogenation catalysis. Since the coordination of the 
metal to the quinoline nitrogen happened so readily, complexes could be made which include 
two metal centres – one via cyclometallation and one through quinoline-nitrogen 
coordination. Since the cationic complex 7g displayed the best antiplasmodial activity, the 
labile chloride ligand could be replaced with a pyridyl group to form a cationic complex. Lastly, 
in order to improve the π-stacking capability of these complexes and thus their antiplasmodial 
activity, the Cp* ligand could be functionalised with a phenyl or biphenyl group as shown in 
Figure 5.1.   
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6.1 General Details 
6.1.1 Chemicals and General Methods 
All reagents and solvents were purchased from commercial sources (Sigma-Aldrich, Merck 
and KIMIX) and were used without further purification. Iridium(III) trichloride trihydrate was 
purchased from Heraeus SA. The iridium Cp* dimer [IrCp*(μ-Cl)Cl]2 was synthesised following 
a literature method.1 All solvents were of analytical grade, with some dried over molecular 
sieves. All reactions were carried out under an inert argon atmosphere using standard Schlenk 
line techniques unless otherwise stated. Reactions were monitored by thin-layer 
chromatography (TLC) using aluminium-backed Merck precoated silica-gel 60 F254 plates and 
compounds were visualised by ultraviolet light at 254 nm. Column chromatography was 
conducted using 60 Å silica gel (70-230 mesh). 
6.1.2 Spectroscopic and Analytical Techniques 
Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker XR600 MHz 
spectrometer (1H at 599.95 MHz and 13C{1H} at 151.0 MHz), a Bruker Topspin GmbH (1H at 
400.22 MHz, 13C{1H} at 100.65 MHz, 19F{1H} at 376.58 MHz and 31P{1H} at 162.01 MHz) or a 
Varian Mercury 300 (1H at 300.08 MHz) spectrometer. These were equipped with a Bruker 
Biospin GmbH casing and sample injector at 30 °C and tetramethylsilane (TMS) was used as 
the internal standard.  
Infrared (IR) spectroscopy was performed on a Perkin-Elmer Spectrum 100 FT-IR 
spectrometer using Attenuated Total Reflectance (ATR) with vibrations measured in units of 
cm-1.
Purity was determined using an analytical Agilant HPLC 1260 equipped with an Agilent infinity 
diode array detector (DAD) 1260 UV-Vis detector, with an absorption wavelength range of 
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210–640 nm. The compounds were eluted using a mixture of solvent A (10 mM NH4OAc/H2O) 
and solvent B (10 mM NH4OAc/MeOH) at a flow rate of 0.9 mL.min−1. The gradient elution 
conditions were as follows: 10% solvent B between 0 and 1 min, 10 – 95% solvent B between 
1 and 3 min, 95% solvent B between 3 and 5 min. High resolution (HR) electrospray ionisation 
mass spectrometry (ESI-MS) was performed on a Waters Synapt G2 QTOF mass spectrometer 
with data recorded using the positive mode.  
Melting points were obtained using a Büchi Melting Point Apparatus B-540 and are 
uncorrected.  
6.2  Synthesis of azide precursor (1) 
6.2.1 4-Azido-7-chloroquinoline2 (1) 
4,7-Dichloroquinoline (1.00 g, 5.05 mmol) was dissolved in anhydrous DMF (5.00 mL). To this, 
NaN3 (0.657 g, 10.1 mmol) was added in one portion and the resulting mixture was stirred at 
65 °C for 5 h and then left to stir at room temperature overnight. The completion of the 
reaction was determined by TLC. Ethyl acetate (100 mL) was then added and the reaction 
mixture was filtered to remove excess NaN3. The resulting filtrate was washed with water   
(5 x 30.0 mL) and brine (3 x 20.0 mL) and dried over anhydrous Na2SO4. The solvent was then 
removed using the rotary evaporator and toluene was used to aid in the evaporation of any 
excess DMF. The resulting product residue was then recrystallised using minimal DCM and 
hexane to yield the final product, 1, as pale yellow, needle-like crystals. Yield: 0.723 g (70.0%). 
1H NMR (300 MHz, CDCl3): δ (ppm) = 8.82 (1H, d, J = 4.94 Hz, H-2); 8.06 (1H, d, J = 2.03 Hz,  
H-8); 8.00 (1H, d, J = 8.94 Hz, H-5); 7.48 (1H, dd, J = 2.08, 8.94 Hz, H-6); 7.13 (1H, d,
J = 4.94 Hz, H-3). 13C{1H} NMR (101 MHz, CDCl3): δ (ppm) = 108.87 (C-3), 120.17(C-10), 123.92













IR (ATR): (νmax/cm-1) 2124 (N=N=N), 1609 (Ar C=N). Melting point: 118.0–118.8 °C 
(lit. 115.0 °C). 
6.3 Synthesis of 7-chloro-4-(1H-1,2,3-triazol-1-yl)quinoline ligands (2a–2h) 
6.3.1 General method 
4-Azido-7-chloroquinoline (1) and a commercial alkyne were dissolved in either DCM or
t-BuOH (2.00 mL). A freshly prepared solution of sodium ascorbate (0.6 eq.) and CuSO4.5H2O
(0.3 eq.) in water (2.00 mL) was then added to the reaction mixture. This was allowed to stir
at 30 °C for 2–72 h and stopped when the reaction was completed, as shown by TLC analysis.
DCM (30.0 mL) was then added to the reaction mixture, which was then washed with a
saturated NH4Cl solution (3 x 30.0 mL) to remove Cu2+ ions and subsequently washed with
water (3 x 30.0 mL). The solution was then dried using anhydrous Na2SO4, filtered and the
solvent was thereafter removed from the filtrate. Purification was achieved via
recrystallization from hot MeOH to yield the pure desired solid product.
6.3.2 7-Chloro-4-(4-phenyl-1H-1,2,3-triazol-1-yl)quinoline3 (2a)  
To a solution of 1 (0.244 g, 1.19 mmol) and phenylacetylene (0.144 mL, 1.31 mmol) in DCM 
(2.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (2.00 mL) was added and 
the reaction mixture was left to stir for 2 h at 30 °C. The product, 2a, was isolated as a white 
powder. Yield: 0.305 g (83.3%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 9.08 (1H, d, J = 4.62 Hz, 




















(2H, m, H-14); 7.62 (1H, dd, J = 2.12, 9.08 Hz, H-6); 7.55 (1H, d, J = 4.62 Hz, H-3); 7.47-7.52 (2H, 
m, H-15); 7.39-7.44 (1H, m, H-16). 13C{1H} NMR (101 MHz, CDCl3 ): δ (ppm) = 151.56 (C-2), 
150.48 (C-9), 148.76 (C-12), 141.20 (C-7), 137.16 (C-4), 129.75 (C-13), 129.65 (C-6), 129.25  
(C-15), 129.23 (C-8), 129.08 (C-16), 126.19 (C-14), 124.82 (C-5), 121.28 (C-11), 120.89 (C-10), 
116.10 (C-3). IR (ATR): (νmax/cm-1) 1608, 1560 (Ar C=N). Melting point: 156.3–158.7 °C (lit. 
148.5–149.2 °C). Purity: 95.2% by LC (tR 2.59 min).  
6.3.3 7-Chloro-4-(4-p-tolyl-1H-1,2,3-triazol-1-yl)quinoline3 (2b) 
To a solution of 1 (0.301 g, 1.47 mmol) and 4-ethynyltoluene (0.187 mL, 1.47 mmol) in DCM 
(2.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (2.00 mL) was added and 
the reaction mixture was left to stir for 2 h at 30 °C. The product, 2b, was isolated as pale-
yellow crystals. Yield: 0.338 g (80.0%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 9.07 (1H, d, 
J = 4.64 Hz, H-2); 8.26 (1H, d, J = 2.05 Hz, H-8); 8.19 (1H, s, H-11); 8.08 (1H, d, J = 9.08 Hz,  
H-5); 7.83 (2H, d, J = 8.14 Hz, H-14); 7.61 (1H, dd, J = 2.11, 9.09 Hz, H-6); 7.55 (1H, d, J = 4.64
Hz, H-3); 7.30 (2H, d, J = 7.91 Hz, H-15); 2.42 (3H, s, H-17. 13C{1H} NMR (101 MHz, CDCl3):
δ (ppm) = 151.38 (C-2), 150.31 (C-9), 148.68 (C-12), 141.08 (C-7), 138. 90 (C-13), 136.97 (C-4),
129.76 (C-15), 129.44 (C-6), 129.02 (C-8), 126.75 (C-16), 125.93 (C-14), 124.73 (C-5), 120.74
(C-11), 115.89 (C-3), 21.32 (C-17). IR (ATR): (νmax/cm-1) 2915, 2858, 1612, 1595, 1559 (Ar C=N).






















6.3.4 7-Chloro-4-(4-(4-propylphenyl)-1H-1,2,3-triazol-1-yl)quinoline (2c) 
To a solution of 1 (0.200 g, 0.977 mmol) and 1-eth-1-ynyl-4-propylbenzene (0.155 mL, 0.977 
mmol) in DCM (2.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (2.00 mL) 
was added and the reaction mixture was left to stir for 19 h at 30 °C. The product, 2c, was 
isolated as beige crystals. Yield: 0.0805 g, (23.4%). 1H NMR (400 MHz, CDCl3 ): δ (ppm) = 9.09 
(1H, br d, J = 5.71 Hz, H-2); 8.26 (1H, d, J = 1.90 Hz, H-8); 8.20 (1H, s, H-11); 8.08 (1H, d, 
J = 9.08 Hz, H-5); 7.86 (2H, d, J = 8.21 Hz, H-14); 7.61 (1H, dd, J = 1.98, 9.09 Hz, H-6); 7.56 (1H, 
d, J = 4.51 Hz, H-3); 7.31 (2H, d, J = 8.24 Hz, H-15); 2.66 (2H, t, H-17); 1.76-1.64 (2H, m, H-18); 
0.98 (3H, t, H-19); 13C{1H} NMR (101 MHz, CDCl3): δ (ppm) = 151.55 (C-2), 150.65 (C-9), 148.94 
(C-12),143.88 (C-7), 141.18 (C-13), 137.09 (C-4), 129.61 (C-6), 129.35 (C-8,15), 127.12 (C-16), 
126.09 (C-14), 124.90 (C-5), 120.93 (C-10), 120.85 (C-11), 116.56 (C-3), 38.02 (C-17), 24.56   
(C-18), 13.91 (C-19). IR (ATR): (νmax/cm-1) 2961, 2930, 2859, 1609, 1595, 1559 (Ar C=N). 
























6.3.5 7-Chloro-4-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)quinoline (2d) 
To a solution of 1 (0.200 g, 0.977 mmol) and 1-ethynyl-4-(trifluoromethyl)benzene (0.206 mL, 
1.46 mmol) in DCM (2.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water 
(2.00 mL) was added and the reaction mixture was left to stir for 20 h at 30 °C. The product, 
2d, was isolated as a yellow crystalline solid. Yield: 0.235 g (64.2%). 1H NMR (400 MHz, CDCl3): 
δ (ppm) = 9.09 (1H, d, J = 4.10 Hz, H-2); 8.32 (1H, s, H-11); 8.27 (1H, d, J = 1.98 Hz, H-8); 8.07 
(2H, d, J = 8.05 Hz, H-14); 8.03 (1H, d, J = 9.08 Hz, H-5); 7.75 (2H, d, J = 8.19 Hz, H-15); 7.62 
(1H, dd, J = 2.02, 9.08 Hz, H-6); 7.56 (1H, d, J = 4.60 Hz, H-3). 13C{1H} NMR (101 MHz, CDCl3): 
δ (ppm) =  151.54 (C-2), 150.49 (C-9), 147.36 (C-12), 140.95 (C-7), 137.29 (C-13), 133.20 (C-4), 
131.00 (q, 2JC−F = 32.7 Hz, C-16), 129.80 (C-6), 129.31 (C-8), 126.36 (C-14), 126.11 (br q, 
3JC−F = 3.6 Hz, C-15), 124.60 (C-5), 124.33 (q, 1JC−F = 272.1 Hz, C-17), 122.10 (C-11), 116.18 
(C-3). 19F{1H} NMR (377 MHz, CDCl3): δ (ppm) = –62.73 (s). IR (ATR): (νmax/cm-1) 1623, 1610, 
1592, 1560 (Ar C=N), 1324 (C-F stretch). Melting point: 181.3–182.7 °C.  Purity: 99.2% by LC 























6.3.6 7-Chloro-4-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)quinoline3 (2e) 
To a solution of 1 (0.300 g, 1.47 mmol) and 1-ethynyl-4-fluorobenzene (0.283 mL, 2.36 mmol) 
in DCM (2.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (2.00 mL) was 
added and the reaction mixture was left to stir for 15 h at 30 °C. The product, 2e, was isolated 
as a bright yellow powder. Yield: 0.296 g (62.3%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 9.10 
(1H, br d, J = 4.36 Hz, H-2); 8.27 (1H, d, J = 2.05 Hz, H-8); 8.19 (1H, s, H-11); 8.06 (1H, d,  
J = 9.08 Hz, H-5); 7.96-7.91 (2H, m, H-14); 7.62 (1H, dd, J = 2.08, 9.08 Hz, H-6); 7.55 (1H, d, 
J = 4.60 Hz, H-3); 7.26-7.30 (2H, m, H-15); 13C{1H} NMR (101 MHz, CDCl3): δ (ppm) = 163.14 
(d, 1JC−F = 248.7 Hz, C-16) , 151.53 (C-2), 150.51 (C-9), 147.90 (C-12), 141.12 (C-7), 137.21  
(C-4), 129.70 (C-6), 129.27 (C-8), 127.83 (d, 3JC−F = 8.23 Hz, C-14), 125.82 (d, 4JC−F = 2.88 Hz,  
C-13), 124.75 (C-5), 121.03 (C-11), 120.88 (C-10), 116.33 (d, 2JC−F = 21.91 Hz, C-15), 116.11
(C-3); 19F{1H} NMR (377 MHz, CDCl3): δ (ppm) = –112.20 (s). IR (ATR): (νmax/cm-1) 1609, 1592,























6.3.7 7-Chloro-4-(4-(naphthalen-2-yl)-1H-1,2,3-triazol-1-yl)quinoline (2f) 
To a solution of 1 (0.200 g, 0.977 mmol) and 2-ethynylnaphthalene (0.149 g, 0.977 mmol) in 
DCM (2.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (2.00 mL) was added 
and the reaction mixture was left to stir for 3 h at 30 °C. The product, 2f, was isolated as a 
beige powder. Yield: 0.273 g (78.3%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 9.12 (1H, br d,   
J = 2.85 Hz, H-2); 8.48 (1H, d, J = 0.63 Hz, H-14); 8.34 (1H, s, H-11); 8.28 (1H, d, J = 1.92 Hz,  
H-8); 8.11 (1H, d,  J = 9.08 Hz, H-5); 8.03 (1H, dd,  J = 1.69, 8.51 Hz, H-22); 7.97 (1H, s, H-21);
7.88 (1H, m, H-19); 7.88 (1H, m, H-16); 7.63 (1H, dd, J = 1.98, 9.09 Hz, H-6); 7.59 (1H, d,
J = 4.56 Hz, H-3); 7.57-7.50 (2H, m, H-17, 18). 13C{1H} NMR (101 MHz, CDCl3): δ (ppm) = 151.48
(C-2), 150.38 (C-9), 147.36 (C-12), 141.02 (C-7), 137.02 (C-13), 133.56 (C-4), 133.52 (C-20),
130.80 (C-10), 129.69 (C-6), 129.28 (C-5), 129.09 (C-21), 128.47 (C-19), 128.03 (C-16), 127.04
(C-15), 126.90 (C-17), 126.76 (C-18), 125.24 (C-14), 124.85 (C-5), 123.91 (C-22), 121.55 (C-11),
116.20 (C-3). IR (ATR): (νmax/cm-1) 1613, 1592, 1558 (Ar C=N). Melting point: 189.5–191.4 °C.
























6.3.8 7-Chloro-4-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)quinoline (2g)  
To a solution of 1 (0.200 g, 0.977 mmol) and 2-ethynylpyridine (0.109 mL, 1.08 mmol) in   
t-BuOH (2.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (2.00 mL) was
added and the reaction mixture was left to stir for 3 d at 45 °C. The product, 2g, was isolated
as a grey powder. Yield: 0.128 g (42.5 %). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 9.29 (1H,
s, H-11); 9.18 (1H, d, J = 4.66 Hz, H-2); 8.69-8.67 (1H, m, H-17); 8.30 (1H, d, J = 2.06 Hz, H-8);
8.19 (1H, dt, J = 1.08, 1.08, 7.91 Hz, H-14); 8.09 (1H, d, J = 9.11 Hz, H-5); 8.00 (1H, td,  J = 1.81,
7.83, 7.87 Hz, H-15); 7.96 (1H, d, J = 4.62 Hz, H-3); 7.80 (1H, dd, J = 2.20, 9.10 Hz, H-6); 7.44
(1H, ddd, J = 1.19, 4.82, 7.57 Hz,  H-16). 13C{1H} NMR (101 MHz, CDCl3): δ (ppm) =  152.28
(C-2), 149.73 (C-17), 149.34 (C-13), 149.12 (C-10), 147.86 (C-12), 140.33 (C-8), 137.34 (C-15),
135.33 (C-4), 128.94 (C-7), 128.03 (C-9), 125.48 (C-6), 125.34 (C-11), 123.47 (C-16), 120.36
(C-5), 119.95 (C-14), 117.19 (C-3). IR (ATR): (νmax/cm-1) 1606 (C=N)pyridyl, 1567 (C=N)quinoline.





















6.3.9 7-Chloro-4-(4-(ferrocenyl)-1H-1,2,3-triazol-1-yl)quinoline (2h) 
To a solution of 1 (0.100 g, 0.489 mmol) and ethynylferrocene (0.103 g, 0.489 mmol) in DCM 
(2.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (2.00 mL) was added and 
the reaction mixture was left to stir for 20 h at 30 °C. The product, 2h, was isolated as an 
orange powder. Yield: 0.142 g (70.2%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 9.07 (1H, d,  
J = 2.04 Hz, H-2); 8.25 (1H, d, J = 1.51 Hz, H-8); 8.09 (1H, d,  J = 9.00 Hz, H-5); 7.89 (1H, s,  
H-11); 7.62 (1H, dd, J = 1.40, 8.92 Hz, H-6); 7.53 (1H, d, J = 2.81 Hz, H-3); 4.83 (2H, br s, H-14);
4.40 (2H, br s, H-15); 4.16 (5H, s, H-16). 13C{1H} NMR (101 MHz, CDCl3): δ (ppm) =  151.57
(C-2), 150.51 (C-9), 148.26 (C-12), 141.12 (C-7), 137.06 (d, C-4, C-13), 129.57 (C-6), 128.96
(C-8), 124.79 (C-5), 120.60 (C-10), 120.16 (C-11), 115.70 (C-3), 71.45-70.98 (m, C-16),
70.61-70.20 (m, C-15), 68.26-67.92 (m, C-14). IR (ATR): (νmax/cm-1) 1611, 1591, 1558 (Ar C=N).
Melting point: 203.0–204.6 °C.  MS (HR-ESI, m/z): 414.0333 (60%, [M]+), calculated 414.0335.
6.4 Synthesis of 7-chloro-4-aminoquinoline precursors (3–5) 
6.4.1  3-((7-Chloroquinolin-4-yl)amino)propan-1-ol 4 (3) 
A mixture of 4,7-dichloroquinoline (3.00 g, 15.2 mmol) and 2-aminopropan-1-ol (8.20 mL,   




































The resulting solution was then refluxed at 130 °C for 17 h with stirring until completion of 
the reaction, as determined by TLC analysis. Once the reaction mixture was cooled to room 
temperature, it was transferred to ice-cold water (50 mL) and stirred for 10 minutes, resulting 
in the precipitation of the product. This was recovered by filtration, washed with cold water 
and dried, yielding 3 as a beige powder. Yield: 3.51 g (97.8%). 1H NMR (400 MHz, DMSO-d6) : 
δ (ppm) = 8.39 (1H, d, J = 5.40 Hz, H-2); 8.24 (1H, d, J = 9.04 Hz, H-5); 7.77 (1H, d, J = 2.22 Hz, 
H-8); 7.43 (1H, dd, J = 2.26, 8.98 Hz, H-6); 7.26 (1H, br t, J = 5.13 Hz, H-11); 6.47 (1H, d,
J = 5.46 Hz, H-3); 4.57 (1H, br s, H-15); 3.55 (2H, t, J = 4.57 Hz, H-12); 3.36-3.31 (2H, m, H-14);
1.82 (2H, p, H-13). 13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 151.85 (C-2), 150.09 (C-4),
149.03 (C-9), 133.26 (C-7), 127.43 (C-8), 123.92 (C-6), 123.90 (C-5), 117.41 (C-10), 98.54 (C-3),
58.56 (C-14), 40.07 (C-12), 31.03 (C-13). IR (ATR): (νmax/cm-1) 3479 (O-H), 3308 (2° N-H), 2967,
2883, 1697, 1586 (Ar C=N). Melting point: 151.0–152.7 °C (lit. 130.0–133.0 °C).
6.4.2 3-((7-Chloroquinolin-4-yl)amino)propyl methanesulfonate4 (4) 
To a solution of 3 (0.500 g, 2.11 mmol) in dry THF (15.0 mL) under argon, Et3N (0.890 mL, 
6.34 mmol) was added and the reaction vessel was placed into an ice bath and cooled to 0 °C. 
Methanesulfonyl chloride (0.250 mL, 3.17 mmol) was then added to the cold reaction mixture 
and this was allowed to stir overnight, allowing the temperature to increase to room 
temperature. A saturated NaHCO3 solution (20.0 mL) was then added to the reaction mixture 
to quench unreacted MsCl and the THF was removed using a rotary evaporator. The aqueous 
layer was then extracted using Et2O (12 x 50.0 mL) until TLC analysis showed no more product 
in the organic layer. The solvent was then removed, yielding 4 as a beige solid. Yield: 0.285 g 
(42.9%). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 8.42 (1H, d, J = 5.40 Hz, H-2); 8.26 (1H, d, 
J = 9.03 Hz, H-5); 7.79 (1H, d, J = 2.12 Hz, H-8); 7.46 (1H, dd, J = 2.04, 8.97 Hz, H-6); 7.33 (1H, 




















(2H, m, H-14); 3.18 (3H, s, H-15); 2.08 (2H, p, H-13). 13C{1H} NMR (101 MHz, DMSO-d6):  
δ (ppm) = 151.38 (C-2), 150.32 (C-4), 148.36 (C-9), 133.69 (C-7), 126.95 (C-8), 124.27 (C-6), 
124.10 (C-5), 117.34 (C-10), 98.73 (C-3), 68.30 (C-14), 39.26 (C-12), 36.63 (C-15), 27.51 (C-13). 
IR (ATR): (νmax/cm-1) 3231 (2° N-H), 2968, 2923, 2851, 1609, 1574 (Ar C=N). 
Melting point: 125.8–127.4 °C (lit. 124.0–126.0 °C). 
6.4.3 N-(3-Azidopropyl)-7-chloroquinolin-4-amine 4 (5) 
Compound 4 (0.285 g, 1.06 mmol) was dissolved in anhydrous DMF (5.00 mL). To this, NaN3 
(0.139 g, 2.13 mmol) was added in one portion and the resulting mixture was stirred at 65 °C 
for 15 h. The completion of the reaction was determined by TLC. Ethyl acetate (100 mL) was 
then added and the reaction mixture was filtered to remove excess NaN3. The resulting filtrate 
was washed with water (5 x 30 mL) and brine (3 x 20 mL) and dried over anhydrous Na2SO4. 
The solvent was then removed using the rotary evaporator and the resulting product residue 
was then recrystallised using minimal DCM and cold hexane to yield the final product, 5, as a 
fluffy, white powder. Yield: 0.152 g (45.2%). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 8.41 
(1H, d, J = 5.40 Hz, H-2); 8.26 (1H, d, J = 9.05 Hz, H-5); 7.79 (1H, d, J = 2.23 Hz, H-8); 7.45 (1H, 
dd, J = 2.19, 8.99 Hz, H-6); 7.29 (1H, br t, J = 5.22 Hz, H-11); 6.49 (1H, d, J = 5.44 Hz, H-3); 3.49 
(2H, t,  J = 6.74 Hz, H-12); 3.51-3.31 (2H, m, H-14); 1.92 (2H, p, H-13). 13C{1H} NMR   
(101 MHz, DMSO-d6): δ (ppm) = 151.88 (C-2), 149.95 (C-4), 149.02 (C-9), 133.33 (C-7), 127.44  
(C-8), 124.00 (C-5,6), 117.44 (C-10), 98.64 (C-3), 48.53 (C-14), 40.07 (C-12), 27.07 (C-13).  
IR (ATR): (νmax/cm-1) 3240 (2° N-H), 2957, 2946, 2872, 2106 (N=N=N), 1613, 1576 (Ar C=N). 

















6.5 Synthesis of 7-chloro-N-(3-(1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine 
ligands (6a–6e) 
6.5.1 General method 
N-(3-azidopropyl)-7-chloroquinolin-4-amine (5) and a commercial alkyne were dissolved in   
t-BuOH (3.00 mL). A freshly prepared solution of sodium ascorbate (0.6 eq.) and CuSO4.5H2O
(0.3 eq.) in water (3.00 mL) was then added to the reaction mixture. This was allowed to stir
at 40 °C for 24 – 48 h and stopped when the reaction was complete, as shown by TLC analysis.
The solvent was removed and the resulting residue was loaded onto silica and purified by
column chromatography (100% EtOAC with TEA). Pentane was then added to the eluted
product, forming a precipitate which was then filtered via suction filtration to afford the pure
solid compound.
6.5.2 7-Chloro-N-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine 5 (6a) 
To a solution of 5 (0.140 g, 0.535 mmol) and phenylacetylene (0.118 mL, 1.07 mmol) in 
t-BuOH (3.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (3.00 mL) was
added and the reaction mixture was left to stir for 24 h at 40 °C. The product, 6a, was isolated
as a beige powder. Yield: 0.165 g (58.4%). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 8.59 (1H,
s, H-15); 8.40 (1H, d, J = 5.37 Hz, H-2); 8.26 (1H, d, J = 9.03 Hz, H-5); 7.84-7.82 (2H, m, H-18);
7.79 (1H, d, J = 2.17 Hz, H-8); 7.50-7.39 (3H, m, H-6,19); 7.35-7.29 (2H, m, H-11,20); 6.48 (1H,
d, J = 5.42 Hz, H-3); 4.56 (2H, t,  J = 6.95 Hz, H-14); 3.36 (2H, q, H-12); 2.30 (2H, p, H-13).
13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 151.85 (C-2), 149.89 (C-4), 149.01 (C-9), 146.26
(C-16), 133.33 (C-7), 130.77 (C-17), 128.77 (C-18), 127.70 (C-20), 127.45 (C-8), 125.06 (C-19),
























(C-12), 28.31 (C-13). IR (ATR): (νmax/cm-1) 3324 (2° N-H), 2977, 2945, 2892, 1611, 1580  
(Ar C=N). Melting point: > 228 °C dec. with melt (lit. > 250 °C dec.). Purity: 98.9% by LC (tR 
2.25 min). 
6.5.3 7-Chloro-N-(3-(4-(p-tolyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine (6b) 
To a solution of 5 (0.101 g, 0.386 mmol) and 4-ethynyltoluene (0.0980 mL, 0.772 mmol) in 
t-BuOH (3.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (3.00 mL) was
added and the reaction mixture was left to stir for 24 h at 40 °C. The product, 6b, was isolated
as a white crystalline powder. Yield: 0.0835 g (64.0%). 1H NMR (400 MHz, DMSO-d6): δ (ppm)
= 8.54 (1H, s, H-15); 8.40 (1H, d, J = 0.53 Hz, H-2); 8.26 (1H, d, J = 9.05 Hz, H-5); 7.79 (1H, d,
J = 1.87 Hz, H-8); 7.72–7.70 (2H, m, H-18); 7.45 (1H, dd, J = 2.10, 8.98 Hz, H-6); 7.35 (1H, t,
J = 5.26 Hz, H-11); 7.25–7.23 (2H, m, H-19); 6.48 (1H, d, J = 5.35 Hz, H-3); 4.55 (2H, t,
J = 6.97 Hz, H-14); 3.35 (2H, q, H-12); 2.33 (3H, s, H-21); 2.29 (2H, p, H-13). 13C{1H} NMR
(101 MHz, DMSO-d6): δ (ppm) = 151.83 (C-2), 149.96 (C-4), 148.99 (C-9), 146.37 (C-16), 137.05
(C-17), 133.51 (C-7), 129.37 (C-19), 128.03 (C-20), 127.44 (C-8), 125.03 (C-19), 124.10 (C-6),
124.06 (C-5), 121.04 (C-15), 117.48 (C-10), 98.76 (C-3), 47.51 (C-14), 39.52 (C-12), 28.34
(C-13), 20.78 (C-21). IR (ATR): (νmax/cm-1) 3325 (2° N-H), 2977, 2949, 2892, 1609, 1581 (Ar


























6.5.4 7-Chloro-N-(3-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine (6c) 
To a solution of 5 (0.103 g, 0.535 mmol) and 1-ethynyl-4-fluorobenzene (0.0944 g, 
0.786 mmol) in t-BuOH (3.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water 
(3.00 mL) was added and the reaction mixture was left to stir for 42 h at 40 °C. The product, 
6c, was isolated as a pale-yellow powder. Yield: 0.165 g (64.3%). 1H NMR (400 MHz,    
DMSO-d6): δ (ppm) = 8.58 (1H, s, H-15); 8.39 (1H, d, J = 5.36 Hz, H-2); 8.25 (1H, d, J = 9.04 Hz, 
H-5); 7.87–7.78 (2H, m, H-18); 7.78 (1H, d, J = 2.22 Hz, H-8); 7.44 (1H, dd, J = 2.26, 8.98 Hz,
H-6); 7.35 (1H, t, J = 5.25 Hz, H-11); 7.30–7.26 (2H, m, H-19); 6.47 (1H, d, J = 5.44 Hz, H-3);
4.56 (2H, t, J = 6.97 Hz, H-14); 3.34 (2H, q, H-12); 2.29 (2H, p, H-13). 13C{1H} NMR (101 MHz,
DMSO-d6): δ (ppm) = 162.54 (C-20), 160.92 (C-17), 151.87 (C-2), 149.98 (C-4), 148.98 (C-9),
145.46 (C-16), 133.43 (C-7), 127.44 (C-8), 127.11 (d, C-18), 124.12 (C-6), 124.06 (C-5), 121.40
(C-15), 117.47 (C-10), 115.88 (d, C-19), 98.76 (C-3), 47.62 (C-14), 39.52 (C-12), 28.33 (C-13).
19F{1H} NMR (377 MHz, DMSO-d6): δ (ppm) = –114.24 (s). IR (ATR): (νmax/cm-1) 3337 (2° N-H),
2956, 2949, 2892, 1609, 1580 (Ar C=N), 1227 (C-F). Melting point: 230.0–232.9 °C.
Purity: 99.0% by LC (tR 2.27 min).
6.5.5 7-Chloro-N-(3-(4-(pyridin-2-yl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine (6d) 
To a solution of 5 (0.145 g, 0.554 mmol) and 2-ethynylpyridine (0.0671 mL, 0.665 mmol) in 



















































added and the reaction mixture was left to stir for 48 h at 40 °C. The product, 6d, was isolated 
as a beige powder. Yield: (0.116 g, 57.3%). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 8.67 (1H, 
s, H-15); 8.60-8.58 (1H, m, H-21); 8.39 (1H, d, J = 5.40 Hz, H-2); 8.25 (1H, d, J = 9.05 Hz, H-5); 
8.03-8.01 (1H, m, H-18); 7.88 (1H, td, J = 1.77, 7.72, 7.81 Hz, H-19); 7.78 (1H, d, J = 2.20 Hz,  
H-8); 7.43 (1H, dd, J = 2.23, 8.99 Hz, H-6); 7.33 (2H, ddd, J = 1.10, 4.89, 7.35 Hz, H-11,20); 6.47
(1H, d, J = 5.46 Hz, H-3); 4.59 (2H, t,  J = 6.88 Hz, H-14); 3.36 (2H, q, H-12); 2.30 (2H, p, H-13).
13C{1H} NMR (101 MHz, DMSO-d6): δ (ppm) = 151.76 (C-2), 149.99 (C-4), 149.96 (C-21), 149.48
(C-17), 148.88 (C-9), 147.20 (C-16), 137.05 (C-19), 133.34 (C-7), 127.34 (C-8), 124.03 (2C,
C-5,6), 123.37 (C-15), 122.82 (C-20), 119.32 (C-18), 117.43 (C-10), 98.70 (C-3), 47.52 (C-14),
40.10 (C-12), 28.31 (C-13). IR (ATR): (νmax/cm-1) 3357 (2° N-H), 2950, 2895, 1605 (C=N)pyridyl,
1580 (C=N)quinoline. Melting point: 183.5–185.2 °C. Purity: 99.9% by LC (tR 2.04 min).
6.5.6 7-Chloro-N-(3-(4-(ferrocenyl)-1H-1,2,3-triazol-1-yl)propyl)quinolin-4-amine (6e) 
To a solution of 5 (0.145 g, 0.554 mmol) and ethynylferrocene (0.128 g, 0.609 mmol) in 
t-BuOH (3.00 mL), a solution of sodium ascorbate and CuSO2.5H2O in water (3.00 mL) was
added and the reaction mixture was left to stir for 27 h at 40 °C. The product, 6e, was isolated
as a yellow powder. Yield: 0.165 g (70.3%). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 8.40 (1H,
d, J = 5.35 Hz, H-2); 8.28 (1H, d, J = 9.06 Hz, H-5); 8.20 (1H, s, H-15); 7.79 (1H, d, J = 2.22 Hz,
H-8); 7.46 (1H, dd, J = 2.24, 9.00 Hz, H-6); 7.33 (1H, t, J = 4.95 Hz, H-11); 6.45 (1H, d,
J = 5.44 Hz, H-3); 4.70 (2H, t, J = 1.84 Hz, H-18);  4.51 (2H, t,  J = 6.96 Hz, H-14); 4.30 (2H, t,
J = 1.83 Hz, H-19); 4.03 (5H, s, H-20); 3.32 (2H, q, H-12); 2.27 (2H, p, H-13). 13C{1H} NMR
(101 MHz, DMSO-d6): δ (ppm) = 151.83 (C-2), 149.91 (C-4), 149.01 (C-9), 145.17 (C-16), 133.34
(C-7), 127.45 (C-8), 124.03 (C-6), 124.00 (C-5), 120.55 (C-15), 117.44 (C-10), 98.62 (C-3), 76.03



























IR (ATR): (νmax/cm-1) 3296 (2° N-H), 3120, 3084, 2949, 2924, 1613, 1575, 1564 (Ar C=N). 
Melting point: 173.9 – 175.4 °C. MS (HR-ESI, m/z): 472.0997 (100%, [M+H]+), calculated 
472.0986.  
6.6 Synthesis of cyclometallated Ir(III) half-sandwich complexes (7a–7f) 
6.6.1 General method 
A solution of the desired ligand (1 eq.), [IrCp*(μ-Cl)Cl]2 (0.7 eq.) and NaOAc (2 eq.) was made 
in anhydrous ACN (20.0 mL). The reaction mixture was refluxed under argon at 65–75 °C for 
48–72 h and then left to stir at room temperature for a further 72 h, after which a yellow 
precipitate formed. This precipitate was filtered and washed with ACN. The resulting yellow 
powder was dissolved in DCM and filtered through Celite™ to remove any excess NaOAc. The 
solvent was then reduced and Et2O was added to produce a yellow precipitate, which was 
then filtered and dried. 
6.6.2 Ir(III) triazole-phenyl complex (7a) 
A solution of 2a (0.100 g, 0.326 mmol), [IrCp*(μ-Cl)Cl]2 (0.182 g, 0.229 mmol) and NaOAc 
(0.0535 g, 0.652 mmol) was made in anhydrous ACN (20.0 mL) and refluxed under nitrogen 
























(400 MHz, CDCl3): δ (ppm) = 9.06 (1H, d, J = 4.62 Hz, H-2); 8.27 (1H, d, J = 1.80 Hz, H-8); 
8.14-8.16 (2H, m, H-5,11); 7.79 (1H, d, J = 7.55, H-14); 7.65 (1H, dd, J = 1.97, 9.11 Hz, H-6); 
7.50 (1H, d, J = 4.63 Hz, H-3); 7.44 (1H, d, J = 7.42 Hz, H-17); 7.06 (1H, t, J = 7.24 Hz, H-15); 
6.88 (1H, t, J = 7.33 Hz, H-16); 1.81 (15H, s, H-20).  13C{1H} NMR (101 MHz, CDCl3): 159.74   
(C-12), 158.61 (C-18), 151.70 (C-2), 150.44 (C-9), 140.59 (C-7), 137.13 (C-4), 136.23 (C-14), 
134.75 (C-13), 129.74 (br s, 2C, C-6,15), 129.29 (C-8), 124.77 (C-5), 122.72 (C-16), 122.27   
(C-17), 120.28 (C-10), 118.66 (C-11), 116.02 (C-3), 89.00 (C-19), 9.25 (C-20). IR (ATR):  
(νmax/cm-1) 1611, 1586, 1560 (Ar C=N). Melting point: > 280 °C dec. MS (HR-ESI, m/z): 
633.1409 (100 %, [M-Cl]+), calculated 633.1397.  
6.6.3 Ir(III) triazole-p-tolyl complex (7b) 
A solution of 2b (0.0700 g, 0.218 mmol), [IrCp*(μ-Cl)Cl]2 (0.122 g, 0.153 mmol) and NaOAc 
(0.0358 g, 0.436 mmol) was made in anhydrous ACN (20.0 mL) and refluxed under nitrogen 
for 48 h. Complex 7b was isolated as a yellow solid. Yield: 0.0481 g, (32.3%).1H NMR     
(400 MHz, CDCl3): δ (ppm) = 9.05 (1H, d, J = 4.64 Hz, H-2); 8.27 (1H, d, J = 1.74 Hz, H-8); 8.18 
(1H, d, J = 9.12 Hz, H-5); 8.10 (1H, s, H-11); 7.65 (1H, dd, J = 2.05, 9.11 Hz, H-6); 7.60 (1H, s,  
H-18); 7.50 (1H, d, J = 4.65 Hz, H-3); 7.34 (1H, d, J = 7.58 Hz, H-14); 6.69 (1H, d, J = 7.45 Hz,
H-15); 2.30 (3H, s, H-17); 1.81 (15H, s, H-21). 13C{1H} NMR (101 MHz, CDCl3): 159.68 (C-12),
158.64 (C-19), 151.67 (C-2), 150.46 (C-9), 140.65 (C-16), 139.29 (C-7), 137.11 (C-4), 136.98



























120.27 (C-10), 118.12 (C-11), 115.92 (C-3), 88.89 (C-20), 21.92 (C-17), 9.25 (C-21);   
IR (ATR): (νmax/cm-1) 1609, 1591, 1560 (Ar C=N). Melting point: > 290 °C dec. MS (HR-ESI, m/z): 
647.1555 (100%, [M-Cl]+), calculated 647.1554.  
6.6.4 Ir(III) triazole-propylphenyl complex (7c) 
A solution of 2c (0.0510 g, 0.146 mmol), [IrCp*(μ-Cl)Cl]2 (0.0815 g, 0.102 mmol) and NaOAc 
(0.0359 g, 0.438 mmol) was made in anhydrous ACN (10.0 mL) and refluxed under argon for 
72 h. Complex 7c was isolated as a yellow solid. Yield: 0.0618 g (85.2%). 1H NMR      
(400 MHz, CDCl3): δ (ppm) = 9.05 (1H, d, J = 4.64 Hz, H-2); 8.27 (1H, d, J = 1.74 Hz, H-8); 8.18 
(1H, d, J = 9.12 Hz, H-5); 8.10 (1H, s, H-11); 7.65 (1H, dd, J = 2.05, 9.11 Hz, H-6); 7.60 (1H, s,  
H-20); 7.50 (1H, d, J = 4.65 Hz, H-3); 7.34 (1H, d, J = 7.58 Hz, H-14); 6.69 (1H, d, J = 7.45 Hz,
H-15); 2.30 (3H, s, H-17); 1.81 (15H, s, H-21);  13C{1H} NMR (101 MHz, CDCl3): 159.59 (C-12),
158.69 (C-21), 151.66 (C-2), 150.42 (C-9), 143.98 (C-16), 140.68 (C-7), 137.12 (C-4), 136.45
(C-20), 132.24 (C-13), 129.71 (C-6), 129.24 (C-8), 124.88 (C-5), 123.17 (C-15), 122.00 (C-14),
120.31 (C-10), 118.16 (C-11), 115.96 (C-3), 88.90 (C-22), 38.56 (C-17) , 24.81 (C-18), 14.17
(C-19), 9.23 (C-23). IR (ATR): (νmax/cm-1) 2869, 2925, 2954, 1607, 1594, 1561 (Ar C=N). Melting




























6.6.5 Ir(III) triazole-4-(trifluoromethyl)phenyl complex (7d) 
A solution of 2d (0.050 g, 0.133 mmol), [IrCp*(μ-Cl)Cl]2 (0.0744 g, 0.0934 mmol) and NaOAc 
(0.0328 g, 0.400 mmol) was made in anhydrous ACN (10.0 mL) and refluxed at 75 °C under 
argon for 72 h. Complex 7d was isolated as a yellow solid. Yield: 0.0121 g (12.3 %). 1H NMR 
(400 MHz, CDCl3 ): δ (ppm) = 9.09 (1H, d, J = 4.65 Hz, H-2), 8.29 (1H, d, J = 2.02 Hz, H-8), 8.22 
(1H, s, H-11), 8.05 (1H, d, J = 9.30 Hz, H-5), 8.04 (1H, s, H-18), 7.66 (1H, dd, J = 2.09, 9.11 Hz, 
H-6), 7.51-7.58 (2H, m, H-3, 14), 7.20 (1H, dd, J = 0.90, 7.91 Hz, H-15), 1.81 (15H, s, H-21);
13C{1H} NMR (101 MHz, CDCl3):  160.21 (C-12), 157.68 (C-19), 151.57 (C-2), 150.57 (C-9),
140.61 (C-13), 138.27 (C-7), 137.48 (C-4), 132.60 (br q, 3JC−F = 3.45 Hz, C-18), 130.62 (q,
2JC−F = 30.75 Hz, C-16), 130.10 (C-6), 129.49 (C-8), 124.68 (q, 1JC−F = 273.14 Hz, C-17), 124.33
(C-5), 122.00 (C-11), 120.41 (C-10), 119.79 (br q, 3JC−F = 3.58 Hz, C-15), 119.63 (C-14), 116.21
(C-3), 89.45 (C-20), 30.28 (C-, 9.20 (C-21). 19F{1H} NMR (377 MHz, CDCl3): δ (ppm) =
–62.13 (s).  IR (ATR): (νmax/cm-1) 1618, 1606, 1595, 1560 (Ar C=N), 1314 (C-F stretch). Melting



























6.6.6 Ir(III) triazole-4-fluorophenyl complex (7e) 
A solution of 2e (0.0762 g, 0.235 mmol), [IrCp*(μ-Cl)Cl]2 (0.131 g, 0.164 mmol) and NaOAc 
(0.0578 g, 0.704 mmol) was made in anhydrous ACN (15.0 mL) and refluxed at 65 °C under 
argon for 72 h. Complex 7e was isolated as a yellow solid. Yield: 0.0336 g (29.8%). 1H NMR 
(400 MHz, CDCl3 ): δ (ppm) = 9.08 (1H, d, J = 4.65 Hz, H-2), 8.28 (1H, d, J = 2.07 Hz, H-8), 8.10 
(1H, d, J = 9.30 Hz, H-5), 8.09 (1H, s, H-11), 7.65 (1H, dd, J = 2.12, 9.12 Hz, H-6), 7.52 (1H, d,  
J = 4.65 Hz, H-3), 7.52-7.43 (2H, m, H-14,17), 6.63 (1H, td, J = 2.36, 8.64, 8.80 Hz, H-15), 1.81 
(15H, s, H-21). 13C{1H} NMR (101 MHz, CDCl3):  163.15 (d, 1JC−F = 251.43 Hz, C-16), 162.86 (d, 
3JC−F = 4.89 Hz, C-18), 157.81 (C-12), 151.63 (C-2), 150.56 (C-9), 140.60 (C-7), 137.27 (C-13), 
130.98 (C-4), 129.86 (C-6), 129.43 (C-8), 124.61 (C-5), 123.49 (d, 3JC−F = 8.68 Hz, C-14), 122.36 
(d, 2JC−F = 17.83 Hz, C-17), 120.31 (C-10), 118.34 (C-11), 116.01 (C-3), 109.77 (d, 2JC−F = 23.34 
Hz, C-15), 89.22 (C-19), 9.20 (C-20). 19F{1H} NMR (377 MHz, CDCl3): δ (ppm) = –112.15 (s).   
IR (ATR): (νmax/cm-1) 1615, 1590, 1560 (Ar C=N). Melting point: > 283 °C dec.  MS (HR-ESI, 


























6.6.7 Ir(III) triazole-naphthalen-2-yl complex (7f) 
A solution of 2f (0.050 g, 0.140 mmol), [IrCp*(μ-Cl)Cl]2 (0.0781 g, 0.0980 mmol) and NaOAc 
(0.0345 g, 0.420 mmol) was made in anhydrous ACN (10.0 mL) and refluxed at 75 °C under 
argon for 72 h. Complex 7f was isolated as a yellow solid. Yield: 0.0100 g (9.9%). 1H NMR    
(400 MHz, CDCl3 ): δ (ppm) = 8.87 (1H, d, J = 4.63 Hz, H-2); 8.34 (1H, s, H-11); 8.26 (1H, d, 
J = 2.03 Hz); 8.16-8.13 (2H, m, H-5,14); 8.14 (1H, s, H-21); 7.73 (1H, d, J = 8.43 Hz, H-6);  
7.74-7.61 (2H, m, H-16,19); 7.45 (1H, d, J = 4.69 Hz, H-3); 7.37-7.32 (1H, m, H-17); 7.22-7.16 
(1H, m, H-18); 1.85 (15H, s, H-24). IR (ATR): (νmax/cm-1) 3084, 2918, 1612, 1595, 1560  


























6.7 Synthesis of neutral monodentate Ir(III) half-sandwich complex (8) 
6.7.1 Ir(III) monodentate triazole-phenyl complex (8) 
A solution of ligand 2a (0.0500 g, 0.163 mmol) and [IrCp*(μ-Cl)Cl]2 (0.0649 g, 0.0815 mmol) 
was made in anhydrous ACN (10.0 mL). The reaction mixture was stirred at room temperature 
under argon for 16 h. A bright yellow precipitate formed, which was then filtered and washed 
with ACN, yielding complex 8 as a bright yellow powder. Yield: 0.0776 g (67.5 %). 1H NMR 
(300 MHz, CDCl3 ): δ (ppm) = 9.50 (1H, br s, H-2); 8.78 (1H, br s, H-8); 8.26 (1H, s, H-11); 8.13 
(1H, d,  J = 9.09 Hz, H-5); 7.98-7.95 (2H, m, H-14); 7.63 (1H, dd, J = 1.89, 9.11 Hz, H-6); 7.57 
(1H, d, J = 5.13 Hz, H-3); 7.53-7.48 (2H, m, H-15); 7.45-7.40 (1H, m, H-16); 1.58 (15H, s, H-18). 
13C{1H} NMR (101 MHz, CDCl3 ): δ (ppm) = 154.48 (C-2), 149.67 (C-9), 148.77 (C-12), 141.85 
(C-7), 137.63 (C-4), 130.15 (C-8), 129.84 (C-6), 129.39 (C-13), 129.09 (C-15), 128.99 (C-16), 
126.11 (C-14), 125.15 (C-5), 121.34 (C-11), 120.41 (C-10), 116.30 (C-3), 86.40 (C-17), 9.11 
(C-18). IR (ATR): (νmax/cm-1) 1611, 1560 (C=N)quinoline. Melting point: > 235 °C dec with melt.  
6.8 Synthesis of cationic Ir(III) half-sandwich complexes (7g, 10) 
6.8.1 General method 
To a solution of the desired ligand (1 eq.) in DCM/EtOH (1:1, 10 mL), a solution of 


























mixture was left to stir at room temperature overnight under argon. After 20–23 h, TLC 
analysis confirmed that there was no ligand left in the mixture. The resulting mixture was 
filtered through Celite™ and washed with minimal DCM/EtOH mixture. NH4PF6 (4 eq.) was 
added to the solution, which was allowed to stir at room temperature under argon for 90 min. 
The solvent was, thereafter, reduced to approximately 5.00 mL, cooled rapidly in an ice bath 
and then put into the fridge for 2 h. The precipitate was filtered, washed with cold EtOH and 
dried, yielding the desired product.  
6.8.2 Ir(III) N,N-chelated 7-chloroquinoline-triazole complex (7g) 
To a solution of 2g (0.0300 g, 0.0975 mmol) in DCM/EtOH (1:1, 10 mL), a solution of 
[IrCp*(μ-Cl)Cl]2 (0.0388 g, 0.0487 mmol) in DCM/EtOH (1:1, 10 mL) was added dropwise and 
the reaction mixture was left to stir at room temperature for 20 h. NH4PF6 (0.0640 g,  
0.390 mmol) was added to the solution, yielding 7g as a pale yellow solid. Yield: 0.0627 g 
(78.9%). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 9.99 (1H, s, H-11), 9.31 (1H, d, J = 4.64 Hz, 
H-2), 9.03 (1H, d, J = 5.47 Hz, H-17), 8.45 (1H, d, J = 7.80 Hz, H-14), 8.41 (1H, d, J = 2.08 Hz,
H-8), 8.34-8.40 (1H, m, H-15), 8.14 (1H, d, J = 4.64 Hz, H-3), 8.02 (1H, d, J = 9.04 Hz, H-5), 7.93
(1H, dd, J = 2.13, 9.10 Hz, H-6), 7.82 (1H, ddd, J = 1.52, 5.73, 7.42 Hz, H-16), 1.76 (15H, s,
H-19); 13C{1H} NMR (101 MHz, DMSO-d6): 152.47 (C-2), 152.36 (C-17), 149.35 (C-9), 148.22
(C-13), 147.51 (C-12), 140.81 (C-15), 139.44 (C-7), 135.91 (C-4), 129.59 (C-6), 128.47 (C-11),

























(C-18), 8.34 (C-19). 19F{1H} NMR (377 MHz, DMSO-d6): δ (ppm) = –70.19 (d, 1JP-F = –711.15 Hz). 
31P{1H} NMR (162 MHz, DMSO-d6): δ (ppm) = –144.17 (sept., 1JF-P = –711.19 Hz). IR (ATR): 
(νmax/cm-1) 3470, 3145, 1630, 1614, 1594 (Ar C=N), 825 (P–F stretch). Melting point: 
249.5–251.2 °C dec. MS (HR-ESI, m/z): 670.1107 (100%, [M-PF6]+), calculated 670.1116.  
6.8.3 Ir(III) N,N-chelated 7-chloroquinoline-4-aminotriazole complex (10) 
To a solution of 6g (0.0500 g, 0.137 mmol) in DCM/EtOH (1:1, 10 mL), a solution of  
[IrCp*(μ-Cl)Cl]2 (0.0546 g, 0.0685 mmol) in DCM/EtOH (1:1, 10 mL) was added dropwise and 
the reaction mixture was left to stir at room temperature for 23 h. NH4PF6 (0.0893 g,  
0.548 mmol) was added to the solution, yielding 10 as a pale yellow solid. Yield: 0.0295 g 
(24.7%). 1H NMR (400 MHz, DMSO-d6): δ (ppm) = 9.33 (1H, s, H-15), 9.23 (1H, br t, H-11); 8.93 
(1H, d, J = 5.60 Hz, H-21); 8.57 (1H, d, J = 6.92 Hz, H-2); 8.53 (1H, d, J = 9.15 Hz, H-5); 8.31-8.27 
(2H, m, H-18,19); 7.94 (1H, d, J = 2.09 Hz, H-8); 7.76 (1H, dd, J = 2.08, 9.07 Hz, H-6); 7.72 (1H, 
ddd, J = 1.89, 5.73, 7.37 Hz, H-20); 6.86 (1H, d, J = 7.03 Hz, H-3); 4.90-4.83 (2H, m, H-14);  
3.70-3.62 (2H, m, H-12); 2.50-2.38 (2H, m, H-13); 1.68 (15H, s, H-23). 13C{1H} NMR (101 MHz, 
DMSO-d6): 154.99 (C-17), 152.30 (C-21), 147.86 (C-9), 147.19 (C-16), 143.99 (C-2), 140.66 
(C-19), 139.33 (C-7), 137.70 (C-4), 127.31 (C-20), 126.75 (C-6), 126.36 (C-15), 125.50 (C-5), 
122.10 (C-18), 119.88 (C-8), 115.66 (C-10), 98.73 (C-3), 88.78 (C-22), 49.94 (C-14), 40.32  
(C-12), 27.63 (C-13), 8.30 (C-23). 19F{1H} NMR (377 MHz, DMSO-d6): δ (ppm) = –70.21 (d, 
1JP-F = –711.11 Hz). 31P{1H} NMR (162 MHz, DMSO-d6): δ (ppm) = –144.18 (sept.,   
1JF-P = –711.15 Hz). IR (ATR): (νmax/cm-1) 3631 (2° N-H), 1615 (C=N)pyridyl, 1590 (C=N)quinoline, 828 
































6.9 X-ray Crystallography Method 
Suitable single crystals of complexes 7a and 8 were grown from the slow diffusion of diethyl 
ether into a concentrated dichloromethane solution. Single-crystal X-ray diffraction data were 
collected on a Bruker KAPPA APEX II DUO diffractometer using graphite-monochromated  
Mo-Kα radiation (χ = 0.71073 Å). Data collection was carried out at 173(2) K. The temperature 
was controlled by an Oxford Cryostream cooling system (Oxford Cryostat). Cell refinement 
and data reduction were performed using the program SAINT6. The data were scaled and 
absorption correction performed using SADABS7.  
The structure was solved by direct methods using SHELXS-977 and refined by full-matrix least-
squares methods based on F2 using SHELXL-20187 and using the graphics interface program 
X-Seed.8,9 The programs X-Seed and POV-Ray were used to prepare molecular graphic images.
All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were placed in 
idealised positions and refined in riding models with Uiso assigned 1.2 or 1.5 times Ueq of their 
parent atoms and the bond distances were constrained to 0.95 and 0.98 Å.  
6.10 Biological methods 
6.10.1 In vitro antiplasmodial assay 
The test samples were tested in triplicate on one or two separate occasions against the 
chloroquine-sensitive (NF54) and chloroquine-resistant (K1) strains of P. falciparum. 
Continuous in vitro cultures of asexual erythrocyte stages of P. falciparum were maintained 
using a modified method of Trager and Jensen.10 Quantitative assessment of antiplasmodial 
activity in vitro was determined via the parasite lactate dehydrogenase assay using a modified 
method described by Makler.11 The test samples were prepared to a 20 mg/mL or a 2 mg/mL 
stock solution in 100% DMSO. Samples were tested as a suspension if not completely 
dissolved. Stock solutions were stored at -20 °C. Further dilutions were prepared on the day 
of the experiment. Chloroquine (CQ) was used as the reference drug in all experiments. A full 
dose-response was performed for all compounds to determine the concentration inhibiting 
50% of parasite growth (IC50 value). Test samples were tested at a starting concentration of 
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10 μg/mL or 100 μg/mL, which was then serially diluted 2-fold in complete medium to give 10 
concentrations, with the lowest concentration being 0.02 μg/mL or 0.2 μg/mL respectively. 
The same dilution technique was used for all samples. The IC50 values were obtained using a 
non-linear dose response curve fitting analysis via Graph Pad Prism v.5.0 software. 
6.10.2 Cytotoxicity assay 
Compounds were tested for in vitro cytotoxicity against the mammalian, Chinese Hamster 
Ovarian (CHO) cell-line using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazoliumbromide) assay. The MTT assay is used as a colorimetric assay for cellular 
growth and survival and compares well with other available assays. The CHO cell line was 
cultured in sterile flasks containing 10% foetal calf serum, 45% DMEM and 45% HAMS F-12 
medium in an environment of 5% CO2 at 37 °C. The cell monolayers were detached with 
trypsin then resuspended with 5 mL culture medium. The number of cells were counted with 
crystal violet dye on a counting chamber to achieve a concentration of 105 cells/mL. Cells were 
distributed in flat-bottomed 96-well plates and incubated at 37 °C for 24 h for attachment. 
The test samples were tested in triplicate on one occasion. The test samples were prepared 
to a 2 mg/mL stock solution in 10% MeOH or 10% DMSO and were tested as a suspension if 
not completely dissolved. Test compounds were stored at -20 °C until use. Emetine was used 
as the reference drug in all experiments. The initial concentration of emetine was 100 μg/mL, 
which was serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, 
the lowest being 0.001 μg/mL. The same dilution technique was applied to all the test 
samples. The highest concentration of solvent to which the cells were exposed had no 
measurable effect on cell viability. After 48 h, an aliquot of 25 µL MTT was added to each well 
and plates were incubated at 37°C for 4 h. Dimethyl sulfoxide (DMSO) was used to dissolve 
the MTT crystals. The plates were read at 570 nm with a ModulusTM microplate fluorometer. 
The IC50 values were obtained from plotting non-linear dose-response curves using Graph Pad 
Prism v.5.0 software.  
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6.10.3 In vitro speed of action assay 
A modified IC50 speed assay was followed in order to categorize Ir(III) complexes 7a, 7e and 
7g as either slow-acting or fast-acting compounds.12 A synchronized, chloroquine-sensitive 
(NF54) strain of P. falciparum in ring phase at 2% haematocrit with 2% parasitemia was used 
to conduct this experiment. Four 96-well plates were set up as described in section 6.10.1 for 
one biological replicate. A diagram of the set-up for each 96-well plate is shown in Figure 6.1. 
The highest testing concentrations for 7a and 7g (column 2; Figure 6.1) was 5000 ng/mL and 
10000 ng/mL for 7e (column 7; Figure 6.1). Chloroquine (CQ), artemisinin (ART) and 
ferroquine (FQ) were used as the controls.  The blank (column 1, Figure 6.1) contained 100 µL 
complete medium and 100 µL 2% haematocrit. A serial dilution was performed from column 
2 to 6 and from column 7 to 12. Columns 2 and 7 had the highest concentration of drugs while 
the lowest concentrations were in columns 6 and 12. Each plate represented a drug exposure 
time-point of 10, 24, 48 or 72 h. At each time-point, the corresponding plate was removed 
and the antimalarial compounds and controls were aspirated. Fresh complete medium 
(200 µL) was, thereafter, added to each well. All four plates were incubated at 37 °C for a total 
of 72 h.  
After 72 h, the parasite viability was assessed using a SYBR-green flow cytometry-based 
method. All the plates were removed, resuspended and the contents of each transferred to 
separate round-bottom plates, which were then centrifuged at 750 rpm for 5 min. The 
Figure 6.1. Diagram of the plate set-up foreach 96-well plate used in the IC50 speed assay, with a total 
volume of 200 µL in each well. 
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complete medium was then aspirated and the parasites were washed twice with 100 µL 
filtered PBS. A SYBR-green solution was made up by adding 1.00 µL SYBR-green into 10.0 mL 
of filtered PBS and, thereafter, 100 µL of this SYBR-green solution was added to each plate. 
The plates were then covered with foil and incubated at 37 °C for 1 hour. After incubation, a 
BD CSamplerTM Plus Flow Cytometer was used to run these plates, with each well being run 
for 10 seconds on medium flow rate with one agitation every 12 wells in a cycle. The IC50 
values obtained from each plate were then calculated as ratios relative to the IC50 value at   
72 h. The following formula, with 72 h being the baseline IC50 value for each drug, was used:  
IC50 of 10 or 24 or 48 h
IC50 of 72 h� = IC50 relative to 72 h
6.10.4 β-Haematin inhibition assay 
The β-haematin formation assay was modified from the method described by Sandlin et al.13 
The test compounds were prepared as 10 mM stock solutions in DMSO. The compounds were 
delivered to a 96-well plate in triplicate and were tested at a starting concentration of  
1000 μM, where the lowest drug concentration was 1 μM. The stock solution was serially 
diluted to give 11 concentrations in the 96-well flat-bottom assay plate. NP-40 detergent was 
then added to mediate the formation of β-haematin (30.55 μM, final concentration). A 
25 mM stock solution of haematin was prepared by dissolving hemin (16.3 mg) in DMSO  
(1.00 mL). A 178 μL aliquot of haematin stock was suspended in 20 mL of a 2 M acetate buffer, 
pH 4.7. The haematin suspension was then added to the plate to give a final haematin 
concentration of 100 μM. The plate was then incubated for 16 h at 37 °C. The compounds 
were analysed using the pyridine-ferrochrome method developed by Ncokazi and Egan.14   
32 μL of a solution of 50% pyridine, 20% acetone, 20% water, and 10% 2 M HEPES buffer 
(pH 7.4) was added to each well. To this, 60 μL acetone was then added to each well and 
mixed. The UV-Vis absorbance of the resulting complex was measured at 405 nm on a 
SpectraMax 340PC plate reader. The IC50 values were obtained using a non-linear dose-
response curve fitting analysis via Graph Pad Prism v.5.0 software. 
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6.11 Transfer hydrogenation methods 
6.11.1 Method for qualitative 1H NMR spectroscopy study 
Approximately 6.00 mg of the complex, 20.0 mg of NAD+ and 40.0 mg of sodium formate were 
weighed. The NAD+ was dissolved in 600 μL of D2O and the sodium formate in 600 μL of 
MeOD, with sonication to aid in dissolving. The complex was then suspended in a mixture of 
100 μL of the sodium formate solution and 300 μL of the NAD+ solution. To this, 300 μL of 
MeOD was added. The suspension was then mixed well and any solid matter that remained 
was filtered off. The solution was then added to an NMR tube. The 1H NMR spectrum was 
recorded prior to incubation at 37°C. The tube was then incubated at 37 °C and the spectra 
recorded at various time intervals thereafter.  
6.11.2 Method for cell-free assay to detect transfer hydrogenation of NAD+ to NADH 
Solutions were made up as follows: 
• A 50.0 mL solution containing NAD+ at pH 7.4 was prepared as follows: Sodium
formate (0.310 g, 4.56 mmol), trizma base (0.330 g, 2.72 mmol) and NAD+ (5.50 mg,
0.00829 mmol) were dissolved in 25.0 mL of distilled water. The pH was then
adjusted to 7.4 using HCl. The volume was made up to 50.0 mL with distilled water.
• The tetrazolium solution (NBT) was made up using nitroblue tetrazolium (NBT)
(80.0 mg, 0.0978 mmol) and phenazine ethosulfate (4.00 mg, 0.0120 mmol)  in
50.0 mL distilled water.
Plate set-up: 
6 mM Stocks of each complex were prepared in DMSO (to 1.00 mL). In a 96-well plate (labelled 
plate 1), 200 μL of the drug solution was added to column 3 in triplicate. 100 μL of DMSO was 
added to each well from column 4 to column 12. The compounds were serially diluted giving 
10 concentrations. 75.0 μL of the solution from each well was transferred into a second  
96-well plate (labelled plate 2) into the corresponding well (eg. 75.0 μL C1 of plate 1 into C1
of plate 2 etc). 100 μL of the NAD+ solution was then added to each well. In column 1, 75.0 μL
DMSO and 100 μL NAD+ solution were added to each well only. In column 2, 175 μL DMSO
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was added to each well only. The plate was read at 600 nm to account for the absorbance of 
the compounds (pre-read). The plate was then covered with a foil plate cover to prevent 
evaporation and was incubated for 6-8 h at 37 °C. After this time, 25.0 μL of the NBT solution 
was added and the plate incubated for a further 24 h to aid plate developing. After this time, 
the absorbance was read at 600 nm again, the data from the pre-read accounted for and the 
data plotted using Graph Pad Prism v.5.0 at the various concentrations (2250 μM to 4 μM). 
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